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Abstract 
The glycine cleavage system (GCS) is a multi-enzyme complex localised in the 
mitochondria and serves as the main catabolic pathway for glycine. It contributes to 
supply of one-carbon units into folate one-carbon metabolism (FOCM) which utilises them 
for vital processes such as purines and thymidylate biosynthesis and methylation 
reactions. This thesis focuses on the role of glycine decarboxylase (Gldc), a member of the 
GCS, in embryonic development of the brain. It utilises two loss-of-function mouse models 
for Gldc which were found to exhibit two distinct disease phenotypes: non-ketotic 
hyperglycinemia (NKH) and neural tube defects (NTDs). The aims of this project are to 
investigate what effects GCS deficiency has on FOCM, the developmental mechanisms 
underlying NTDs caused by loss of Gldc expression, and suitability of the Gldc mice models 
as animal models for classical NKH. 
NKH is a rare metabolic disease caused by mutations of GCS genes (mainly GLDC) and 
characterised by accumulation of glycine in body fluids, resulting in severe neurological 
dysfunction and poor survival. Gldc-deficient mice exhibited features of NKH including 
elevated glycine, early post-natal lethality, and hydrocephalus. Enlargement of the brain 
ventricles was found to already be present at late-foetal stage, while glycine levels in 
whole embryos were already elevated shortly after neurulation. Gldc-deficient embryos 
also displayed NTDs, a common birth defect of the central nervous system that result from 
failure of the neural tube to close. Gldc-deficient embryos displayed abnormal folate 
metabolism, growth retardation and reduced cell proliferation. Supplementation with one-
carbon units through dietary means was able to normalise folate profiles, completely 
rescue the NTDs, and normalise proliferation and growth in Gldc-deficient embryos. Diet-
induced folate deficiency and interactions with the Mthfr mutation (which results in a 
methylation defect) did not exacerbate the NTDs caused by the Gldc mutation. 
This study provides the first mouse model for classical NKH and suggests that the 
pathology of NKH begins earlier in development than suspected. It also suggests that Gldc 
deficiency causes NTDs by reducing the supply of glycine-derived, mitochondrial one-
carbon units for FOCM reactions. 
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polyA/ pA Polyadenylation  
qRT-PCR Quantitative RT-PCR 
RBC Red blood cell 
RFC Reduced folate carrier 
RNA Ribonucleic acid 
RNAPII RNA polymerase II 
rpm Revolutions per minute 
RT-PCR Reverse-transcriptase PCR 
SA Splice acceptor 
SAH S-adenosyl homocysteine 
SAM S-adenosyl methionine 
SCO Subcommissural organ 
SD Splice donor 
SDS Sodium dodecyl sulphate 
SE Surface ectoderm 
SEM Standard error of mean 
Shh Sonic hedgehog 
SHMT Serine hydroxymethyltransferase 
SN Somite number 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween 
TCA Tricarboxylic acid 
TGF Transforming growth factor 
THF Tetrahydrofolate 
TYMS Thymidylate synthase 
VEGF Vascular endothelial growth factor 
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1. General Introduction 
 
 
1.1. Glycine cleavage system 
 
The glycine cleavage system (GCS) is the predominant pathway for glycine catabolism 
present in animals, plants, and bacteria. It is localized to the inner membrane of the 
mitochondria and contributes to a larger metabolic pathway: folate one-carbon 
metabolism (FOCM). It catalyses the cleavage of glycine in the presence of NAD+ to yield 
carbon dioxide, ammonia, NADH, and a one-carbon (1C) unit. 
 
1.1.1. Biochemistry of the GCS 
The GCS is a multi-enzyme complex comprising three enzymes: glycine decarboxylase 
(GLDC, or P-protein), aminomethyltransferase (AMT, or T-protein), and dihydrolipoamide 
dehydrogenase (DLD, or L-protein), and a carrier protein, glycine cleavage system H-
protein (GCSH), which contains a bound lipoic acid group. They are encoded by the 
distinct genes GLDC, AMT, DLD, and GCSH, respectively (Kikuchi et al., 2008).  
GLDC, AMT, and GCSH (at both mRNA and protein levels) were shown to be expressed in 
the liver, kidney, and astrocytes of the brain, with AMT and GCSH also showing low levels 
of expression in the heart and spleen (Kure et al., 1991, Sato et al., 1991). Unlike GLDC, 
AMT and GCSH, the DLD enzyme is not specific to the GCS and also participates in other 2-
oxoacid dehydrogenase multi-enzyme complexes in the mitochondria. 
Figure 1 illustrates the steps in the GCS. The first step involves the decarboxylation of 
glycine by GLDC, with GCSH as a co-substrate. The first of the two carbon units of glycine, 
1C-glycine, is converted to carbon dioxide, while the other, 2C-glycine, is transferred to a 
sulfhydryl group of GCSH attached to its covalently bound lipoate group (Fujiwara and 
Motokawa, 1983, Ando et al., 1968). In the next reaction catalysed by AMT, the GCSH-
bound carbon is then transferred to tetrahydrofolate (THF) to generate 5,10-methylene-
THF and ammonia. The now-reduced form of GCSH is reoxidized by the action of DLD in an 
NAD+-dependent manner, thus generating NADH and a hydrogen ion, and is then ready to 
participate in the next glycine cleavage reaction (Fujiwara et al., 1984, Fujiwara and 
Motokawa, 1983).  
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In the absence of THF, AMT converts the GCSH-bound intermediate into ammonia and 
formaldehyde, but at an extremely low velocity (2,400-fold lower turnover rate than when 
THF is present). All reactions in the GCS are reversible, though the conversion of 5,10-
methylene THF back into glycine at the AMT-catalysed step is 6-fold slower than its 
forward reaction (Fujiwara et al., 1984, Okamura-Ikeda et al., 1987). 5,10-methylene-THF, 
formed after receiving the 1C unit from glycine, enters the one-carbon cycle in the 
mitochondria (see Section 1.4.2.2 for details and Figure 4 for a diagram of the full cycle).  
 
 
Figure 1. Glycine cleavage system 
The glycine cleavage system (GCS) consists of four components: glycine decarboxylase 
(GLDC), aminomethyltransferase (AMT), GCS H-protein (GCSH), and dihydrolipoamide 
dehydrogenase (DLD), that collectively break down glycine, releasing one 1C unit as 
carbon dioxide (CO2) and transferring the other to tetrahydrofolate (THF), converting it to 
5,10-methylene-THF. All components of the GCS are localised within the inner 
mitochondrial membrane. 
Reference: Kikuchi et al. (2008) 
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1.1.2. Defects of the GCS 
Mutations in GLDC or AMT are typically known to cause non-ketotic hyperglycinemia 
(NKH, or glycine encephalopathy). NKH is an inborn error of metabolism characterised by 
abnormally high levels of glycine in body fluids, especially in the cerebrospinal fluid (CSF). 
It is an autosomal recessive condition that results in the complete or partial loss of GCS 
enzymatic activity, causing an accumulation of glycine to levels that are double to tenfold 
that of normal plasma and CSF ranges (Kure et al., 1997, Hoover-Fong et al., 2004, 
Hennermann et al., 2012). Details on NKH are provided in the next section, 1.2. 
In addition to causing NKH, impaired GCS activity also predispose to neural tube defects 
(NTDs) (Narisawa et al., 2012), which result from failure of the neural tube to close during 
early embryonic development. Sequencing of GLDC, AMT, and GCSH genes was carried out 
on control and NTD patients, revealing novel missense and splice acceptor site mutations 
in GLDC and AMT of NTD patients. Interestingly, missense variants identified in GLDC in 
the NTD patients exhibited significantly lowered enzymatic activity compared with 
controls. The findings from this study strongly indicate a link between GCS function and 
NTDs. Neural tube defects are described in Section 1.3. 
When components of the GCS are over-expressed, however, this was found to produce a 
pro-oncogenic effect in various cancer cell lines. For example, GLDC was found to be 
upregulated in 158 out of 606 human cancer cell lines, and GLDC overexpression was 
shown to promote cell proliferation, glycolysis and tumorigenesis of lung cancer cells 
(Zhang et al., 2012). GCS involvement was also implicated alongside de novo serine 
biosynthesis and FOCM in a novel ATP production pathway hypothesised to be active in 
proliferating cancer cells (Vazquez et al., 2011, Tedeschi et al., 2013), with similar findings 
also observed in embryonic stem (ES) cells (Tedeschi et al., 2013). In support of this is the 
finding that rapidly proliferating cancer cell lines consume unusually high amounts of 
glycine and highly express glycine synthesis enzymes (Jain et al., 2012). While some 
studies report contradictory results on the pro-oncogenic role of the GCS or of glycine 
requirement (as opposed to serine) for cancer cell proliferation (Rose et al., 1999, 
Labuschagne et al., 2014), it remains clear that GCS enzyme activities, GCS-driven changes 
in glycine levels and its contribution to FOCM play an important role in cancer cell 
metabolism. A review of the contribution of serine, glycine, and one-carbon metabolism in 
cancer is provided by Locasale (2013) and Amelio et al. (2014). 
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1.2. Non-ketotic hyperglycinemia 
 
NKH is a rare disorder with a prevalence of 1 in 63,000 in British Columbia (Applegarth et 
al., 2000) and 1 in 55,000 in Finland (von Wendt et al., 1979). Higher incidence can be 
found in certain geographical regions and ethnic groups, such as in north Finland with 1 in 
12,000 (von Wendt et al., 1979) and in Israeli Arab families (Kure et al., 1998, Boneh et al., 
2005, Flusser et al., 2005). 
 
1.2.1. Clinical presentation  
Disease presentation can be generally divided into three clinical sub-groups: the classical 
neonatal form, the atypical mild form, and the transient form. 
Classical NKH is the most common and severe form of NKH, with a neonatal onset often 
within hours or days of birth. Patients present with a highly elevated CSF/plasma glycine 
ratio with negligible levels or complete absence of GCS activity in the liver. The initial 
symptom is hypotonia, followed by (though not always inclusive of) apnea in which 
intubation is often necessary, persistent and intractable seizures, coma, spasticity, a burst 
suppression pattern or hypsarrhythmia EEG reading, frequent hiccupping, feeding 
difficulties often requiring gastric tube feeding, and occasional microcephaly, choreiform 
movements, and severe hyperactivity (Hennermann et al., 2012).  
Severe cases often present with brain malformations that can be detected by MRI scans, or 
were discovered upon autopsy. Common malformations include white matter atrophy, 
corpus callosum agenesis or hypoplasia, delayed or loss of myelination (Press et al., 1989, 
Viola et al., 2002), non-specific gyral malformations (Dobyns, 1989), and hydrocephalus 
often accompanied by presence of a posterior fossa cyst resembling the Dandy-Walker 
malformation (Van Hove et al., 2000, Hoover-Fong et al., 2004, Yis et al., 2009, Manel et al., 
2012, Van Hove et al., 1998, Tsuyusaki et al., 2012). A rare case of pachygyria has also 
been reported in an NKH patient who also presented with agenesis of the corpus callosum 
(Fletcher et al., 1995).  
Atypical NKH is much rarer and milder, with onset most commonly at the infantile age 
(although both neonatal and an older age of onset have been reported). Biochemical tests 
typically report modest elevation of glycine and CSF/plasma glycine ratios that do not 
reach the diagnostic threshold of the classical form, thus often complicating differential 
diagnoses of these patients. Hepatic GCS activity is also generally higher compared to 
classical NKH (Dinopoulos et al., 2005, Kure et al., 2004, Kure et al., 1997). The clinical 
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presentation of atypical NKH tends to be non-specific and heterogeneous with symptoms 
that include occasional seizures of any kind, febrile illness, episodes of ataxia, chorea, optic 
atrophy, vertical gaze palsy, delays in psychomotor and expressive language development, 
behavioural problems such as aggressiveness and outbursts of rage, autistic features, and 
intractable attention deficit hyperactivity disorder (ADHD).  
While atypical NKH is not life-threatening, a majority of patients (about 61%) will suffer 
from severe mental retardation (Applegarth and Toone, 2001, Flusser et al., 2005). The 
modest elevations in glycine and non-specific nature of the symptoms sometimes overlap 
with other mental disorders such as ADHD and autism (Yu et al., 2013), and may cause 
atypical NKH to be underreported.  
The transient, neonatal form of NKH is the rarest form, defined as a neonatal presentation 
of biochemical features and EEG burst-suppression patterns resembling classical NKH, but 
with symptoms that resolve completely or partially within days or months (Kure et al., 
2002, Aliefendioglu et al., 2003). Diagnosis of transient NKH has often been debated. The 
seven cases of transient NKH reviewed by Applegarth and Toone (2001) did not have 
hepatic GCS activity tested, leading to the validity of their diagnoses being questioned. 
Kure et al. (2002) reported three cases of transient NKH with heterozygous mutations in 
GLDC in two of the patients, and a first report of a heterozygous GCSH mutation in the 
third. One of their patients with the GLDC mutation was followed up by Hamosh and Van 
Hove (2003), who reported that the patient’s symptoms were not, in fact, “transient.” They 
also raised the possibility that a second mutation may have been missed during the initial 
screen by Kure et al. (2002) and questioned the heterozygosity of those mutations.  
Three cases of transient NKH were also reported by Korman et al. (2004), who found 
novel homozygous mutations in GLDC in those patients with high levels of residual GLDC 
activity (at 32%). Unlike previous cases of transient NKH in which biochemical features 
resolve within months along with symptoms, their patients’ biochemical features 
persisted up to three and nine years of age despite resolution of symptoms within months. 
They suggested a new variant or form of NKH in these patients. 
Gender differences in the clinical presentation of NKH have been suggested by Hoover-
Fong et al. (2004). They reported significantly higher number of newborn deaths among 
girls compared with boys with NKH, and that boys reported better mental outcome. 
However, no gender differences were found with other parameters that were studied, 
such as total death and death in proportion to gender. In addition, no other survey of NKH 
patients has reported any gender differences (Hennermann et al., 2012).  
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1.2.2. Diagnostic history 
The first diagnosis of NKH was made by Gerritsen et al. (1965) who described a 
hyperglycinemic patient who was non-ketotic. Early diagnoses of this condition were 
focused on differentiating it from the ketotic form of hyperglycinemia, which is not 
ascribed to single enzymatic defects and which can be seen in other metabolic conditions 
such as methylmalonic acidemia, proprionic acidemia, and isovaleric acidemia (Trijbels et 
al., 1974, Applegarth and Toone, 2001). Like NKH, ketotic hyperglycinemia presents with 
encephalopathy, hypotonia, and respiratory distress (Wajner and Goodman, 2011), but in 
addition to that patients also suffer from metabolic ketoacidosis which does not occur in 
NKH (Ando et al., 1972). Gerritsen et al.’s patient also had a defect in oxalic acid excretion, 
leading to an initial proposal that the disease was caused by a defect in the glycine oxidase 
system (Gerritsen et al., 1965).  
Ando et al. (1968) then devised a method using labelled 1-14C-glycine (carbon 1 of glycine 
which contributes to formation of CO2) and 2-14C-glycine (carbon 2 of glycine which gets 
incorporated into tetrahydrofolate, THF, or may alternatively become carbon 3 of serine) 
injected into NKH patients. They found a huge decrease in levels of exhaled 14CO2 as well 
as virtually no incorporation of 2C-glycine to THF, as reflected by failure of 2-14C-glycine to 
incorporate into serine.  
Follow-up studies by the same group later found that the defect in conversion of 1C-
glycine to CO2 can occur in both the ketotic and non-ketotic form of hyperglycinemia, but 
that conversion of 2C-glycine to 5,10-methylene-THF resulted in defective conversion of 
2C-glycine to 3C-serine in only the non-ketotic form (Ando et al., 1972). This led them to 
conclude that NKH patients have a defect in an enzyme that converts glycine to CO2, NH3, 
and THF, as opposed to other pathways of glycine catabolism such as the glycine oxidase 
system, and this condition was distinct from the ketotic form of hyperglycinemia. Their 
methods and findings were successfully replicated in subsequent studies (Tada et al., 
1969, De Groot et al., 1970) and further supported by evidence that conversion of 
propionyl-CoA to methylmalonyl-CoA and methylmalonyl-CoA to succinyl-CoA (as would 
be expected in ketotic hyperglycinemia) in the liver of an NKH patient was, in fact, normal 
(Baumgartner et al., 1969, Tada and Arakawa, 1970).  
Work done in the following decades was then able to characterise all four enzymatic 
components of the glycine cleavage system, which became recognized as the major 
pathway for glycine catabolism (Fujiwara and Motokawa, 1983, Fujiwara et al., 1984, 
Hiraga and Kikuchi, 1980, Kanno et al., 2007, Kure et al., 1997, Kure et al., 2006a). 
Mutations in genes that encode two of its components were found to be responsible for 
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nearly all cases of NKH. GLDC mutations account for approximately 80% of cases, while 
the rest were AMT mutations. Although no GCSH mutations have been found in NKH 
patients thus far, heterozygous mutations for GCSH have been reported in patients 
diagnosed with transient neonatal hyperglycinemia (Applegarth and Toone, 2001, 
Hennermann et al., 2012, Kure et al., 2002).  
As the DLD enzyme is not specific to the GCS, mutations in DLD do not result in NKH. Due 
to its participation in three other alpha-ketoacid dehydrogenase multi-enzyme complexes 
in the mitochondria, DLD mutations result in L-protein deficiency with lactic acidosis, a 
variant of the maple syrup urine disease with none of the classical symptoms of NKH (Liu 
et al., 1993, Applegarth and Toone, 2001).  
Currently, diagnosis of NKH begins with identification of the cardinal symptoms (e.g. 
hypotonia, apnea, and seizures) and biochemical studies showing elevated glycine in CSF 
and plasma, as well as increased CSF/plasma glycine ratio in which a threshold above 0.8 
is considered diagnostic of classical NKH (Applegarth and Toone, 2001). The diagnosis is 
confirmed with enzymatic essays on liver biopsy or lymphoblast samples. The glycine 
exchange reaction between CO2 and glycine using 14C-bicarbonate (NaH14CO3) (i.e. 
decarboxylation assay) is used to assess activity of GLDC and GCSH, while the glycine 
synthesis reaction from methylene-THF, ammonium chloride (NH4Cl), and NaH14CO3 is 
used for AMT (Hiraga et al., 1981, Kure et al., 1992). Kure et al. (2006b) also developed a 
rapid, non-invasive breath test by administering 1-13C-glycine to NKH patients via gastric 
feeding and measuring amounts of 13CO2 in breath samples. Mutation analysis is 
performed to identify the gene mutation. Brain imaging by itself is not diagnostic but is 
valuable for prediction of outcome of the severe form, as brain malformations seen in 
classical NKH tend to confer poor prognosis (Hoover-Fong et al., 2004).  
 
1.2.3. Current GCS mice models 
Two GCS mice models were created to assess the link between extracellular glycine 
concentration and ischemia via N-methyl-D-aspartate receptor (NMDAR) signalling (Oda 
et al., 2007). Both mice were generated by subcloning human GLDC cDNA (one normal and 
one carrying a dominant-negative mutation identified from an NKH-affected family) into 
pCAG vectors, injecting them into fertilised eggs of BDF1 mice, and backcrossing the mice 
into a C57BL/6 background. The mouse with wild-type human GLDC cDNA was designated 
high-GCS and expressed GCS activity that is 3.4X higher than in wild-type mice, while the 
mouse carrying the mutant cDNA, designated low-GCS, expressed 29% of GCS activity 
compared to wild-type mice. Both mice showed changes in cerebral glycine concentration 
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that corresponded to their respective levels of GCS activity. They showed that 
manipulating the level of GCS activity was able to alter infarct size produced by ischemic 
injury, and that the infarct volume could be ameliorated by administering an NMDAR 
antagonist.  
In a second study by the same group, the high-GCS and low-GCS models were assessed for 
behavioural features resembling mild NKH. A third transgenic mouse was generated by 
injection of the same vector used in the making of the low-GCS mouse, and then 
backcrossing with C57BL/6 mice. This mouse was designated low-GCS-2 and had 33% GCS 
activity compared with wild-type mice (Kojima-ishii et al., 2008). Neither low-GCS mice 
exhibited brain malformations common in NKH patients (such as agenesis of the corpus 
callosum), but they did exhibit higher spontaneous locomotor activity, higher seizure 
susceptibility, elevated aggressiveness, and anxiety-like behaviour. All behavioural 
abnormalities were able to ameliorated using NMDAR antagonists.  
In the Narisawa et al. (2012) study, a knockout mouse for Amt (Amt-/-) was generated 
which exhibited undetectable levels of GCS enzymatic activity. The Amt-/- embryos 
developed NTDs (exencephaly at a frequency of 82% and craniorachischisis at 5%), and 
showed sensitivity to methionine and combined methionine plus thymidine 
monophosphate treatment but not to folic acid. 
Unfortunately, none of the existing mice models are suitable as models for classical NKH. 
The low-GCS and high-GCS models were used for investigating the effect of glycine 
concentration on NMDAR signalling and certain behavioural features of mild NKH, but do 
not exhibit the hallmark features of the more common classical form, while the Amt 
knockout mouse with its very high incidence of NTDs would not have sufficient mutant 
survivors to be an effective working model for NKH.  
 
1.3. Neural tube defects 
 
Neural tube defects (NTDs) are a group of congenital defects that arise when the neural 
tube fails to close during development. They are amongst the most severe and second 
most common group of birth defects after heart defects, and affect approximately 0.5-2 
per 1000 pregnancies worldwide (Mitchell, 2005). The aetiology of NTDs is complex and 
remains largely unknown due to their multifactorial nature. Despite having identified over 
200 genes required for neural tube closure in mice (Harris and Juriloff, 2007, Harris and 
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Juriloff, 2010), no single genetic defect has been identified as the major cause of NTDs in 
humans, suggesting a contribution of multiple genetic and environmental factors. 
 
1.3.1. Mammalian neurulation 
As a vast majority of clinically classified NTDs are associated with neural tube 
development, an understanding of the embryological process of neural tube closure is 
important to investigate the pathology of these defects. The neural tube is the embryonic 
precursor of the central nervous system from which all neural precursor cells that later 
make up the brain and spinal cord derive. Neural tube closure, or neurulation, is 
evolutionarily conserved in amniotes like mammals, birds, and reptiles, and have been 
extensively studied in classical developmental biology animal models such as the fly, 
zebrafish, frog, chicken, and mouse. The description provided here is largely based on the 
mouse model, which has many parallels to human neurulation.  
The process of neurulation occurs in two distinct phases: primary and secondary.  
Primary neurulation involves the invagination of specialised, flat, ectoderm cells into the 
embryo body that then fold to form a closed tube along the midline axis of the embryo 
(Figure 2B). During gastrulation, a subset of cells on the dorsal surface ectoderm of the 
embryo, anterior to the primitive streak, acquire neural identity and thicken to form the 
flat neural plate in a process known as neural induction (Levine and Brivanlou, 2007). At 
the onset of primary neurulation, these cells and cells of the underlying axial mesoderm 
converge towards the midline and intercalate medio-laterally. This process of convergent-
extension narrows the width while extending the length of the neural plate in concert with 
elongation of the embryo body’s rostro-caudal axis (Copp et al., 2003, Keller et al., 2000, 
Keller, 2002, Ybot-Gonzalez et al., 2007b). 
The neural plate then begins to bend in the midline with formation of the median hinge 
point (MHP) directly above the notochord. This forms a “groove” that runs along the 
length of the body axis, with the lateral neural folds elevating dorso-ventrally as the MHP 
gets more pronounced. A second bending event follows: the formation of dorsolateral 
hinge points (DLHPs), which directs the bilateral tips of the neural folds toward the 
midline.  
Dorso-laterally bending is more dramatic in the cranial region, where the neural folds 
initially take on a convex curvature with its tips facing outwards after MHP formation 
(Figure 2C). The neural folds substantially thicken and bulge out into the lumen, 
accompanied by vast proliferation and expansion of the underlying mesenchyme. When 
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the DLHPs form, the folds take on a concave curvature instead and the tips flip towards the 
midline to form a keyhole-shaped lumen  (Morriss-Kay, 1981). 
The DLHPs bring the tips of the neural folds in apposition of one another for the final step 
of adhesion and fusion. The tips reach out and adhere to one another with the aid of cell 
surface protrusions (Geelen and Langman, 1979, Pyrgaki et al., 2010) and fuse to form a 
closed tube. The dorsal epithelia then undergo remodelling and the neural tube, consisting 
of a pseudostratified layer of neuroepithelial cells, is separated from the overlying surface 
ectoderm layer. 
In primary neurulation, 3 distinct locations of closure initiation is known to occur in the 
mouse embryo (Figure 2A) (Golden and Chernoff, 1993). The first point of closure, known 
as closure 1, occurs at the future hindbrain-cervical boundary on embryonic day 8 (E8), at 
the third somite level of a 6-7 somite stage embryo (Copp et al., 2000). This is equivalent 
to days 22-23 in human embryos (Lew and Kothbauer, 2007). Closure proceeds 
bidirectionally from there: rostrally up the hindbrain, and caudally down the spine.  
Closure 2 occurs at the forebrain-midbrain boundary at the 13-14 somite stage, also 
spreading bidirectionally and meeting the rostrally-moving closure front from closure 1 at 
the hindbrain neuropore (HNP). At the same time, closure 3 starts at the extreme rostral 
end of the forebrain. It proceeds up the forebrain towards the midbrain to meet the fusion 
front from the direction of closure 2 at the anterior neuropore (ANP). Cranial closure is 
complete at E9.5, at somite stage 17-18, or day 24 in human embryos. 
Closure proceeds caudally down the spine from the closure 1 point in a zippering fashion 
and ends with the closure of the posterior neuropore (PNP) at the 29-30 somite stage on 
E10.5 (Copp et al., 2000), or days 26-28 in human embryos. Primary neurulation is 
complete after approximately 36 hours from time of onset. 
Completion of primary neurulation is succeeded by secondary neurulation at E11 at the 
32-34 somite level, and continues through gestation in mice (days 28-48 in human 
embryos). This forms the spinal cord at the lower sacral and caudal levels utilising a 
process known as “canalisation” (Copp and Greene, 2010 , Lew and Kothbauer, 2007, 
Schoenwolf, 1984). Directly caudal to the closed posterior neuropore, cells in the tail bud 
(known as the caudal cell mass in humans) acquire a neuroepithelial fate and begin to 
aggregate. They condense to form a medullary cord-like structure under the surface 
ectoderm, their apico-basal polarity leading to a radial orientation around the future 
lumen. A central cavity opens, becoming a tube that is directly continuous with that 
formed during primary neurulation (Harrington et al., 2009, Copp and Greene, 2010 , 
Schoenwolf, 1984).  
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Figure 2. Overview of mouse primary neurulation. 
(A) (i) Closure 1 begins at the level of the 3rd somite of a 6-8 somite stage and occurs 
bidirectionally. The forebrain (FB), midbrain (MB), and hindbrain (HB) of the embryo is 
indicated. The future closure 2 site is located at the FB-MB boundary, closure 3 at the 
rostral end of the forebrain. (ii) At the 12-14 somite stage, closure 2 and closure 3 has 
initiated. Closure 1 and 2 meet at the hindbrain neuropore (HNP), closure 2 and 3at the 
anterior neuropore (ANP). Closure 1 proceeds caudally to close the posterior neuropore 
(PNP). 
(B) (i) Primary neurulation begins with the induction of a group of flat epithelial cells 
during gastrulation to become neural ectoderm. (ii) Formation of the median hinge point 
(MHP) elevates the neural folds dorso-ventrally. (iii) Formation of the dorso-lateral hinge 
points (DLHPs) bring the tips of the neural folds toward the midline. (iv) Fusion of the 
neural folds and remodelling of the cells at the fusion point produces a closed neural tube 
(NT) with an overlying surface ectoderm (SE). 
(C) (i) In the cranial region, formation of the MHP is succeeded by thickening of the 
neuroepithelium (NE), producing a convex curvature. (ii) Dorso-lateral bending flips the 
tips of the cranial neural folds toward the midline, obtaining a convex curvature (arrows). 
(iii) Fusion of the neural tips result in a keyhole-shaped lumen. 
References: Greene and Copp (2009) and Copp (2005) 
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Figure 2. Overview of mouse primary neurulation.  
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In the final stages of secondary development, the medullary cord at the caudal end is 
sculpted by tissue degeneration and retrogressive differentiation. In mice and tailed 
mammals, the medullary cord and vertebrate column form the tail. In humans and tailless 
mammals, canalisation at the caudal-most terminal ends with the formation of the 
ventriculus terminalis. Throughout the rest of the human gestational period, this structure 
“ascends” relative to the elongation of the vertebral canal and forms the conus, cauda 
equina and fibrous strands of the filum terminale (Lew and Kothbauer, 2007, Pang et al., 
2011, Tortori-Donati et al., 2000). 
 
1.3.2. Classification of NTDs 
Neural tube defects can be broadly classified as open and closed subtypes according to 
embryonic origin of the defect (Copp and Greene, 2013). Open NTDs occur when primary 
neurulation fails, leaving a part of the neural tube unfused. This exposes the brain tissue to 
the extra-embryonic environment, resulting in in utero degeneration and subsequent 
damage as embryonic development progresses. Closed NTDs have skin covering the lesion, 
and are attributed to failed secondary neurulation. The herniation subtype results from 
defective development of the overlying skeletal structure, causing the closed neural tube 
to herniate out with the meninges.  
Craniorachischisis, exencephaly, and open spina bifida are open NTDs corresponding to 
the axial level at which the neural tube fails to close (Copp et al., 2003).  
Failure of closure 1, the first and earliest closure event, results in craniorachischisis where 
the entire length of the neural tube caudal to the midbrain remains open. This condition is 
the rarest and severest form of NTD, and is combined with a shorter anterior-posterior 
embryo length due to a defect in convergent-extension (Copp and Greene, 2013). 
When closure 2 is not completed, the hindbrain and/or anterior neuropore remain open. 
The cranial neural folds splay apart, get exposed to amniotic fluid, and gradually 
degenerate in utero, resulting in exencephaly. This condition then progresses to 
anencephaly (literally meaning “no brain”), where there is massive loss of brain tissue and 
failure of the skull vault to form (Copp, 2005). Failure of the anterior neuropore to close 
results in a condition known as “split face.” Patients born with anencephaly die at or 
shortly after birth. 
Open spina bifida (or spina bifida aperta) occurs when caudal progression from closure 1 
down the spine arrests midway. The size of the spina bifida lesion depends on which axial 
level closure fails: the rest of the neural tube caudal to that point remains open. Similar to 
29 
 
the skull deformity accompanying exencephaly, the vertebrate arch fails to form around 
the open spinal folds, leaving an exposed lesion. Open spina bifida is divided to the rare 
myelocoele (or myeloschisis), in which the lesion is completely exposed, and the 
considerably more common myelomeningocoele (or spina bifida cystica), in which the 
lesion is covered by a meninges sac (Greene and Copp, 2014, Copp and Greene, 2013, 
Tortori-Donati et al., 2000). Unlike anencephaly and craniorachischisis, open spina bifida 
is not lethal but causes life-long disabilities and complications such as paralysis of the 
lower limbs, bladder incontinence and urinary tract infections, and bowel dysfunction. It is 
also frequently associated with other conditions such as hydrocephalus with Chiari type II 
malformations, in which the hindbrain herniates into the foramen magnum (Copp et al., 
2003, Copp and Greene, 2010 ). 
Defects in secondary neurulation result in closed defects (where neural tissue is 
unexposed under a skin covering) due to never having been “open” and exposed to extra-
embryonic environment during development. They are often classified under a more 
diverse group of spinal malformations clinically known as occult spinal dysraphism (OSD, 
or spina bifida occulta) that vary in severity (Greene and Copp, 2014, Copp et al., 2015). 
They are also often accompanied by tethering of the spinal cord and lumbosacral 
cutaneous lesions that may serve as skin markers (Guggisberg et al., 2004, Drolet and 
Boudreau, 2004, Lew and Kothbauer, 2007). Examples of OSD subtypes include 
lipomyelomeningocoele in which neural and fatty tissue protrude through a defective 
vertebrate (Lew and Kothbauer, 2007), and dermal sinus tracts in which an epithelial tract 
joins the skin and dermal tissue to the spinal cord (Ackerman and Menezes, 2003). 
Herniation-type NTDs can be divided to encephalocoele, where herniation of a region of 
the brain occurs through a skull defect, and spinal meningocoele, where meningeal tissue 
and spinal fluid herniate through an opening in the vertebrae and dura (Greene and Copp, 
2009, Greene and Copp, 2014, Copp and Greene, 2013). 
 
1.3.3. Differences between human and mouse primary neurulation 
Anencephaly constitutes about half of human NTDs, but in mice models, it is the most 
common type of NTD observed (Copp et al., 2003, Copp et al., 2013). While the 
morphogenetic sequences of primary and secondary neurulation are mostly conserved 
between human and mouse embryos, some variation does exist. These variations may 
account for differences observed in the incidence of NTDs between the two. When 
comparing between stage-matched human and mouse embryos, one striking difference is 
that human embryos have noticeably smaller heads in proportion to the body (Copp, 
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2005). This suggests that cranial neurulation may be more easily achieved in human 
embryos than in mice for simple, mechanistic reasons. 
Primary neurulation in human embryos was initially thought to begin with a single initial 
closure event at the brain-spinal cord junction, is followed by bidirectional zippering in a 
rostral and caudal direction, and end with the closure of rostral and caudal neuropores 
(O'Rahilly and Muller, 1994). However, the findings of multiple closure sites in mice 
embryos prompted a multi-site closure model in human embryos as well. This resulted in 
some studies describing 5 closure sites to account for the various types of human NTDs 
(Van Allen et al., 1993, Seller, 1995, Martinez-Frias et al., 1996). While the events of 
closure 1 and closure 3 in the human neural tube are generally agreed upon by most 
studies, the existence of closure 2 is debatable. Examination of human neurulating 
embryos and still-births with neural tube defects have led to some studies reporting a 
closure 2 event (Golden and Chernoff, 1995, Nakatsu et al., 2000, Seller, 1995) and others 
not (O'Rahilly and Muller, 2002). 
The precise location of the closure 2 site also varies amongst various mice strains (Juriloff 
et al., 1991, Fleming and Copp, 2000). Closure 2 occurred consistently in the 
forebrain/midbrain boundary of some strains (such as randomly bred CD1 mice), while in 
others it consistently initiated further rostral into the forebrain region or caudal into the 
midbrain. This difference appears to affect the susceptibility of the strain to develop 
cranial NTDs, with a more rostrally located closure 2 conferring a higher, genetically-
predetermined risk for cranial closure to fail (Fleming and Copp, 2000). Remarkably, mice 
on the SELH/Bc background strain do not undergo a closure 2 event (Macdonald et al., 
1989). While 17% of these mice spontaneously develop exencephaly, the fact that the rest 
of them are able to successfully close their cranial neural tubes suggests that closure 2 is 
not essential for closure in mice embryos, but that its absence increases the risk of failure 
of closure to occur.  
 
1.3.4. Aetiology of NTDs 
The aetiology of NTDs is complex and involves both environmental and genetic factors. 
Maternal disease states, nutritional and socioeconomic statuses, intake of folic acid, and 
exposure to teratogens can all contribute to NTD risk. A genetic component to the 
aetiology of NTDs also exists. Variations in family inheritance patterns, degree of 
penetrance, and severity of disease manifestation all point to the involvement of multiple 
genes in a polygenic (i.e. combination of heterozygosity across multiple risk alleles), or 
oligogenic (i.e. presence of a second, or more, gene modifying the effect of a dominant 
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gene) inheritance pattern. Thus, NTDs appear to follow a multifactorial threshold model in 
which the additive effects of multiple genetic and non-genetic risk factors above a certain 
“threshold” is required to precipitate the phenotype (Harris and Juriloff, 2007, Copp and 
Greene, 2010 , Copp et al., 2013). Notable environmental and genetic factors gleaned from 
clinical and epidemiological findings as well as studies on mice models are outlined below. 
 
1.3.4.1. Environmental factors 
Due to the multifactorial nature of NTDs, identification of independent, definitive 
environmental factors is difficult and often complicated by the contribution of genetic 
factors and gene-environment interactions. Table 1 provides an overview of notable non-
genetic factors with established associations to NTDs (Copp and Greene, 2010 ). Many 
other factors such as maternal smoking, alcohol use, stress, and water chlorination have 
been proposed. While these are plausible factors, studies yield largely inconsistent 
findings, show weak association, or are relatively rare, and thus they would only 
contribute to a small proportion of all NTD cases (Wyszynski, 2006, Copp et al., 2015). 
The link between poor nutrition and/ or lower socioeconomic status and birth defects has 
been observed since the Dutch winter famine of the mid-1900s. The biggest revelation to 
come out of pursuing this link is the finding that maternal folate status is an NTD risk 
factor, and that periconceptual folic acid supplementation is able to significantly reduce 
occurrence and recurrence of NTDs (see Section 1.4). 
In addition to folate, low maternal blood vitamin B12 levels was also discovered to be an 
independent NTD risk factor (Kirke et al., 1993, Suarez et al., 2003), that women in the 
group with the lowest levels of both folate and B12 demonstrated the highest risk (Kirke 
et al., 1993), and that this finding remains true in populations with or without folic acid 
fortification (Ray et al., 2007, Molloy et al., 2009b). 
Inositol deficiency was first shown to increase susceptibility to exencephaly of genetically 
predisposed, folate-resistant, curly tail mouse model in an embryo culture system 
(Cockroft et al., 1992). The spinal NTDs in curly tail embryos can be significantly rescued 
by myo-inositol and D-chiro-inositol through increased activation of specific isoforms of 
protein kinase C, which in turn increases proliferation in the hindgut of these embryos 
(Greene and Copp, 1997, Cogram et al., 2002, Cogram et al., 2004) (see Section 1.3.4.2.5). 
Studies of inositol deficiency in human NTDs is scarce, with just one study showing an 
association between low maternal inositol levels and a 2.6-fold increased risk of spina 
bifida (Groenen et al., 2003). This study also found an association between low maternal 
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zinc levels and increased spina bifida risk, zinc being another repeatedly cited 
micronutrient deficiency associated with NTDs with an unknown underlying mechanism 
(Milunsky et al., 1992). 
 
Environmental risk factor Proposed mechanism 
Maternal nutrition  
     Folate Disturbance in folate metabolism 
     B12 Disturbance in folate metabolism 
     Inositol Disturbance in downstream protein kinase C signalling 
Maternal diabetes 
     (hyperglycaemia) 
Disturbance in glucose homeostasis, increased production 
of reactive oxygen species, increased apoptosis 
Maternal obesity Unknown 
Maternal medication  
     Carbamazepine Folic acid antagonist 
     Trimethoprim Folic acid antagonist 
     Valproic acid Disturbance in histone deacetylase activity 
Other exposures  
     Fumonisin Disturbance in sphingolipid synthesis 
Maternal hyperthermia Unknown 
Table 1. Notable environmental risk factors associated with NTDs. 
 
Maternal diabetes has long been recognised as a risk factor for various organ 
malformations, including the central nervous system, heart, eye, kidney, lower limbs and 
lower spine (Martinez-Frias, 1994, Correa et al., 2008). Maternal genes involved in glucose 
homeostasis, type-2 diabetes, and obesity have been associated with NTDs. These include 
glucose transporter (GLUT1), leptin (LEP), leptin receptor (LEPR), hexokinase (HK1), and 
transcription factor 7-like 2 (TCF7L2) (Davidson et al., 2008, Carter et al., 2011, Lupo et al., 
2012). As pancreatic β cells do not develop until 7-8 weeks into gestation  after most 
organogenesis processes have passed (Jovanovic-Peterson and Peterson, 1993), it has 
been suggested that teratogenicity is caused by the developing embryo being unable to 
cope with a hyperglycaemic in utero environment brought about by maternal diabetes. 
The teratogenic effects of hyperglycaemia are hypothesised to occur through induction of 
changes in lipid peroxidation, resulting in increased production of reactive oxygen species 
which subsequently activates apoptotic pathways (Loeken, 2005, Reece, 2012). Induction 
of hyperglycaemia in mice was shown to inhibit Pax3 expression and increase 
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neuroepithelial apoptosis and rate of NTDs (Fine et al., 1999). There is recent evidence 
that activation of the ASK1-FoxO3a-Caspase 8 pathway occurs in hyperglycaemic states 
through oxidative stress, resulting in increased apoptosis in the neuroepithelium of 
diabetic mice. Deletion of Ask1, FoxO3a or Casp8 in these mice was able to reduce 
apoptosis and NTD incidence (Yang et al., 2013).  
Many studies over the years have associated pregnancy weight, both underweight and 
overweight, to NTDs [reviewed in Wyszynski (2006) and Carmichael et al. (2010)] and 
other congenital malformations. Maternal obesity is often quoted as an NTD risk factor 
alongside diabetes, but it is not clear if obesity, without the effects of hyperglycaemia or 
other confounding factors (e.g. maternal nutrition or history of NTD-affected pregnancy), 
is in itself a risk factor. Studies have found association between overweightness and 
obesity with increased NTD risk when pre-existing diabetic mothers were excluded 
(Watkins et al., 2003). It should be noted, however, that some of the women may have 
undiagnosed diabetes or pre-diabetic glucose intolerance. Hyperinsulinaemia was found 
to be an NTD risk factor independent of diabetic history, and has been hypothesised to 
cause the increased risk in obese women (Hendricks et al., 2001).  
In addition to nutritional risk factors, other substances and conditions have been 
identified as teratogenic and disruptive to neural tube closure. These include folate 
antagonists such as carbamazepine and trimethoprim, contaminants such as fumonisin, 
the anti-convulsant drug valproic acid, and maternal hyperthermia (Copp and Greene, 
2010 , Copp and Greene, 2013).  
The observation of low maternal folate being linked to increased NTD risk prompted 
research into folic acid antagonists (FAA) as potential risk factors. Hernandez-Diaz et al. 
(2001) looked into maternal exposure of FAAs in NTD-affected pregnancies and found 
increased risk upon exposure to the antiepileptic drug carbamazepine and antibiotic 
trimethoprim (taken in combination with a sulphonamide). This risk was further 
increased in mothers without folic acid supplementation. The effect of carbamazepine on 
NTD risk was also noted in other studies (Kaaja et al., 2003, Werler et al., 2011).  
Antiepileptic drugs have long been linked to congenital malformations (Wlodarczyk et al., 
2012). Where NTDs are concerned, the effects of valproic acid (VPA) was first noticed by 
Robert and Guibaud (1982) and later listed (alongside carbamazepine) to show 
association with increased risk of congenital malformations, notably NTDs, in mothers on 
antiepileptic medication (Kaaja et al., 2003, Werler et al., 2011).  VPA is also capable of 
inducing NTDs in rodent models (Finnell et al., 1988, Ehlers et al., 1992, Menegola et al., 
2005). VPA is proposed to cause its teratogenic effect by inhibiting histone deacetylase 
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(HDAC) activity and causing hyperacetylation in embryos, a hypothesis that is supported 
by similar findings with another HDAC inhibitor, Trichostatin A (Menegola et al., 2005). 
Fumonisin is a corn mould mycotoxin that was shown to inhibit sphingolipid biosynthesis, 
leading to disruption of cellular uptake of 5-methyl-THF by glycosylphosphatidylinositol 
(GPI)-anchored folate receptors in vitro (Stevens and Tang, 1997). Fumonisin-induced 
disturbance in sphingolipid synthesis is also suggested to affect other cell signalling 
pathways that are important to neurulation. Increased maternal exposure to fumonisin 
from ingestion of contaminated corn products was found to be associated with increased 
risk of NTDs (Missmer et al., 2006). Fumonisin treatment also induced NTDs in a rodent 
embryo culture system which could be partially rescued by co-treatment with folinic acid 
(Sadler et al., 2002), as well as in a mouse in vivo model which could be partially rescued 
by folic acid (Gelineau-van Waes et al., 2005, Gelineau-van Waes et al., 2012). 
Hyperthermia is commonly reported as an NTD-causing teratogen in many rodents 
(Edwards, 1986, Finnell et al., 1986). A meta-analysis of cases of maternal hyperthermia 
during the first trimester of pregnancy, caused by fever or external heat sources such as 
saunas, found an association between hyperthermia and increased risk of NTDs in humans 
as well (Moretti et al., 2005). 
 
1.3.4.2. Genetic factors 
A strong case can be made for the presence of a genetic predisposition to NTDs from 
family history of NTD-affected pregnancies. There exists a recurrence risk of 2 to 5% 
among siblings that cannot be accounted for by exposure to a similar environmental 
teratogen. In addition, twin studies revealed a higher penetrance in monozygotic 
compared to dizygotic twins, which would be expected if a genetic component is present 
(Detrait et al., 2005, Deak et al., 2008, Knox, 1974). Chromosomal aberrations such as 
trisomy 18 and trisomy 13 are often reported in NTDs, especially in encephalocoele and 
spina bifida (often accompanied by additional anomalies), and tend to result in 
spontaneous abortions (Coerdt et al., 1997, Kennedy et al., 1998, Sepulveda et al., 2004). 
A striking gender bias exists in the occurrence of anencephaly, with consistently higher 
prevalence in females in both humans and mice (Juriloff and Harris, 2012b). Extreme 
examples of this gender bias, in which exencephaly occurs almost exclusively in females, is 
seen in some mice models such as the Trp53 and Nf1 mutants (Harris and Juriloff, 2007). 
The cause of this female preponderance is not known, and several hypotheses that have 
been proposed include inactivation of one X chromosome, death of affected males, and 
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developmental delay in females (Juriloff and Harris, 2012b). Data from Chen et al. (2008) 
suggested that incidence of NTDs in p53-null mice with transgene manipulation of the 
testis-determining gene Sry was higher when two copies of the X chromosome are present, 
independent of the presence or absence of the Y chromosome.  However, the mechanism 
by which two X chromosomes can confer higher risk of NTDs is still unknown. 
The search for NTD candidate genes tends to follow two main strategies: genes found to 
result in NTDs when mutated in mice, and genes related to known environmental factors 
such as maternal hyperglycaemia and folate metabolism (Greene and Copp, 2014). It must 
be noted that there are three times as many NTD mice models with exencephaly as there 
are spina bifida, which have to be taken into consideration when evaluating NTD mice 
models. In addition, many mice models with a single-gene knockout can result in NTDs, 
some with almost full penetrance in homozygotes, which is unlike the polygenic or 
oligogenic patterns of human NTDs. Nevertheless, mice models have been valuable in 
identifying pathways in which to look for candidate genes for human NTDs and have 
greatly contributed to the understanding of the cell biology of mammalian neurulation 
(Copp and Greene, 2010 ). A comprehensive list of over 200 NTD mice models was 
provided in Harris and Juriloff (2007) and Harris and Juriloff (2010), and a few pathways 
are noted as followed. 
 
1.3.4.2.1. Planar cell polarity genes 
The planar cell polarity (PCP) pathway is required for convergent-extension in the neural 
plate. A defect in PCP signalling results in the widening of the midline during gastrulation, 
such that the neural folds become spaced too far apart to close (Ybot-Gonzalez et al., 
2007b). Mutations in many PCP pathway genes (e.g. Scrb1, Vangl2, Celsr1, and Dvl family) 
prevent closure 1 from happening and result predominantly in craniorachischisis when 
present in homozygosity (e.g. Celsr1-/- and Vangl2Lp/Lp) or as digenic mutants in various 
combinations (e.g. Vangl2Lp/+;Celsr1Crsh/+, Vangl2Lp/+;Scrb1+/-, Dvl1-/-;Dvl2-/-, and 
Vangl2Lp/+;Dvl2-/-) (Murdoch et al., 2003, Murdoch et al., 2001a, Curtin et al., 2003, Hamblet 
et al., 2002, Etheridge et al., 2008, Murdoch et al., 2001b, Wang et al., 2006, Juriloff and 
Harris, 2012a).  
In humans, putative mutations in core PCP (e.g. VANGL1, VANGL2, CELSR1, and PRICKLE1) 
and PCP-related genes (e.g. SCRIB and LRP6) have been found in patients with various 
NTD types including craniorachischisis, anencephaly and open and closed spina bifida 
(Kibar et al., 2007, Merello et al., 2015, Lei et al., 2010, Robinson et al., 2012, Lei et al., 
2013, Allache et al., 2014). Putative mutations in VANGL1, VANGL2, and CELSR1 were also 
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found in defects of secondary neurulation, especially involving the filum terminale (Juriloff 
and Harris, 2012a). 
1.3.4.2.2. Sonic hedgehog and BMP genes 
The sonic hedgehog (Shh) and bone morphogenetic protein (BMP) signalling pathways act 
in antagonism to one another in dorso-ventral patterning of the neural tube. They are both 
implicated in NTDs in mice. Ectopic expression of Shh and mutations in negative 
regulators of Shh signalling, e.g. Ptch1, Sufu, Rab23, and Tulp3, result in exencephaly 
and/or spina bifida (Echelard et al., 1993, Goodrich et al., 1997, Cooper et al., 2005, 
Gunther et al., 1994, Eggenschwiler et al., 2001, Ikeda et al., 2001, Patterson et al., 2009, 
Murdoch and Copp, 2010). This indicates that increased activation of Shh signalling, 
resulting in an expansion of ventral markers, prevents neural tube closure.  
Various cellular mechanisms have been proposed for the action of Shh in the NTD 
phenotype, such as disruption in the balance of neuroepithelial cell proliferation, 
differentiation, and apoptosis. The most persuasive evidence is that of inhibition of DLHP 
formation by ventral Shh signalling (Ybot-Gonzalez et al., 2002). Shh and BMP signalling is 
able to inhibit the BMP antagonist, noggin, which is required for appropriate dorsolateral 
bending. Zic2Ku/Ku mutants (i.e. Kumba mutants where there is loss of function of Zic2) 
display downregulated noggin expression, lack DLHPs, and develop spina bifida (Ybot-
Gonzalez et al., 2007a). 
1.3.4.2.3. Proliferation, differentiation, and apoptosis genes 
Mice with mutations in genes that regulate or alter cell-cycle progression and/or 
proliferation, e.g. Jarid2 or jumonji, Nf1, and Nup50 (Takeuchi et al., 1995, Lakkis et al., 
1999, Smitherman et al., 2000), neuronal differentiation, e.g. Pax3 and Notch pathway 
genes like Hes1 and Notch3 (Epstein et al., 1991, Ishibashi et al., 1995, Lardelli et al., 1996), 
and apoptosis, e.g. Bcl10, Apaf1, and Casp3/9 (Ruland et al., 2001, Yoshida et al., 1998, 
Kuida et al., 1998 ) often exhibit exencephaly. This suggests that cranial neurulation is 
especially sensitive to perturbations in the balance between neuroepithelial cell 
proliferation, differentiation, and death. However, the precise morphological changes 
underlying the NTDs in these mutants and which step of neurulation is affected remain 
unclear. The role of apoptosis is further complicated by conflicting evidence: mutations 
that result in either excessive or insufficient cell death can result in NTDs, but embryos 
treated with apoptosis inhibitors showed no effect on neurulation (Massa et al., 2009 ). 
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1.3.4.2.4. Genes in cytoskeletal regulation 
Exencephaly (and much less commonly, spina bifida) occurs in mutants of cytoskeletal 
components, e.g. vinculin, shroom and n-cofilin, as well as signal transduction proteins 
involved in cytoskeletal assembly, e.g. MARCKS, p190 RhoGAP, and Mena/VASP (Xu et al., 
1998, Hildebrand and Soriano, 1999, Gurniak et al., 2005, Stumpo et al., 1995, Brouns et 
al., 2000, Menzies et al., 2004, Copp and Greene, 2010 ). In addition, earlier studies with 
embryos treated with cytoskeletal-disrupting teratogens also resulted in exencephaly but 
not spina bifida (Ybot-Gonzalez and Copp, 1999), revealing a higher sensitivity to 
cytoskeletal disruptions in cranial neurulation.  
1.3.4.2.5. Curly tail model 
The curly tail (ct) mouse is one of the most extensively studied NTD mouse model and 
demonstrates how a defect in adjacent, non-neural tissue can give rise to a failure of 
neural tube closure on mechanistic grounds. In the ct mouse, an increase in ventral 
curvature of the caudal region prevents the neural folds of the posterior neuropore from 
elevating and fusing, resulting in spina bifida (Brook et al., 1991). This increased curvature 
is brought about by an imbalance between decreased proliferation of hindgut endoderm, 
and normal proliferation of the neuroepithelium. The gene responsible for the ct 
phenotype remained elusive for many decades (van Straaten and Copp, 2001), and was 
finally discovered to be grainyhead-like 3 (Grhl3) (Ting et al., 2003, Gustavsson et al., 
2007). The effect of the Grhl3 mutation is also influenced by modifier genes: the presence 
of a variant of the lamin B1 gene (Lmnb1) disrupts nuclear morphology, cell-cycle 
progression, and proliferative capacity of hindgut epithelium, and significantly increases 
NTD incidence in Grhl3ct mutants (De Castro et al., 2012). 
 
Informative as mice models are, the search for associations between mutations in mice 
models and cases of human open NTDs  have yielded largely insignificant results (Boyles 
et al., 2005, Greene et al., 2009). The only mutations that consistently show significant 
association, whether through NTD mice models or environmental risk factors, are those 
that encode maternal hyperglycaemia and/or obesity-related proteins, components of the 
PCP pathway and folate metabolism (see following section). It should be noted, however, 
that most studies have only focussed on specific polymorphisms. There is limited 
availability of whole exome data, and regulatory mutations have not been considered to a 
great extent. Identification of NTD risk alleles would likely require large-scale next 
generation sequencing with large patient cohorts.  
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1.4. Folate metabolism and NTDs 
 
1.4.1. History of folic acid treatment 
The association between folate status and NTDs first started with observations made on 
the Dutch famine or “Hunger Winter” of 1944, when poor nutrition was observed to 
precipitate developmental defects. Kalter and Warkany (1959) conducted animal studies 
and found that feeding pregnant mothers with vitamin-deficient diets or vitamin 
antagonists induced developmental defects in their foetuses. In the same period, a link was 
made between folic acid deficiency during pregnancy and megaloblastic anaemia in 
addition to defective foetal growth (Chanarin et al., 1959). The anaemia was found to 
respond to folic acid treatment (Gatenby and Lillie, 1960). Hibbard and Hibbard (1963) 
then found a relationship between maternal folic acid deficiency and abruptio placentae 
alongside a high incidence of megaloblastic anaemia. However, up until then, there was no 
clear evidence to link nutritional deficiency with foetal malformations in humans. 
In 1964, a study conducted in Liverpool was published, suggesting a possible relationship 
between folic acid deficiency and foetal malformation (Hibbard, 1964). They presented 
evidence that a deficiency in folate metabolism causing a deficiency in folic acid (that may 
not be caused by insufficient dietary intake) could produce megaloblastic anaemia, 
abruptio placentae, and possible foetal malformations. They also observed that folic acid 
deficiency has a tendency to recur in successive pregnancies. The same group then found 
that women near delivery who had babies with severe (mostly CNS) malformations 
excreted abnormally high levels of formiminoglutamic acid (FIGLU), which indicated 
impaired folate absorption or metabolism (Hibbard and Smithells, 1965). 
In the 1970s, Smithells et al. began scrutinising the link between maternal diet and NTDs. 
They found that women with NTD-affected pregnancies showed significantly lower red 
blood cell folate and white blood cell vitamin C compared with control groups, supporting 
the hypothesis that nutritional deficiencies can cause significant disturbances to CNS 
development (Smithells et al., 1976). They also reported that social class, maternal age, 
smoking, and vomiting during pregnancy can influence maternal diet during early 
pregnancy at the critical period for neural tube development (Smithells et al., 1977). These 
findings prompted them to investigate the prophylactic use of vitamin supplementation 
using a commercially available mixture of vitamins and folic acid to prevent NTDs, leading 
to a preliminary intervention study (Smithells et al., 1980) that then expanded into the 
Leeds Intervention Studies (Smithells et al., 1981). These intervention studies found 
highly significant, 7-fold decrease in NTD recurrence in the supplemented group 
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compared to unsupplemented, and they suggested repeating the study with a more 
selective mix of vitamins or with folic acid alone. Further evidence on a possible protective 
effect by folic acid then came in subsequent studies (Smithells et al., 1983, Schorah et al., 
1983, Seller and Nevin, 1984, Sheppard et al., 1989, Smithells et al., 1989, Bower and 
Stanley, 1989, Milunsky et al., 1989, Mulinare et al., 1988). However, many of these 
findings were met with criticism due to the lack of randomised, double-blinded trial 
designs which had not been approved to them by research ethics committees (Oakley et 
al., 1983, Elwood, 1983, Wald and Polani, 1984). Most of these trials also used a 
multivitamin mix which did not single out folic acid as the main preventive element. 
Finally, a randomised, double-blinded prevention trial was approved and carried out by 
the Medical Research Council (MRC). Experimental groups were given supplements of folic 
acid alone, other vitamins, both, or neither. Folic acid dose was at 4 mg/day, while that of 
other vitamins were relatively low. The folic acid-containing groups showed a 72% 
protective effect (calculated from a relative risk of 0.28, 95% confidence interval 0.12-
0.71) while that of the other vitamins showed a decrease in relative risk that was not 
significant compared to controls (MRC, 1991). This provided conclusive evidence for the 
effectiveness of maternal folic acid supplementation during the periconception period in 
preventing recurrence of NTDs. Maternal folic acid supplementation was then shown to 
also reduce the first occurrence of NTDs in Hungary by about 70% (Czeizel and Dudas, 
1992). Since then, further studies followed that linked folate metabolism with NTDs. 
Reduced maternal folate levels and elevated maternal homocysteine levels (an inverse 
marker of folate cycle production of 5-methyl-THF) are now well-established risk factors 
of NTDs (Kirke et al., 1993, Molloy et al., 1998, Steegers-Theunissen et al., 1994, Mills et al., 
1995).  
Soon after the results of the MRC and Hungarian trials, periconceptional folate 
supplementation was recommended by most governments to all women or women 
planning a pregnancy (Cornel and Erickson, 1997, Lee, 2013). However, the stages of 
neural tube closure are completed before many pregnancies are noticed, especially if 
unplanned, thus prevalence of NTDs was not significantly reduced by simply 
recommending supplementation (Botto et al., 2005, Blencowe et al., 2010). In the United 
Kingdom and Ireland, assessing the effectiveness of supplementation policies was 
complicated by the already declining rates of NTDs of 12-16 per 10,000 births in the 
1990s compared with 49 per 10,000 births in 1980, though the decline might itself be a 
result of overall improved diet and folate status (Busby et al., 2005). 
Several countries such as USA, Canada, South Africa, and most of Latin America introduced 
mandatory fortification of cereal grains with folic acid to ensure adequate folic acid 
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consumption by all women, which led to raised blood folate levels and a significant 
decrease in prevalence of NTDs (Honein et al., 2001, Lawrence et al., 1999, De Wals et al., 
2007, Sayed et al., 2008, Hertrampf and Cortes, 2004, Rosenthal et al., 2014, Yoshida and 
Kikuchi, 1972). The preventive effect of folic acid appeared to be highest in countries, even 
regions within a country, with higher pre-existing “baseline” rates of NTDs (De Wals et al., 
2007, Rosenthal et al., 2014), while countries that do not implement mandatory folic acid 
fortification of foods, i.e. Europe, did not show any significant decrease in NTD prevalence 
(Busby et al., 2005). 
It is interesting to note that prevention of NTDs has never reached 100%, with a 70% 
estimated reduction in NTD recurrence and 62% in primary occurrence globally 
(Blencowe et al., 2010). In the United States, mandatory fortification of food with folic acid 
decreased the overall prevalence of NTDs by 19-32% (Crider et al., 2011), but taking 
additional folic acid supplements does not appear to confer any further protective effect 
(Mosley et al., 2009). In other countries where mandatory fortification is carried out, e.g. 
Canada and Latin America, the decline in NTD prevalence still leaves a baseline prevalence 
of 5-6 per 10,000 pregnancies (Crider et al., 2011). This strongly indicates that folic acid 
fortification is highly effective in reducing prevalence of folic acid-sensitive NTDs 
especially in high-risk populations. However, a proportion of remaining NTD cases appear 
to be resistant to folic acid and increasing the dosage of folic acid is not likely to be 
effective (Heseker et al., 2009). 
Despite the link between folate metabolism and NTDs provided by the intervention 
studies, and the success of folic acid supplementation and fortification, a direct causal 
relationship between defective FOCM and NTDs remains unclear. While there is evidence 
noting that risk of an NTD pregnancy is inversely proportional to red blood cell folate 
concentration (Daly et al., 1995, Arakawa et al., 1972), it should be noted that most women 
with NTD-affected pregnancies had folate levels within the ‘normal’ range (Kirke et al., 
1993). This indicates that while blood folate levels can serve as a predictor of NTD risk, 
having a normal folate status does not eliminate the risk of having an affected pregnancy. 
It also suggests that folic acid supplementation may be producing its protective effect in 
ways other than simply correcting a nutritional deficiency. Metabolic studies carried out 
on cell lines derived from NTD patients indicated that genetically-determined 
abnormalities in foetal folate metabolism may be contributing to the development of some 
NTDs (Dunlevy et al., 2007). 
The evidence for a genetic predisposition to NTDs and the protective effect of folic acid 
make genes encoding folate-metabolising enzymes good candidates as NTD risk genes and 
targets for exploring gene-environment interactions.   
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1.4.2. Folate one-carbon metabolism 
Folate one-carbon metabolism (FOCM) comprises a large network of enzymatic reactions 
that convert one folate species to another by shuttling one-carbon (1C) units in the form of 
methyl groups between them. Folates are obtained through dietary sources such as green 
leafy vegetables (e.g. spinach, broccoli, and Brussels sprouts), dried beans and peas, citrus 
fruits, and liver (Brouwer et al., 1999, Matherly and Hou, 2008), with folic acid being a 
synthetic form that is converted to tetrahydrofolate (THF) upon entry into the folate cycle. 
1C units are derived from various donors such as serine, glycine and methionine, which in 
turn can be obtained through dietary means or in vivo biosynthesis pathways. Through 
FOCM reactions, 1C units are directed to de novo synthesis of thymidylate and purines, the 
methylation cycle, and polyamine synthesis (Beaudin and Stover, 2009).  
 
1.4.2.1. Folate transport mechanisms 
The basic structure of a folate compound is a 2-amino-4-hydroxy-pteridine double ring 
connected to a p-aminobenzoic acid ring which is linked to glutamic acid (Figure 3). In its 
various oxidation states, 1C units are added to the N-5 and/or N-10 positions. Folates can 
exist in polyglutamated, i.e. containing a chain of five to eight glutamate peptides (longer 
in mitochondrial folates), or monoglutamated form (Blom et al., 2006, Tibbetts and 
Appling, 2010). Polyglutamated folates are the form that dietary folates mostly comprise 
of, and that is used for storage or retention within cells. On the other hand, folates have to 
be transported through cell membranes in monoglutamated forms due to the high affinity 
binding of folate transport proteins to the monoglutamates. As such, transport of folates 
first begins with conversion of dietary folates to their monoglutamated forms to allow 
intestinal absorption (Zhao et al., 2009, Visentin et al., 2014).  
Cleaving of the glutamate moieties is carried out by the intestinal glutamate 
carboxypeptidase II (GCPII, or folate hydrolase) enzyme. Another enzyme that does this is 
γ-glutamyl hydrolase (γ-GH), an intracellular hydrolase localised in the lysosome of 
enterocytes and hepatocytes. γ-GH removes glutamate residues of stored folates to allow 
release of their monoglutamated forms (primarily as 5-methyl-THF) into systemic 
circulation and to be taken up by target tissue (Visentin et al., 2014). In rodents, intestinal 
cleavage is achieved by γ-GH and not GCPII (Shafizadeh and Halsted, 2007). Within cells, 
folypoly-γ-glutamate synthetase (FPGS) reattaches the glutamate residues, converting the 
monoglutamates back to their polyglutamated forms so that they can be retained for 
storage or participation in FOCM reactions (Tibbetts and Appling, 2010).  
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Figure 3. Structural representation of tetrahydrofolate. 
Tetrahydrofolate (THF) consists of a double ring structure connected to p-aminobenzoic 
acid capped with a glutamate tail (grey dotted box). 1C units (red) are added to THF at the 
N-5 and/or N-10 positions (green dotted boxes) in the form of methyl (N-5 only), formyl 
(N-5 or N-10), or methylene (N-5, N-10 bridge) moieties. Glutamate molecules are added 
at the terminal γ-carboxyl residue (-COO-) to form polyglutamated chains.  
Adapted from: Blom et al. (2006), Zhao et al. (2009) and Tibbetts and Appling (2010) 
 
The passage of folates through cell membranes is facilitated by various membrane 
transport proteins [reviewed by Zhao et al. (2011) and Visentin et al. (2014)]. A major 
transporter of folate in mammalian cells is the transmembrane protein, reduced folate 
carrier (RFC, or SLC19A1). RFC is expressed in all tissue and cell types and is the main 
route of entry for folates into cells. It also aids in intestinal absorption, transport across 
the blood-brain barrier, renal tubular secretion and reabsorption, and transplacental 
transfer of folates (Matherly and Hou, 2008). 
Another route through which uptake of cellular folate is achieved is via folate receptors 
(FRs) in humans, or their murine homologues, the folate-binding proteins (Folbps, or 
Folrs). FRs are GPI-anchored, high-affinity receptors that, unlike the ubiquitous RFC, show 
tissue-specific expression. The FRα and FRβ isoforms are expressed in foetal, placental 
and adult tissue, with FRα localising in epithelial tissue and FRβ in hematopoietic tissue 
(Zhao et al., 2011). The isoforms also have varying folate-binding affinities, FRβ being the 
weaker of the two (Ross et al., 1994). 
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The proton-coupled folate transporter (PCFT, or SLC46A1, previously known as pH-
independent heme carrier protein, HCP1) is a relatively new addition to the folate 
transport mechanism. It was first implicated as the optimal means of folate transport at 
more acidic pH (Qiu et al., 2006), when RFC, which has optimal activity at neutral pH, was 
still considered the prime route through which folates are absorbed in the gut and 
received in cells from circulation. It is now known that while RFC is still largely 
responsible for the latter, PCFT holds a critical role in intestinal absorption of folate (Zhao 
et al., 2011), and mutations in human PCFT were found in patients with hereditary folate 
malabsorption syndrome (Qiu et al., 2006, Zhao et al., 2007). 
The mitochondrial folate transporter (MFT) is a specific carrier with which folates 
transverse mitochondrial membranes (Titus and Moran, 2000, McCarthy et al., 2004, 
Lawrence et al., 2011). In both the cytoplasm and mitochondria, the monoglutamated 
folates are converted back to their polyglutamated forms to participate in one-carbon 
metabolism. The FPGS enzyme is also present in the mitochondria to help maintain 
mitochondrial folate pools, as polyglutamated folates are unable to cross the 
mitochondrial membrane (Lawrence et al., 2014). 
 
1.4.2.2. Compartmentalisation of FOCM reactions  
In the cytoplasm (Figure 4 - unshaded area), dietary folates enter the one-carbon cycle 
primarily as 5-methyltetrahydrofolate (5-methyl-THF) and is a substrate for methionine 
synthase (MS) (also known as 5-methyltetrahydrofolate-homocysteine-methyltransferase, 
MTR). The 1C/methyl group from 5-methyl-THF is transferred by MTR to homocysteine 
generating methionine and THF. Methionine then enters the methylation cycle while THF 
is utilised in the folate cycle. MTR requires the presence of vitamin B12 as a cofactor, and 
is dependent on methionine synthase reductase (MTRR) for activation.  
THF can receive a 1C unit and be converted to 5,10-methylene-THF, either in a 3-step 
reaction catalysed by a cytoplasmic member of the methylenetetrahydrofolate 
dehydrogenase (MTHFD) family, the trifunctional MTHFD1, or by the action of serine 
hydroxymethyltransferase 1 (SHMT1). 
MTHFD1 has three domains which mediate different activities that act in sequential order. 
First, the 10-formyl-THF synthetase domain combines THF with available formate (the 1C 
source) and generates 10-formyl-THF, followed by 5,10-methenyl-THF cyclohydrolase 
which converts that to 5,10-methenyl-THF, and lastly 5,10-methylene-THF dehydrogenase 
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which finally yields 5,10-methylene-THF (Momb et al., 2013). 10-formyl-THF is also a 
purine precursor, and may be shuttled towards de novo purine biosynthesis. 
SHMT1, or cytoplasmic SHMT, breaks down serine to obtain 1C units in the presence of 
THF, thus generating glycine and 5,10-methylene-THF. SHMT can also catalyse conversion 
of 5,10-methenyl-THF to 5-formyl-THF, which does not participate in FOCM reactions but 
may be a stable storage form. The reverse reaction is catalysed by 5,10-
methenyltetrahydrofolate synthetase (MTHFS) (Field et al., 2011). 
5,10-methylene-THF, the product of MTHFD1 or SHMT1-catalysed reactions, has two 
fates. Thymidylate synthase (TYMS) may transfer its 1C unit to deoxyuridine 
monophosphate (dUMP) to generate thymidine monophosphate or thymidylate (dTMP), 
as part of the de novo thymidylate synthesis pathway. This reaction also produces 
dihydrofolate (DHF), which is subsequently reduced to THF by dihydrofolate reductase 
(DHFR) (Tibbetts and Appling, 2010). Folic acid enters FOCM at this point, being reduced 
to DHF. 5,10-methylene-THF may alternatively serve as a substrate for 5,10-
methylenetetrahydrofolate reductase (MTHFR) which irreversibly converts it to 5-methyl-
THF and shunts the 1C unit towards the methylation cycle.  
In more recent studies, there is increasing emphasis on the importance of the highly 
compartmentalized nature of FOCM reactions, with particular interest in mitochondrial 
reactions (Tibbetts and Appling, 2010, Christensen et al., 2014). Stable isotope labelling in 
cell culture revealed that the mitochondria supplies greater than 75% of one-carbon units 
that are used in methylation reactions in the cytoplasm (Pike et al., 2010).  
In the mitochondria (Figure 4 – pink shaded area), conversion of THF to 5,10-methylene-
THF is achieved either through the AMT-catalysed step of the GCS (Figure 1, Section 
1.1.1), or through the reaction of mitochondrial SHMT (SHMT2) (Anderson and Stover, 
2009). Either route serves to attach a 1C unit, donated from glycine (AMT) or serine 
(SHMT2), to THF.  
Another member of the MTHFD family, the mitochondrial MTHFD2 in embryonic tissue 
(or its isozyme MTHFD2L in adult tissue), is a bifunctional enzyme that carries out the 
dehydrogenase and cyclohydrolase steps to yield 10-formyl-THF (Bolusani et al., 2011). 
The synthetase step to convert 10-formyl-THF to THF is carried out by MTHFD1L, which 
unlike its cytoplasmic, trifunctional counterpart MTHFD1, only shows 10-formyl-THF 
synthetase activity (Walkup and Appling, 2005). This step releases formate from 10-
formyl-THF, which regenerates THF, thus restarting the cycle. Most mitochondrial-derived 
formate enters the cytoplasm to participate in cytosolic FOCM reactions (Pike et al., 2010). 
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Figure 4. Overview of folate one-carbon metabolism. 
Folate one-carbon metabolism (FOCM) is compartmentalised to cytoplasmic, mitochondrial, and nuclear (not shown) reactions. Dietary folates enter the 
cycle primarily as 5-methyl-THF. The methylation cycle (purple-shaded area) is closely linked to the one-carbon cycle through the action of MTR, which 
transfers the 1C unit from 5-methyl-THF to homocysteine to generate methionine and THF. Methionine is converted to S-adenosyl methionine (SAM) and 
used in the methylation cycle as a 1C donor for methyltransferases or as substrate for polyamine synthesis. 
THF in the cytoplasmic one-carbon cycle (unshaded area) combines with formate (majority of which is generated by the mitochondrial cycle) to form 10-
formyl-THF (which may enter the purine synthesis pathway) and subsequently converted to 5,10-methylene-THF by MTHFD1. THF may also receive 1C 
units from serine to generate 5,10-methylene-THF through the action of SHMT1. 5,10-methylene-THF then either donates its 1C unit to dUMP for 
pyrimidine synthesis and regenerates THF in the process, or reduced by MTHFR to regenerate 5-methyl-THF. 
In the mitochondria (pink-shaded area), THF combines with 1C units generated primarily from serine and glycine sources (through SHMT2 and the 
glycine cleavage system).  The  action of MTHFD2/2L and MTHFD1L produces formate and regenerates THF. 
Adapted from: Copp et al. (2013) and Tibbetts and Appling (2010) 
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Figure 4. Overview of folate one-carbon metabolism. 
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1.4.2.3. FOCM outputs  
The main outputs of FOCM are de novo biosynthesis of purines, thymidylate, and 
transferable methyl groups for which methylation processes are the biggest use.  
De novo purine synthesis in mammals is a 10-step pathway catalysed by six enzymes to 
produce inosine monophosphate (IMP), the precursor to the adenine and guanine bases. 
The two folate-dependent enzymes of this pathway are the trifunctional GART1 and 
bifunctional ATIC2, which incorporate 1C units from 10-formyl-THF into the purine ring 
(Knox et al., 2009, Zhao et al., 2014, Field et al., 2011). The salvage pathway converts an 
already-produced precursor, hypoxanthine, back to IMP by action of the enzyme HPRT3 
(Zhao et al., 2014).  
Synthesis of the thymine pyrimidine also occurs through de novo synthesis or a salvage 
pathway. In the de novo pathway, 5,10-methylene-THF supplies the 1C for methylation of 
dUMP to dTMP by TYMS. dTMP is then further phosphorylated to form the triphosphate, 
dTTP, the precursor to the thymine base. The salvage pathway converts thymidine to 
thymidylate through the action of thymidine kinase 1 (TK1).  Both pathways also exist 
within the mitochondria for regulation of mitochondrial dTTP pools (Anderson et al., 
2011).  
In the methylation cycle, methionine is converted to S-adenosyl methionine (SAM) 
through action of methionine adenosyltransferase (MAT). SAM serves as a 1C donor to 
methylate DNA, RNA, proteins and lipids. Methyltransferases such as DNA 
methyltransferase (DNMT), RNA methyltransferase (RNMT), protein arginine 
methyltransferase (PRMT), and isoprenylcysteine carboxyl methyltransferase (ICMT), 
utilise 1C units from SAM converting it to S-adenosyl homocysteine (SAH). SAH is 
hydrolysed to homocysteine by adenosylhomocysteine hydrolase (AHCY). Remethylation 
of homocysteine to methionine can be catalysed by MTR or betaine-homocysteine-
methyltransferase (BHMT) (Locasale, 2013, Greene et al., 2011). 
Another fate of SAM is as substrate for SAM decarboxylase (SAMDC) in polyamine 
synthesis, for conversion of putrescine to spermidine and spermidine to spermine. 
Polyamines are implicated in multiple processes such as DNA conformational changes, 
cancer cell proliferation, glutamate receptor potentiation, and free-radical scavenging 
(Casero and Marton, 2007, Pegg, 2009).  
                                                          
1 Phosphoribosylglycinamide formyltransferase (GARFT)/ phosphoribosylglycinamide synthetase 
(GARS)/ phosphoribosylaminoimidazole synthetase (AIRS) 
2 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICART)/ IMP 
cyclohydrolase 
3 Hypoxanthine phosphoribosyltransferase 
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1.4.3. Association between genetic polymorphisms of FOCM genes with NTDs 
MTHFR was the first folate enzyme-encoding gene in which a polymorphism was found 
that was significantly associated with human NTDs. Severe deficiency in MTHFR is an 
inborn error of metabolism characterised by hyperhomocysteinemia and homocystinuria 
and, in severe cases, can result in postnatal lethality within the first year.  
van der Put et al. (1995)’s study was among the earliest to report a higher incidence of the 
677C>T (A222V) variant of the MTHFR gene in Dutch NTD triads compared to controls. In 
a large genetic study of the variant in the Irish population, significant association with 
NTDs was found with patient TT genotype (i.e. homozygous for the 677C>T variant), but 
not with mothers (i.e. maternal TT genotype) (Shields et al., 1999). A meta-analysis 
performed by Botto and Yang (2000) reported increased spina bifida risk with a TT 
genotype (as well as a combination of the 677C>T and 1298A>C variants) in the infant or 
mother. Both variants have since been screened in many populations and the 677C>T is 
now an established NTD risk factor. However, this association is not found in all 
populations and most TT individuals are apparently healthy [reviewed by Boyles et al. 
(2005), Molloy et al. (2009a) and Greene et al. (2009)]. 
The significant findings in MTHFR spurred a search for variants in other FOCM-related 
genes, but these studies have generated largely negative, inconsistent or conflicting 
results. These include genes for enzymes within the one-carbon cycle (e.g. MTHFD2, 
SHMT1 and DHFR), homocysteine remethylation (e.g. MTR, MTRR and BHMT), methylation 
reactions (e.g. PRMT1 and PRMT2), purine or pyrimidine synthesis (e.g. GART and TYMS), 
and folate carriers (e.g. RFC1, GCPII, FRα and FRβ) (Boyles et al., 2005, Molloy et al., 2009a, 
Greene et al., 2009). The limitation of most of these studies is that only specific 
polymorphisms were studied. Results from large scale sequencing studies, which may 
reveal causative mutations, are awaited. Nevertheless, several genes conferring significant 
risk have been successfully identified. 
The 1958G>A (R653Q) mutation in MTHFD1 was first suspected to be a risk factor in a 
Dutch population (Hol et al., 1998) and later found to be associated with spina bifida in an 
Irish population (Brody et al., 2002), especially when present as a maternal homozygous 
AA genotype (Parle-McDermott et al., 2006). However, another study in the Dutch 
population a decade after the 1998 study did not find any association with spina bifida 
risk (van der Linden et al., 2007). A polymorphism in the MTHFD1L gene encoding the 
mitochondrial isozyme of MTHFD1 was also found to be strongly associated with NTDs in 
the Irish population (Parle-McDermott et al., 2009). A larger study looking at common 
variants in 82 candidate NTD genes in the Irish population picked up variants in 9 genes 
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that showed the most significant associations (Pangilinan et al., 2012). These included 
genes that have previously been looked at, such as MTHFD1, GART (purine synthesis), and 
DNMT3A (methylation reactions). They also identified significant association with a new 
gene, MFTC, which encodes the mitochondrial folate transporter. 
Of the FOCM-related genes found to show strong association with NTDs so far (i.e. MTHFR, 
MTHFD1, MTHFD1L, and MFTC), two pertain to mitochondrial FOCM reactions. This 
finding is noteworthy in itself, considering the much larger number of genes encoding 
cytoplasmic FOCM that showed no (or conflicting) association.  
 
1.4.4. FOCM-related mouse models 
In normal mice, severe, diet-induced folate deficiency results in high resorption rates and 
failure of implantation, but surviving embryos do not have NTDs (Heid et al., 1992). 
However, diet-induced folate deficiency can exacerbate or induce NTDs in mouse models 
with a genetic predisposition. This genetic predisposition can be a mutation in an FOCM 
enzyme-encoding gene such as Shmt1 (Beaudin et al., 2011) or in mutations where a 
genetic link to FOCM is not recognised, such as the Pax3 mutant, Splotch (Sp2H) (Burren et 
al., 2008), and the Grhl3 hypomorph, curly tail (Burren et al., 2010). In addition, folic acid 
supplementation has a preventive effect in some NTD mice models, such as Splotch (Sp2H) 
(Fleming and Copp, 1998, Wlodarczyk et al., 2006), and Cited2 (Barbera et al., 2002).  
Mouse models carrying mutations in genes encoding FOCM-related enzymes have been 
made in attempts to probe FOCM function and investigate NTDs, congenital heart defects, 
folate deficiency syndromes, hyperhomocysteinemia, and hypomethylation. The models 
described below are summarised in the context of NTDs. 
 
1.4.4.1. Genes encoding folate receptors and carriers 
Deletions of folate receptor and carrier genes in mouse models result in early embryonic 
lethality and very severe developmental anomalies, thus demonstrating the importance of 
adequate supply of folates in general embryonic development. This partially recapitulates 
the finding in the diet-induced folate deficiency model. 
Homozygous deletion of the mouse reduced folate carrier gene, Rfc1, results in embryonic 
lethality by E9.5. Maternal folic acid supplementation was able to support survival in some 
embryos to E18.5 and birth, but neonatal animals develop multi-organ malformations and 
die within 12 days due to failure of erythropoiesis (Zhao et al., 2001, Gelineau-van Waes et 
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al., 2008). The Rfc1 mouse model showed that folic acid was important in pre-neurulation 
stages of development, erythropoiesis, and development of various organs including the 
neural tube, heart, lungs, eyes and limbs.  
Knockout mice for folate-binding protein, Folbp1 (murine homologue of human FRα) 
displayed similarly severe phenotypes and also resulted in NTDs. Homozygous mutants 
for the Folbp1 gene were severely growth retarded and exhibited aberrant morphology of 
the neural tube, craniofacial region, limbs, and cardiovascular system by E8.5. They were 
embryonically lethal by E10, but had only developed to pre-neurulation somite stages. 
Maternal supplementation with folinic acid was able to rescue a significant proportion of 
embryonic lethality and malformations in a dose-dependent manner, and improved 
survival in utero, but a proportion of the survivors exhibited NTDs (Piedrahita et al., 1999, 
Spiegelstein et al., 2004). On the other hand, null mice for Folbp2 are phenotypically 
normal but showed increased sensitivity towards arsenic-induced exencephaly compared 
with wild-types (Piedrahita et al., 1999, Wlodarczyk et al., 2001). 
Pcft-deficient mice were generated as a model for hereditary folate malabsorption 
syndrome. Homozygous mice survived to birth but failed to thrive, showed impaired 
erythropoiesis and megaloblastic anaemia, and responded to folinic and folic acid 
treatment. There were no reports of malformations (Salojin et al., 2011). 
 
1.4.4.2. FOCM mutations conferring pre-neurulation lethality 
Mouse models with FOCM gene mutations that are lethal before or by neurulation include 
Mtr (or MS), Mtrr, cytoplasmic Mthfd1, and Mthfs.  
No MS null embryos were successfully recovered, and the loss of mutants through early 
resorptions (prior to E9.5) was unable to be rescued by dietary treatment with 5-formyl-
THF, 1C donors (methionine, choline, and betaine), purines and thymidine, threonine, or 
inositol, although the authors speculated that insufficient dosage may have been the 
reason for this (Swanson et al., 2001).  
A hypomorphic gene-trap mutant of Mtrr was generated, in which homozygotes displayed 
mild hyperhomocysteinemia and heart defects (Elmore et al., 2007, Deng et al., 2008). The 
authors also reported unpublished preliminary results of a true Mtrr knockout conferring 
embryonic lethality (R. Gravel, unpublished), which is consistent with the role of Mtrr in 
activating MS. 
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Homozygous Mthfd1 gene-trap mice exhibited embryonic lethality, while heterozygotes 
showed reduced hepatic adenosylmethionine levels. They reported a surprising decrease 
in uracil misincorporation into DNA which they interpreted as an indication of increased 
thymidylate synthesis (MacFarlane et al., 2009). An Mthfd1S mutant was also generated, in 
which only the 10-formyl-THF synthetase activity of the MTHFD1 enzyme was disrupted. 
Homozygous mutants were also embryonically lethal. Mthfd1S-/- embryos at E10.5 were 
severely delayed with abnormalities in the neural tube (but were not NTDs), somites, and 
heart, while Mthfd1S+/- pregnant females showed reduced white blood cell counts 
(Christensen et al., 2013).  
A null mutation of Mthfs, whose enzyme substrate is non-cofactor 5-formyl-THF, is also 
not viable. Embryonic lethality occured pre-neurulation and was not rescued by 
hypoxanthine supplementation (Field et al., 2011). 
 
1.4.4.3. FOCM mutations not presenting with NTDs 
FOCM mouse models that survived past neurulation but did not display NTDs include 
mitochondrial Mthfd2, Mthfr and Shmt1.  
Mthfd2 (or nmdmc) homozygous mutants died after E12.5, potentially from defects in 
erythropoiesis, but did not display any severe malformations or neural tube abnormalities 
before that. Embryonic lethality was not rescued by formate treatment or a glycine-rich 
diet (Di Pietro et al., 2002, Patel et al., 2003).  
The Mthfr knockout mouse presented with early postnatal loss and homocystinuria, which 
mimics some of the human phenotypes for MTHFR deficiency. The SAM/SAH ratio was 
severely decreased, and correspondingly, global DNA methylation was decreased as well 
at post-natal stages (Chen et al., 2001, Schwahn et al., 2004). The MTHFR mutation is of 
particular interest as it is the first genetic risk factor to be associated with human NTDs. 
However, this knockout mouse did not exhibit NTDs and showed Mendelian genotype 
ratios at birth. Postnatal mutants displayed facial abnormalities, cerebellar defects, and 
aortic lipid deposition (Chen et al., 2001). 
Cytoplasmic Shmt1 null mice were viable and fertile, but displayed increased levels of SAM 
combined with decreased levels of SAH, i.e. elevated SAM/SAH ratio (MacFarlane et al., 
2008). An isoform of Shmt2 which localises to the cytoplasm and nucleus was 
hypothesised to provide redundancy to Shmt1 function, which may explain the viability of 
Shmt1 null mice (Anderson and Stover, 2009). However, Shmt1+/- and Shmt1-/- embryos 
did exhibit exencephaly when challenged with induced folate deficiency, indicating that 
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the Shmt1 mutation confers a genetic predisposition to higher NTD risk (Beaudin et al., 
2011, Beaudin et al., 2012). Interestingly, treatment of Shmt1-/- with uridine nucleosides 
also increased NTD incidence, while deoxyuridine supplementation showed a rescue effect 
in NTDs induced by folate deficiency (Martiniova et al., 2015). 
 
1.4.4.4. FOCM mutations that cause NTDs 
FOCM mouse models that do display NTDs without treatment of any kind include Mthfd1L, 
Amt, and Gldc.  
Mthfd1L null mice were embryonically lethal. No homozygous mutants were recovered 
after E12.5, and some did not survive to neurulation stages. All mutants that survived to 
neurulation stages (and up to E12.5) showed complete penetrance of exencephaly (one 
embryo had craniorachischisis), with E12.5 embryos also showing immature mandibular 
processes. Supplementation with sodium formate conferred partial rescue of the NTD 
phenotype and allowed some mutants to be retrieved at E15.5 (Momb et al., 2013). 
The Amt gene-trap mouse (briefly mentioned in Section 1.2.3) generated a null allele 
which was also embryonically lethal in a homozygous state. At E17.5, 87% of homozygous 
mutants exhibited NTDs (82% exencephaly and 5% crahiorachischisis). No post-natal 
survivors were retrieved. Treatment with folic acid or TMP alone was non-responsive, but 
treatment with methionine or methionine and TMP combined produced significant rescue 
effect and reduced the rate of NTDs from 87% in untreated mutants to about 60% 
(Narisawa et al., 2012). 
The Gldc mouse model is described in this thesis. 
 
Hence, consistent with studies of FOCM-encoding genes in human NTDs, FOCM mouse 
models that survive past gastrulation but fail neurulation without requiring additional 
insult (i.e. Mthfd1L, Amt, and Gldc) are mitochondrial FOCM models. 
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1.5. Overview of thesis 
 
Despite the historical link between folate one-carbon metabolism (FOCM) and neural tube 
defects (NTDs), the precise mechanism by which defective FOCM may lead to the 
development of NTDs is still poorly understood, as is the mechanism behind folate-
resistant NTDs. Recent studies of FOCM enzyme-encoding genes in human NTDs and 
FOCM-related NTD mice models hint at the importance of the mitochondrial component of 
FOCM in the pathogenicity of NTDs. The mitochondria-specific glycine cleavage system 
(GCS) is thus an attractive and relatively unexplored candidate for probing the 
contribution of mitochondrial FOCM. In addition, GCS mutations are known to result in 
non-ketotic hyperglycinemia (NKH), the pathogenicity of which is also not well 
understood and which lacks a working animal model.  
This thesis investigates the effect of loss of function of a member of the GCS, glycine 
decarboxylase (GLDC), during mouse embryonic and post-natal development. Gldc was 
chosen for this study because Amt, another GCS component, has been demonstrated to 
result in NTDs when mutated in the mouse but the developmental mechanisms were not 
investigated and it is not known if Gldc is also essential for neural tube closure. In addition, 
the NTD phenotype in the Amt model was too severe and post-natal mutant survivors too 
few to allow for observations of possible NKH-like phenotypes. This study introduces two 
novel gene-trap models (GldcGT1 and GldcGT2), which are found to exhibit both NTDs and 
NKH-like phenotypes, with the purpose of addressing the following specific questions: 
 What are the biochemical and cellular mechanisms underlying the NTDs in Gldc 
loss-of-function mice models, and do they result from an FOCM disturbance?  
 How does a Gldc mutation alter FOCM and its downstream pathways? 
 Are NTDs caused by a Gldc mutation rescued by folate-related metabolites? 
 Can effects of the Gldc mutation be influenced by environmental factors (e.g. folate 
deficiency) and mutations in other folate enzyme-encoding genes (e.g. Mthfr)? 
 Are Gldc mutants suitable as animal models for studying the pathogenesis and 
treatment options for classical NKH? 
Chapter 3 begins with an analysis of the spatial expression pattern of Gldc in wild-type 
neurulating embryos. Characterisation of the loss-of-function gene-traps used and the 
NTD phenotype of neurulation-staged mutant embryos are then provided. The correlation 
between level of gene knockdown and NTD incidence is investigated to account for the 
observed partial penetrance. Additional developmental phenotypes and unusual cranial 
abnormalities are also described. 
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Chapter 4 attempts to elucidate how GCS deficiency affects FOCM which may 
subsequently result in NTDs. Changes in folate profiles and amino acid levels in mutant 
conditions are presented. This is then followed by rescue and exacerbation experiments 
(via dietary supplementation) to further probe how this model responds to environmental 
interventions as well as to provide information for potential therapeutic strategies. The 
effect of GCS deficiency on cellular proliferation is explored in an attempt to understand 
how defective FOCM can lead to NTDs. Genetic interactions between Gldc and Mthfr is also 
investigated by crossing the two loss of function models together.  
The moderately low penetrance of NTDs in the GldcGT1 model allowed sufficient numbers 
of homozygous mutants to survive to post-natal stages where NKH manifests. Thus, 
Chapter 5 focuses on the evaluation of late-foetal and post-natal mutant phenotypes to 
assess their suitability as models for classical NKH. Emphasis is given on post-natal 
survival, biochemical parameters, and brain malformations commonly associated with 
NKH, i.e. corpus callosum defects and hydrocephalus. 
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2. Methodology 
 
 
2.1. Mice colonies 
 
2.1.1. Generation of Gldc mutant mice 
An embryonic stem cell line carrying a gene-trap allele of Gldc (clone EUCG0001_D02; 
denoted as GldcGT1) was obtained from the European Conditional Mouse Mutagenesis 
(EUCOMM) project. Chimeric mice were generated by blastocyst injection of ES cells 
(carried out the Embryonic Stem Cell Facility, UCL Institute of Child Health). These mice 
were crossed with wild-type 129/Sv mice to confirm germ-line transmission. Due to high 
levels of embryonic lethality in the 129/Sv background, the chimeras were then 
outcrossed to wild-type mice on a C57BL/6 background for 5 generations and a 
heterozygous colony was established. Experimental litters were generated by mating 
heterozygous mice from this cross. 
A second Gldc gene-trap mouse (clone CMHD-GT_519C8; denoted GldcGT2) was similarly 
generated from a cell line provided by the North American Conditional Mouse 
Mutagenesis (NorCOMM) project, bred onto a C57BL/6 background and a heterozygous 
colony established. Experimental litters were generated by mating heterozygous mice. 
 
2.1.2. Generation of GldcGT2;Mthfr mutant mice 
Targeted Mthfr null mice were obtained from the Rozen lab (Chen et al., 2001) and 
maintained as a colony by backcrossing to BALB/c mice, the genetic background of the 
Mthfr mutant strain. Mthfr+/- heterozygous mice were crossed to GldcGT2/+ heterozygous 
mice to obtain double heterozygous mutants (GldcGT2/+;Mthfr+/-) on a mixed C56BL/6 and 
BALB/c background.  Experimental litters were generated by mating double heterozygous 
mice together.  
Generation and maintenance of all mice colonies was performed by Dawn Savery.  
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2.1.3. Genotyping and sexing PCRs 
A lysis buffer solution was prepared containing 1M Tris at pH 8, 0.5M of EDTA, 5M of 
sodium chloride (NaCl), and 10% sodium dodecyl sulphate (SDS). Ear clips, tail tips, or 
yolk sacs collected for genotyping purposes were lysed in 180 µL of lysis buffer with 20 µL 
of 10 mg/mL proteinase K overnight at 55 °C. 80 µL of saturated NaCl was added to each 
tube, vortexed briefly, and placed on ice for 20 min. The tubes were then centrifuged at 
14,000g for 20 min at 4 °C to pellet cell debris. The supernatants were transferred to fresh 
tubes and 1 mL of 100% ethanol added. The tubes were inverted several times and then 
spun at 14,000g for 20 min in 4 °C. The supernatants were discarded and 70% ethanol 
added to wash the DNA pellets. The tubes were spun again and the supernatants 
discarded. The remaining pellets were allowed to air dry for several hours. When dry, the 
DNA pellets were re-suspended in 50 µL of deionized, distilled water and stored at -20 °C. 
A second, quicker alternative to salt extraction was used later for genotyping large batches 
of samples. This method involved incubation of samples in 50 µL of DirectPCR®-Tail Lysis 
Reagent (Peqlab), and 1 µL of 10 mg/mL proteinase K for 3 hrs at 55 °C followed by a 45 
min enzyme inactivation step at 85 °C. The sample was then ready to be added to a PCR 
reaction mix. 
All primer sequences with band sizes, reaction mixes, and PCR conditions mentioned 
below are provided in Table 2, Table 3, and Table 4 respectively. 
For genomic DNA genotyping of GldcGT1 mice and embryos, 3 PCRs were used. The first 
reaction consisted of primers that amplify the neo reporter sequence (primers F3 and R2 
in Table 2, reaction mix 1 in Table 3, PCR condition 1 in Table 4). The second reaction 
consisted of a forward primer which binds to a region in intron 3-4 of the Gldc gene, and a 
reverse primer in the Long Terminal Repeat (LTR) region of the gene-trap (primers F2 
and R1, reaction mix 2, PCR condition 2). The third reaction, for detecting the wild-type 
allele, targets a region in intron 3-4 that flanks the gene-trap insertion site and will only 
amplify the wild-type locus in the absence of the gene-trap (primers F1 and R3, reaction 
mix 3, PCR condition 2). The gene-trap design, location of all genotyping primers, and 
genotyping strategy are illustrated in Chapter 4, Figure 4.   
For genotyping of the GldcGT2 allele, primers binding to the EGFP reporter sequence of the 
GldcGT2 gene-trap was used to detect the mutant allele (primers F5 and R4, reaction mix 1, 
PCR condition 2), while a forward primer in exon 19 and reverse in intron 19-20, located 
3’ to the gene-trap, were used to amplify the wild-type allele (primers F4 and R5, reaction 
mix 1, PCR condition 2). In the GldcGT2;Mthfr cross, the Mthfr allele was genotyped by 3 
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primers in one reaction as reported by (Chen et al., 2001) (primers M1, M2 and M3, 
reaction mix 1, PCR condition 1). 
The sex of embryos and P1 pups was determined by PCR using sex-specific primers to the 
Smcx and Smcy genes (primers SMCX1 and SMC4-1, reaction mix 1, PCR condition 2). 
 
Allele Primers Sequences (5’ – 3’) Band size (bp) 
GldcGT1 mutant 1 
(neo) 
F3 CTGTGCTCGACGTTGTCACTG 
567 
R2 GATCCCCTCAGAAGAACTCGT     
GldcGT1 mutant 2 
F2 GTGAACGGAGTCCCTCTCTCTCCC 
602 
R1 GTCCTCCGATTGACTGAGTCG 
GldcGT1 wild-type 
F1 TACAGTCTGTGAACGGAGTCC 
644 
R3 TCACTTTCTGAAGGGTTGGAGAGG 
GldcGT2 mutant 
(EGFP) 
F5 GCGAGGAGCTGTTCACCGGG 
325 
R4 ACCTCGGCGCGGGTCTTGTA 
GldcGT2 wild-type 
F4 TCTGCCGCCCTGGGGACTTT 
658 
R5 GCTGTCTGCCTTCCAACTA 
Mthfr 
M1 GAAGCAGAGGGAAGGAGGCTTCAG 
216 (KO allele) 
145 (WT allele) 
M2 AGCCTGAAGAACGAGATCAGCAGC 
M3 GACTAGCTGGCTATCCTCTCATCC 
Smcx and Smcy 
SMCX1 CCGCTGCCAAATTCTTTGG ~330 (both) 
~300 (male only) SMC4-1 TGAAGCTTTTGGCTTTGAG 
Table 2. Primer sequences for genotyping and sexing GldcGT1, GldcGT2, and Mthfr 
samples. 
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PCR reagent Volume per reaction (µL) 
 Mix 1 Mix 2 Mix 3 
10X PCR buffer 5 5 5 
dNTP mix (2 mM) 5 5 5 
MgCl2 (50 mM) 1.5 2 1.5 
Forward primer (40 µM) 0.3 0.3 0.3 
Reverse primer (40 µM) 0.3 0.3 0.3 
Taq DNA polymerase (5 U/µL) 0.25 0.25 0.25 
Betaine - - 5 
Distilled, deionized water 35.65 35.15 30.65 
Template DNA 2 2 2 
Total 50 50 50 
Table 3. PCR reaction mixes for genotyping and sexing. 
 
PCR step 
PCR conditions No. of 
cycles 1 2 3 
Initial denaturation 2 min, 94 °C 5 min, 94 °C 5 min, 94 °C 1 
Denaturation 30 sec, 94 °C 1 min, 94 °C 1 min, 94 °C 
30-32 Annealing 30 sec, 60 °C 1 min, 58 °C 1 min, 60 °C 
Extension 45 sec, 72 °C 1 min, 72 °C 1 min, 72 °C 
Final extension 5 min, 72 °C 5 min, 72 °C 5 min, 72 °C 1 
Table 4. PCR conditions for determination of genotype and sex. 
  
59 
 
2.1.4. Long-Range PCR and sequencing of gene-trap 
Long-Range PCR was carried out on GldcGT1 samples using the SequalPrep™ Long PCR kit 
(Invitrogen) to amplify the entire GldcGT1 construct. The PCR reaction mix used is detailed 
in Table 5 and amplification was performed using the following conditions: initial 
denaturation for 3 min at 93 °C, followed by 35 cycles of 15 sec denaturation at 93 °C, 30 
sec annealing at 62 °C, and 4 min extension at 68°C (1 min/kb), and a final extension step 
for 5 min at 68 °C. Fragments of the construct obtained from Long-Range PCR reactions 
were sequenced using a primer walking strategy from both 5’ and 3’ ends to confirm the 
presence of all loxP and Frt sites Figure 5.  All primers used for the primer walking and 
sequencing of the gene-trap are listed in Table 6. All sequencing was carried out by the 
UCL Wolfson Centre for Biomedical Science genomics services. 
 
Long-Range PCR reagent Volume per reaction (µL) 
10X Reaction buffer with MgCl2 5 
dNTP mix (10 mM) 2.5 
Forward primer (40 µM) 0.3 
Reverse primer (40 µM) 0.3 
Long Polymerase (5 U/µL) 0.4 
Distilled, deionized water 40.5 
Template DNA 1 
Total 50 
Table 5. Long-Range PCR reaction mix. 
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Figure 5. Primer walking strategy for sequencing of the GldcGT1 construct. 
Approximately 2 and 4 kb fragments of the GldcGT1 construct were successfully amplified 
using Long-Range PCR with the [LTR6 x R2], [F3 x R1], and [B/P F x R3] primer pairs. 
Sequencing of both 2 kb fragments were carried out using the primers indicated in red to 
confirm the sites and sequences of all loxP and Frt regions (triangles). 
 
Primer orientation Primer  Sequences (5’ – 3’) 
Forward F2 GTGAACGGAGTCCCTCTCTCTCCC * 
 B/P F TTCTCAGGCCCACCACTGAAAGA  
 LTR6 GCGACTCAGTCAATCGGAGGAC 
 F3 CTGTGCTCGACGTTGTCACTG * 
 R2-RC ACGAGTTCTTCTGAGGGGATC 
 LR-F1 ATTGCATCGCATTGTCTGAG 
Reverse R1 GTCCTCCGATTGACTGAGTCG * 
 R2 GATCCCCTCAGAAGAACTCGT * 
 LR-R1 CGTTGGGTTACCTTCTGCTC 
 R3 TCACTTTCTGAAGGGTTGGAGAGG * 
Table 6. Primers used for GldcGT1 construct sequencing. 
* The F2, F3, R1, R2, and R3 primers are the same genotyping primers listed in Table 2. 
Primers indicated in red were used for sequencing reactions. 
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2.1.5. Treatments and dietary interventions 
Formate treatment was performed by addition of 30 mg/mL sodium formate (Sigma-
Aldrich) to drinking water of females on the day a vaginal plug was found (E0.5), and 
maintained until the litters were collected.  
For diet-induced folate deficiency experiments, female mice were kept on an ad libitum 
folic acid-deficient diet containing 1% succinylsulfathiazole (10 g/kg) (Harlan Teklad; 
TD.02490) for at least 3 weeks before mating (Burren et al., 2008). This diet was 
maintained throughout pregnancy until collection of litters. 
All mice were placed on an 18% sterilisable rodent diet with fenbendazole (8 mg/kg) 
(Harlan Teklad; TD.01432) for treatment of pinworm infection over a period of 3 months. 
Litters collected during this treatment period were analysed separately and are indicated 
in the appropriate results chapters. 
 
2.1.6. Survival studies 
Litters from GldcGT1 heterozygous mice crosses were allowed to litter down and monitored 
from birth until 1 year of age. A cohort of homozygous mutant mice (GldcGT1/GT1) that were 
viable and healthy past 6 weeks of age were inter-crossed to establish a homozygous 
colony and expedite collection of mutants. The numbers of surviving pups were followed 
throughout, with any ill or dead mice collected for genotyping and sexing. Mice that 
developed acute hydrocephalus were culled within 48 hours due to rapidly deteriorating 
health. 
 
2.2. Sample collection, fixation, and storage 
 
2.2.1. Embryonic samples 
E9.5 and E10.5 embryos were dissected out of the uterus in Dulbecco’s Modified Eagle’s 
Medium (DMEM) with high glucose and HEPES formulation (Invitrogen; 42430), with 10% 
fetal bovine serum (Sigma-Aldrich), and rinsed briefly in cold phosphate buffered saline 
(PBS). Embryos at E11.5 and older were dissected out in cold PBS. 
Embryos to be used for mRNA extraction and metabolic studies were immediately frozen 
on dry ice and stored at -80 °C.  
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Embryos for in situ hybridisation and antibody detection studies were fixed in 4% 
paraformaldehyde (PFA) overnight at 4 °C, while those to be used only for morphological 
studies were fixed in Bouin’s solution (Sigma-Aldrich). They were then washed briefly in 
PBS, dehydrated in ascending concentrations of methanol (25%, 50%, 75%, 100%), and 
stored in absolute methanol at -20 °C. For X-gal staining, embryos were fixed in 0.2% 
gluteraldehyde for an hour at 4 °C and processed immediately (see Section 2.4.2). 
 
2.2.2. Late-foetal and post-natal samples 
For analysis of E18.5 foetal brains, the foetuses were dissected out of the mother’s uterus 
in cold PBS and decapitated. The heads were then skinned with forceps to allow better 
penetration of the fixative and solutions in subsequent processing steps. They were fixed 
in 4% PFA (for antibody detection) or Bouin’s solution (for morphological studies) for 48 
hours on a roller at 4 °C. Samples fixed with 4% PFA were given a fresh solution change 
after the first 24 hours. For 5-week old mice brains, the brain was carefully removed from 
the skull, rinsed briefly in cold PBS, and similarly fixed. The E18.5 foetal heads and 5-week 
brains were then dehydrated with ethanol (25%, 50%, 70%) and stored at 70% ethanol at 
4 °C. Brains to be used for corpus callosum studies were processed immediately after 
fixation without dehydrating (see Section 2.7). 
Gldc adult liver and brain samples at 8–12 weeks of age were harvested for mRNA 
extraction and measurements of Gldc enzymatic activity. The samples were rinsed briefly 
in cold PBS, immediately frozen on dry ice, and stored on -80 °C. 
 
2.2.3. Adult mice blood and urine samples 
Blood from Gldc mutant mice was collected by cardiac puncture, transferred to lithium-
heparin tubes (BD Microtainer), and spun at 3,500 rpm for 5 min. The plasma layer was 
carefully transferred to 1.5 mL tubes, immediately frozen on dry ice, and stored at -80 °C. 
For the collection of urine, Gldc mice were placed in metabolic cages designed for urine 
and faeces collection, one mouse to a cage, overnight. Urine collected from this method 
was then centrifuged briefly to remove any debris in the sample, frozen on dry ice, and 
stored at -80 °C. 
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2.3. Investigating expression of Gldc mRNA 
 
2.3.1. RNA isolation and cDNA synthesis 
500 mL of TRIzol® Reagent (Ambion® RNA) was added to the tube containing E9.5/E10.5 
embryo sample or a sliver of liver/ brain sample (at a similar wet weight as an E10.5 
embryo). The tissue was homogenized by pipetting in Trizol several times, then incubated 
in room temperature for 5 min. 100 mL of chloroform (BDH, UK) was added and the tube 
shaken vigorously. The tube was incubated at room temperature for 2 to 3 min, and then 
spun at 12,000 g for 15 min at 4 °C. The upper, aqueous phase was transferred to a new 
tube and 250 mL of isopropyl alcohol added to it. It was then incubated on ice for 10 min, 
and then spun at 18,800 g for 10 min at 4 °C. The supernatant was decanted and the RNA 
pellet washed with 500 mL of 75% ethanol. The sample was vortexed briefly and spun 
again at 14,000 rpm (18,800 g) for 5 min at 4 °C. The pellet was air dried for 5 to 10 min 
and re-suspended in 20 µL of DEPC-treated water. 
The RNA sample was then DNase-treated to remove DNA contamination using a DNA-
free™ DNase Treatment and Removal kit (Ambion® RNA). 0.5 µL of RNAse Inhibitor 
(Roche), 2.5 µL of 10X DNase 1 buffer, and 0.5 µL rDNase-1 enzyme were added to the re-
suspended RNA. The mix was then incubated at 37 °C for 30 min. 2.5 µL of DNase 
Inactivation Reagent was added, further incubated for 2 min and spun at 10,000 rpm 
(9,600 g) for 2 min. The supernatant was transferred to a fresh tube and stored at -80 °C. 
The purity of the RNA sample was assessed by its absorbance ratio at 260/280 nm and 
260/230 nm wavelengths using the Nanodrop Spectrophotometer ND-1000 (Thermo 
Scientific). Ideally, this ratio would be in the 2.0-2.2 range; ratios appreciably lower than 
that indicates the presence of phenol or DNA contamination. As the same nucleic acid 
sample may give a ±0.4 difference in 260/280 ratio on any 2 similar spectrophotometers, 
samples that differed by more than ±0.5 from the ideal range were discarded. The 
concentration of the sample in ng/µL was also ascertained with the Nanodrop machine. 
RNA samples were used to generate cDNA using the SuperScript® VILO™ cDNA Synthesis 
Kit (Invitrogen). 4 µL of 5X VILO™ Reaction Mix and 2 µL of 10X SuperScript® Enzyme Mix 
were added to 2 µg of RNA. The mix was topped up to 20 µL total volume using DEPC-
treated water. It was than incubated at 25 °C for 10 min, followed by 42 °C for an hour, and 
lastly 85 °C for 5 min. The resultant cDNA was stored at -20 °C and diluted 1:5 to a 
concentration of 400 ng/µL for use in quantitative, real-time, reverse-transriptase PCR 
(qRT-PCR; see Section 2.4.1) 
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The quality of the cDNA was assessed by RT-PCR using primers that amplify an 
endogenous control, i.e. the gene for the housekeeping enzyme glyceraldehyde-3-
phosphate dehydrogenase (Gapdh). The reaction mix was set up as outlined in Table 7 
below. The mix was vortexed briefly and the RT-PCR reaction was carried out with 35 
cycles of 1 min at 94 °C, 1 min at 60 °C, and 1 min at 72 °C. 
 
Reagent Volume per reaction (µL) 
10X PCR buffer 2.5 
dNTP mix (2 mM) 2.5 
MgCl2 (50 mM) 0.75 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
Taq DNA polymerase (5 U/µL) 0.2 
Distilled, de-ionized water 15.05 
cDNA sample 1 
Total 25 
Table 7. RT-PCR reaction mix for amplification of Gldc cDNA. 
 
2.3.2. Cloning of Gldc cDNA into vector for in situ probe preparation 
 
2.3.2.1. Gldc probe design 
A 587 bp probe complimentary to nucleotide 30,151,484–30,139,376 of the Gldc 
transcript coding sequence (ENSMUST00000025778) was designed and amplified by RT-
PCR using cDNA prepared from wild-type embryos. Primer sequences were: 5’-
GCCAACGCTTCCCTGCTGGA-3’ forward in exon 4, and 5’-AGGGCCTGAGCCGTGCAGAT-3’ 
reverse in exon 8/9 (crosses exon-intron boundaries), carried out in the reaction mix used 
in Table 7 with 35 cycles of 1 min at 94 °C, 1 min at 58 °C, and 1 min at 72 °C. The PCR had 
been optimised to produce a single band. 
 
2.3.2.2. Ligation into vector system 
The PCR product containing the probe sequence was ligated into pGEM®-T Easy Vector 
System (Promega) which contains T7 and Sp6 polymerase recognition sites. This was done 
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by incubating a ligation mixture containing 5 µL of 2X Ligation Buffer, 1 µL of pGEM-T 
Easy Vector, 3 µL of the PCR product, and 1 µL of T4 Ligase for an hour at room 
temperature. The amount of PCR product added to the mix was calculated for optimal 
ligation efficiency with a 3:1 product/insert to vector ratio as followed: 
 
𝑛𝑔 𝑣𝑒𝑐𝑡𝑜𝑟 × 𝑘𝑏 𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡
𝑘𝑏 𝑠𝑖𝑧𝑒 𝑣𝑒𝑐𝑡𝑜𝑟
 × 
𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑜𝑟 𝑖𝑛𝑠𝑒𝑟𝑡
𝑣𝑒𝑐𝑡𝑜𝑟
 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 = 𝑛𝑔 𝑃𝐶𝑅 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 
50 𝑛𝑔 × 0.6 𝑘𝑏 [𝐺𝑙𝑑𝑐 𝑝𝑟𝑜𝑏𝑒]
3.0 𝑘𝑏
 ×  
3
1
 = 30 𝑛𝑔 𝑃𝐶𝑅 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 
 
2.3.2.3. Transformation into competent cells 
After ligation, 50 µL of DH5α™ competent cells was added to 2 µL of ligation reaction. The 
tube was flicked gently to mix and incubated on ice for 20 min. The cells were then heat-
shocked for 45–50 sec at 42 °C, and incubated on ice for a further 2 min. 950 µL of Luria 
Bertani (LB) broth was then added to the tube and the mix was incubated at 37 °C, 
shaking, for 90 min. 100 µL of this mix was then plated onto an LB plate containing 100 
µg/mL of Ampicillin, 100 µM of isopropyl β-D-1-thiogalactopyranoside (IPTG), and 0.3% 
of X-gal (Sigma-Aldrich; prepared in dimethyl formamide), and incubated overnight (16–
18 hrs) at 37 °C. White colonies (carrying the vector insert) were picked out, plated onto 
fresh LB plates containing 100 µg/mL of Ampicillin (LB-Amp), and incubated at 37 °C 
overnight. The following day, the colonies were inoculated into 10 mL of LB-Amp broth. 
After incubation at 37 °C overnight on a shaker, the broth was ready for plasmid 
preparation. 
 
2.3.2.4. Plasmid preparation 
Plasmid preparation was performed using the QIAprep Spin Miniprep Kit (Qiagen). First, 
the broth was centrifuged at 4,600 rpm for 15-30 min at room temperature. The 
supernatant was discarded and the pelleted cells resuspended in 250 µL of chilled Buffer 
P1 (Resuspension Buffer). 250 µL of Buffer P2 (Lysis Buffer) was then added and mixed, 
followed by addition of 350 µL of Buffer N3 (Neutralization Buffer). This solution was then 
spun for 10 min at 13,000 rpm. The resultant supernatant was added to the QIAprep spin 
column and spun for 1 min at 13,000 rpm. The flow-through was discarded and the 
column spun dry for an additional minute to remove residual wash buffer. 50 µL of 
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deionized, distilled water was added to the column, let stand for 1 min, and spun for 1 min 
at 13,000 rpm to elute DNA from the column. The concentration of the DNA was 
determined using the Nanodrop spectrophotometer. 
The 5’-3’ directionality of the insert within the vector was determined by PCR with probe 
primers combined with Sp6 and T7 primers. Using this method, the Gldc probe sequence 
was determined to be 5’ at the T7 end and 3’ at the Sp6 end, thus an antisense probe 
would be generating by a digestion at the T7 promoter end, followed by RNA synthesis 
using the Sp6 RNA polymerase, and a sense probe by digestion at the Sp6 promoter end 
followed by RNA synthesis using the T7 polymerase. For further confirmation of the probe 
sequence, a sample of the DNA extracted from the plasmids was sent for sequencing at the 
UCL Wolfson Centre for Biomedical Science. The DNA could then be used for preparation 
of an RNA probe, or further amplified by repeating the transformation (with 50–100 ng of 
plasmid) and plasmid preparation steps. 
 
2.3.3. RNA probe preparation for in situ hybridisation 
 
2.3.3.1. Plasmid DNA digestion 
Test digests of the plasmids were first carried out using 200–500 ng of plasmid DNA 
(approximately 1 µL from a QIAprep Spin Mini preparation) and 5–10 U of the appropriate 
restriction enzyme (see Table 8), and ran on an agarose gel to confirm the presence of a 
single, linearized plasmid DNA band at approximately 4kb. This was followed by a large-
scale digest using 3–5 µg of plasmid DNA and 20–50 U of restriction enzyme in 1X 
restriction enzyme buffer, made up to a 50 µL total reaction volume. The reaction mix was 
left to incubate for 2 hrs at 37 °C. 
After digestion was complete, the linearized DNA was purified using the QIAquick PCR 
Purification Kit (QIAGEN) protocol. 5 volumes of Buffer PBI (Binding Buffer) was added to 
1 volume of DNA and inverted several times. The DNA was bound to a QIAquick 
membrane by pipetting it into a QIAquick spin column and centrifuging for 1 min at 
17,900 g. The flow-through was discarded. 750 µL of Buffer PE (Wash Buffer) was applied 
to the column and spun for 1 min at 17,900 g to wash the column. The resultant flow-
through was discarded again and the column re-spun for a further 1 min to remove 
residual wash buffer. 30 µL of DEPC-treated water was carefully applied to the centre of 
the membrane to elute the DNA. The column was left to stand for 1 min, and then spun for 
1 min at 17,900 g. The concentration of resultant DNA was ascertained using Nanodrop. 
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2.3.3.2. DIG probe transcription 
A digoxigenin(DIG)-labelled, single-stranded RNA probe was prepared by transcribing the 
purified digest in the following mixture: 1 µg of digested plasmid DNA, 2 µL of DIG RNA 
labelling mix (Roche), 2 µL of transcription buffer (Roche), 0.5 µL of RNAse Inhibitor 
(Roche), and 2 µL of the appropriate RNA polymerases (see Table 8), made up to a 20 µL 
reaction mix with DEPC-treated water. The mix was incubated for 2 hrs at 37 °C, and 1 µL 
of this mix was then run on an agarose gel to assess transcription efficiency by the 
presence of two clean bands. 
The DIG-labelled probe was purified using CHROMA SPIN-1000 DEPC-H2O Columns 
(ClonTech). An empty spin was first performed by centrifuging the columns at 700 g for 5 
min at 4 °C to dry the columns. The probe was then applied to the centre of the column 
and spun at 700 g for 5 min at 4 °C into a clean, RNAse-free tube. 1 µL of RNAse Inhibitor 
(Roche) was added to the purified probe, and the probe was stored at -20 °C until use. 
 
Probe 
Restriction enzyme, 
RE (Promega) 
Catalogue 
number 
RE Buffer 
(Promega) 
RNA Polymerase 
(Roche) 
Gldc antisense 
Apa1 R6361 A Sp6 
Nco1 R6513 D Sp6 
Gldc sense Sal1 R6051 D T7 
Table 8. Restriction enzymes and RNA polymerases for generation of Gldc in situ 
hybridisation probes. 
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2.3.4. Whole mount in situ hybridisation 
 
2.3.4.1. Hybridisation of probe 
The embryos were first rehydrated from storage with a series of methanol washes (100%, 
75%, 50%, 25%) in PBS containing 0.1% Tween-20 (PBT), followed by brief PBT washes. 
They were then bleached with 6% hydrogen peroxide in PBT for 1 hr on ice, treated with 5 
µg/ mL of proteinase K in PBT at room temperature for 2 min (for E9.5 embryos) or 7 min 
(for E10.5 embryos), and briefly incubated in 2 mg/mL of glycine in PBT for 5 min at room 
temperature. The embryos were then re-fixed in 0.2% gluteraldehyde prepared in 4% PFA 
for 20 min at room temperature. After fixation, the embryos were washed in PBT, 
transferred to 1 mL of pre-warmed pre-hybridisation buffer containing 50% formamide, 
5X saline sodium citrate (SSC) at pH 4.5, 50 ug/mL yeast RNA, 1% SDS, and 50 µg/mL 
heparin in DEPC-treated water, and incubated at 70 °C for 2 hours. 10 µL of each Gldc RNA 
probe was added per 1 mL of pre-hybridisation buffer and left to incubate overnight at 70 
°C. 
 
2.3.4.2. DIG antibody detection 
Following hybridisation, the embryos were washed in pre-warmed formamide solutions: 
twice in Solution 1 (50% formamide, 5X SSC, and 1% SDS in DEPC-treated water) for 30 
min each at 70 °C, and then twice in Solution 2 (50% formamide, 2X SSC, and 1% SDS in 
DEPC-treated water) for 30 min each at 65 °C. A TBST wash solution was prepared with 
1% Tween-20 in tris-buffered saline (TBS; made with 50 mM of Tris-Cl at pH 7.6 and 150 
mM of NaCl) and approximately 0.2 g (per 500 mL of TBST solution) of tetramisole 
hydrochloride (Sigma-Aldrich). The embryos were washed in TBST and blocked with 10% 
heat-inactivated sheep serum (Invitrogen) in TBST for at least an hour at room 
temperature. The blocking solution was replaced with anti-DIG-AP antibody (Roche; 11 
093 274 910) at 1:2,000 dilution prepared in TBST containing 1% sheep serum. The 
embryos were left to incubate on a shaker at 4°C overnight.  
The following day, the embryos were washed with five, 1 hr washes in TBST. After the last 
wash, the embryos were left washing in TBST on a shaker at 4°C overnight. 
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2.3.4.3. Colour development 
An NTMT wash solution was prepared consisting of 100 mM NaCl, 100 mM Tris at pH 9.5, 
50 mM magnesium chloride (MgCl2), 1% Tween-20, and approximately 25 mg (per 50 mL 
of NTMT solution) of tetramisole hydrochloride, in distilled water. The colour developing 
solution was prepared with 4.5 µL/mL 4-nitroblue tetrazolium chloride, NBT (Roche) and 
3.5 µL/mL 5-bromo-4-chloro-3-indoylphosphate, BCIP (Roche) in NTMT solution. The 
embryos were washed thrice in NTMT for 10 min each and then incubated with the 
developing solution at room temperature in the dark. Signal development was stopped 
after sufficient staining was achieved (about 7.5 hr) by making brief PBT washes. The 
embryos were photographed at this point and then re-fixed in 4% PFA overnight at 4°C. 
 
2.3.4.4. Vibratome sectioning 
Embryos labelled by whole mount in situ hybridisation were embedded in a 
gelatin/albumin mix (0.45% gelatin, 27% albumin, and 18% sucrose in PBS) for vibratome 
sectioning, which allows 50 µm sections (or thicker) to be obtained. Following fixation, the 
embryos were washed in PBS and incubated in 1 mL of the gelatin/albumin embedding 
medium overnight at 4°C. Approximately 200 µL of embedding medium was pipetted into 
plastic embedding moulds. 20 µL of gluteraldehyde (0.2%) was added to the medium in 
each mould and mixed in quickly. The embryos was transferred into the moulds and 
orientated as quickly as possible. The blocks were left to set completely for 30 min, then 
cut out of the mould and incubated in PBS for at least 1 hr in 4°C. Vibratome sectioning 
was then performed on the blocks to obtain sections at a thickness of 50 µm. The sections 
were mounted in 50% glycerol and coverslips sealed with clear nail varnish. 
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2.4. Assessing efficiency of Gldc gene-traps 
 
2.4.1. Quantitative, real-time PCR (qRT-PCR) 
The GldcGT1 and GldcGT2 gene-trap vectors contain splice acceptor sites. Transcription of 
Gldc from the endogenous promoter splices the mRNA to the gene-trap construct, 
resulting in early termination and a truncated mRNA. To assess the efficiency of the 
trapping, qRT-PCR was used to measure the levels of wild-type Gldc transcripts produced 
by the gene-trapped alleles.  
For the GldcGT1 allele which was inserted in intron 2, primers were designed to bind to 
exon 2 and exon 4 of the Gldc transcript which would not amplify a product if alternative 
splicing occurred. For GldcGT2 inserted in intron 19, primers in exon 19 and 21 were used. 
A range of annealing temperatures and several primer designs were tested to ensure 
amplification of a single band and avoid non-specific amplification. Primer sequences are 
provided in Table 9. The Gapdh gene was used as an endogenous control to which all 
target samples were normalised. 
Allele Primer Sequence (5’-3’) 
GldcGT1 
Exon 2 forward AGCATTGATGAGCTCATCGAG 
Exon 4 reverse TCCAGCAGGGAAGCGTTGGC 
GldcGT2 
Exon 19 forward TTCTGCATTCCCCACGGA 
Exon 21 reverse AGGCCCTTTCCACCCATCAT 
Gapdh 
Forward ATGACATCAAGAAGGTGGTG 
Reverse  CATACCAGGAAATGAGCTTG 
Table 9. Primer sequences for quantification of Gldc mRNA by qRT-PCR 
 
RNA and subsequent cDNA samples of all genotypes of GldcGT1 and GldcGT2 E9.5 and E10.5 
embryos were prepared as outlined in Section 2.3.1. The cDNA samples were loaded onto 
Optical 96-Well Fast Thermal Cycling Plates (Applied Biosystems) in triplicates, 1 µL per 
well. A master mix of MESA Blue qPCR MasterMix Plus for SYBR® Assay Low ROX 
(Eurogentec) was prepared, containing 12.5 µL Mesa Blue reaction buffer, 2 µL of 10 µM 
forward primer, 2 µL of 10 µM reverse primer, and 7.5 µL of DEPC-treated water (per 
reaction). 24 µL of this mix was pipetted into each well. The plate was sealed with a clear 
adhesive, vortexed, centrifuged, and loaded into a 7500 Fast Real-Time PCR System 
machine (Applied Biosystems). 
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A standard qPCR cycle run was used: 2 min at 50 °C, 5 min at 95 °C, and 40 cycles of 95 °C 
for 15 sec (denaturation) and 60 °C for 1 min (annealing and extension). A dissociation 
curve was run after every successfully completed qPCR run to check for presence of 
primer dimers, genomic DNA, or non-specific products.  
Analysis of results was carried out using the 7500 Software v2.0.6. For every primer pair 
used, the baseline value was set to above background fluorescence (prior to target 
amplification) and threshold value set above the baseline and at the point when the 
exponential region of the amplification curve begins. Any samples flagged by the software 
as containing outlier values or not producing a clean, single peak on the dissociation curve 
(thus indicating presence of contaminants) was discarded.  A wild-type sample was set as 
the reference value with a Relative Quantification value of 1 (RQ = 1). All other samples 
were quantitated relative to this reference value. 
 
2.4.2. Whole mount X-gal staining 
The GldcGT1 construct was reported by EUCOMM to contain a β-Geo reporter cassette which 
produces β-galactosidase in tissue where Gldc is expressed and can be stained for with an 
X-gal solution. The X-gal reaction buffer was prepared containing 2 mM of MgCl2, 20 mM of 
Tris-HCl in pH 7, 0.2% of Nonidet P-40, 10 mM of potassium ferricyanide (K3Fe(CN)6), and 
10 mM of potassium ferrocyanide (K4Fe(CN)6.3H2O) in PBS. A 100 mg/mL dilution of X-gal 
was made in dimethyl sulfoxide (DMSO), added to 10 mL of reaction buffer, filtered 
through a 0.2 µm filter (Millipore), and warmed to 37 °C. Embryos were fixed as described 
in Section 2.2.1 and washed several times in PBT. They were then incubated in X-gal 
staining solution overnight in the dark at 37 °C. The next day, the embryos were washed in 
PBS and photographed. 
 
2.4.3. Glycine cleavage enzymatic assay 
Gldc enzymatic activity was determined by a decarboxylation assay on Gldc adult mice 
liver samples. The liver samples were homogenised in cofactor solution containing THF, 
pyridoxal phosphate, and NAD, and incubated with [1-14C]glycine. The amount of 14CO2 
released from the reaction was trapped in filter paper, measured with a scintillation 
counter, and normalised to protein content. The assay was carried out by Dr Tim Hutchins 
(Birmingham Children’s Hospital).  
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2.5. Histological studies 
 
2.5.1. Paraffin processing and sectioning 
E9.5, E10.5 and E11.5 embryos (stored in absolute methanol) were first incubated in two 
changes of absolute ethanol for 30 min at room temperature each. The embryos were then 
cleared with Histo-Clear® solution (Agar Scientific) for 20 min for E9.5 embryos and 30 
min for E10.5 and E11.5 embryos in room temperature. They were then given a fresh 
change of Histo-Clear solution and placed in a 60 °C oven to incubate for a further 20 or 30 
min for E9.5 and E10.5/E11.5 embryos respectively. This was followed by four changes of 
paraffin wax at 30 min each. The samples were then given a fresh change of paraffin wax, 
placed on the stage of a stereomicroscope (Leica), and quickly orientated for transverse or 
coronal sections to be made. Once the wax has set overnight, the embryos were cut with a 
microtome (Leica) to obtain serial sections at a thickness of 7 µm or 4 µm (the latter for 
immunofluorescence staining using anti-Phospho-Histone-H3 antibody, see Section 
2.5.4). 
For E18.5 foetal heads and 5-week brains (stored in 70% ethanol), samples were brought 
to 100% ethanol with 1hr incubations of 85% and 95% ethanol each, followed by two 1 hr 
incubations with 100% ethanol. Samples were subsequently cleared with Histo-Clear for 1 
hr at room temperature and a further 1 hr (with fresh solution change) in a 60 °C oven. 
The samples were then incubated in a pre-warmed mix of Histo-Clear and paraffin wax at 
a 50:50 ratio for 1hr 30 min in the oven. This is followed by four 100% paraffin wax 
changes for 1 hr each.  The samples were then transferred to plastic moulds and similarly 
orientated and sectioned. 
 
2.5.2. Hematoxylin and eosin staining 
Paraffin wax sections of E9.5–E18.5 embryos were stained with Mayer’s hematoxylin 
solution (Sigma-Aldrich) and a 1% solution of Eosin Y (ACROS Organics), a routinely used 
cytoplasmic and nucleic histology stain for morphological studies.   
Sections were first deparaffinised with Histo-Clear, rehydrated with two 100% ethanol 
solutions followed by 95% and 70% ethanol solutions, and brought to water. They were 
then stained in hematoxylin for 1-3 min, and then submerged in gently running water for 
2-3 min until the water ran clear. The purplish staining of hematoxylin on the sections was 
assessed under a stereomicroscope. As Mayer’s hematoxylin is a progressive stain, slides 
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were returned to the staining solution at this point and left to stain until a satisfactory 
level of staining was achieved. Sections were then stained with eosin for 1-3 min, and then 
briefly submerged in water. The pinkish orange staining of eosin was similarly assessed 
and the sections returned to eosin solution if needed. Sections were then quickly 
dehydrated with ethanol (70%, 95%, 100%) and cleared in Histo-Clear. The slides were 
mounted in DPX mounting media with coverslips and left to dry in the fume hood 
overnight. 
 
2.5.3. Cresyl violet staining 
5-week brain sections were stained for morphological studies using cresyl violet, a routine 
stain for Nissl substances (rough endoplasmic reticulum) in the cell bodies of neurons. The 
staining solution was prepared with 0.1% cresyl violet acetate (Alfa Aesar) and 1% glacial 
acetic acid. Deparaffinized and rehydrated slides were stained for 15 min, dipped quickly 
in water, and differentiated in 95% ethanol to remove background and improve staining 
contrast. The violet staining was assessed under a stereomicroscope and further stained 
and differentiated if required. Slides were dehydrated to absolute ethanol, cleared, and 
mounted with DPX. 
 
2.5.4. Immunofluorescence staining of Phospho-Histone-H3 (PHH3) 
Slides were deparaffinised, rehydrated, placed in a 1:20 dilution (with distilled water) of 
Declere (Cell Marque), and steamed for 40 minutes. They were left to cool to room 
temperature. The slides were then washed three times in TBST solution. Blocking was 
performed using a solution containing 2 mg/mL bovine serum albumin (BSA; Sigma-
Aldrich), 0.15% glycine, 0.1% Triton X-100, and 5% heat-inactivated sheep serum 
prepared in TBST. The sections were blocked for at least 30 min at room temperature. The 
blocking solution was then replaced with rabbit, anti-PHH3 primary antibody (Millipore; 
06-570) at a 1:250 dilution (in blocking solution) and the slides were left to incubate 
overnight in a humidified chamber at 4 °C.  
The next day, the slides were washed in three changes of TBST solution. Next, they were 
incubated in goat, anti-rabbit, Alexa Fluor® 488-conjugated, secondary antibody (Life 
Technologies; A11070) at a 1:500 dilution (in blocking solution) for 1 hr at room 
temperature in a humidified chamber and in the dark. Slides were then washed once in 
TBST solution, and then twice in TBS solution.  
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DAPI (Invitrogen) nucleic acid staining was then performed using a 1:10,000 dilution (in 
TBS) for 5 min. The slides were mounted with Mowiol® 4-88 (Sigma-Aldrich) mounting 
medium (prepared in a pH 6.8 solution containing 12% Mowiol, 0.2 M Tris Base, 0.2 M Tris 
HCl, and 30% glycerol) and coverslips were secured with clear nail varnish. 
Mitotic cells were scored by visual inspection, counted, and normalised against DAPI-
stained cell counts to obtain a percentage of PHH3-stained cells.  
 
2.6. Metabolic studies 
 
2.6.1. Sample preparation 
E11.5 embryo extracts for glycine measurements were prepared by first sonicating them 
in PBS containing 1X cOmplete, Mini Protease Inhibitor Cocktail (Roche) to homogenise 
them. For samples to be used in folate metabolite analysis, sonication was performed in 
folate buffer (20 mM ammonium acetate, 0.1% ascorbic acid, 0.1% citric acid, 15 mg/mL 
dithiothreitol, adjusted to pH 7.0 with ammonia) containing 0.2 µM methotrexate. 10 µL of 
the homogenised samples were kept for protein assay (see Section 2.6.2). Two volumes of 
acetonitrile were then added to the samples to precipitate protein. The precipitate was 
removed by centrifugation at 14,000 g for 15 min at 4 °C. Supernatants were transferred 
into fresh tubes, lyophilised, and stored at -80 °C. Prior to mass spectrometry analysis, the 
samples were re-suspended in deionized, distilled water. 
 
2.6.2. Protein assay 
Total protein quantitation was carried out on E11.5 embryos with the Pierce™ BCA™ 
Protein Assay (Thermo Scientific). A set of diluted BSA standards was prepared with a 
working range of 20–2,000 µg/mL using the 2 mg/mL albumin standard ampules 
provided. A working reagent mix of Reagent A and Reagent B was made to a 50:1 ratio, for 
1 mL per sample of total volume. 1 mL of this working reagent was added to 50 µL of each 
standard and 50 µL of diluted sample. A dilution factor of X50 was generally used and 
increased when necessary. All standard/sample tubes were prepared in duplicates.  
The tubes were incubated for 30 min at 37 °C, then transferred to cuvettes and their 
absorbance read at 562 nm, beginning first with the standards (from blank to highest 
concentration) in order for a calibration curve to be plotted, quickly followed by the 
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samples. Protein concentration of each sample in µg/mL was read from the curve and total 
protein content in mg was determined by multiplying back to the sample dilution factor. 
 
2.6.3. Amino acid analysis 
Amino acid analysis was carried out on blood, urine, and E11.5 embryo samples (prepared 
as outlined in Section 2.6.1) by ion-exchange chromatography (Biochrom 30 Amino Acid 
Analyser). Protein was first precipitated with 5-sulphosalicylic acid and removed by 
centrifugation. The supernatant was then filtered, injected on a Lithium High Performance 
Physiological (cation-exchange) Column, and measured at 570 nm using post-column 
ninhydrin derivatisation. Embryo samples were normalised to total protein content (as 
determined in Section 2.6.2), while urine samples were normalised to creatinine levels. 
Amino acid analysis was performed by Helen Prunty and Dr Simon Heales (Great Ormond 
Street Hospital for Children NHS Foundation Trust). Measurement of creatinine levels was 
carried out by Dr Kit-Yi Leung (UCL Institute of Child Health). 
 
2.6.4. Folate profiling 
Folate profiling was carried out on E11.5 embryo samples (prepared as described in 
Section 2.6.1) by ultra-performance liquid chromatography tandem mass spectrometry 
(UPLC/MS/MS). Samples were injected on an ACQUITY UPLC BEH C18 column and 
resolved by reserved-phase UPLC (Waters Corporation) coupled to a XEVO TQ-S tandem 
quadrupole mass spectrometer (Waters Corporation) in negative-ion mode. The relative 
abundance of mono- and polyglutamated forms of six folate species were quantified by 
multiple reaction monitoring (MRM) of precursor and product ions, normalised to DNA 
concentration (Leung et al., 2013, Pai et al., 2015). Analysis of folate metabolites was 
performed by Dr Kit-Yi Leung. 
 
2.6.5. Assessment of formate levels 
Formate levels in blood and urine samples were measured by gas chromatography mass 
spectrometry (GC-MS). Formate was derivatised by incubating with pentafluorobenzyl 
bromide in acetone (alkylating reagent) and the organic phase extracted by addition of n-
hexane. The organic phase was then injected on an Agilent DB-225 J&W GC column and 
resolved with a Thermo Fisher TRACE ULTRA Gas Chromatograph coupled to an ISQ mass 
selective detector and AS3000 Autosampler in electron-impact ionisation mode. Formate 
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was quantified with reference to a standard curve (Lamarre et al., 2014). Formate levels 
were analysed by Dr John Brosnan and Dr Margaret Brosnan (Memorial University of 
Newfoundland, Canada). 
 
2.7. Gold chloride en bloc staining 
 
Gold chloride stains for myelinated axons and was used for studies on the corpus 
callosum.  The protocol used was simplified from an en bloc staining technique outlined by 
(Wahlsten et al., 2003). After a 48 hr fixation in 4% PFA, the 5-week brains were rinsed 
briefly in distilled water. They were then carefully sliced mid-sagitally into left and right 
halves with a scalpel and incubated in 0.1% gold chloride solution (Sigma-Aldrich) at 37 
°C. Incubation was stopped after approximately 1 hr 30 min, when staining of the corpus 
callosum became visible to the naked eye. The staining was then fixed by immersing in 
2.5% sodium thiosulfate (Sigma-Aldrich) for 5 min. The half brains were transferred to 
PBS for measurement of the corpus callosum under a stereo microscope using an eyepiece 
graticule.  
 
2.8. Image capture and data analysis 
 
All images of whole embryos and brains were captured with a DFC490 camera (Leica) 
mounted on a Stemi SV11 stereomicroscope (Zeiss). For sections, bright-field micrographs 
were captured on an Axioplan 2 microscope (Zeiss) using the AxioVision v4.8.2 software, 
while fluorescence images were taken with an Axiophot microscope (Zeiss) mounted with 
a Leica DC500 camera using the Leica FireCam software.  
Brightness and contrast adjustments, image cropping, and composite image assemblies 
were done with Adobe Photoshop CS3 or the ImageJ 1.47v software (National Institutes of 
Health, USA). Cell counting for proliferation studies using anti-phospho-histone H3 
staining was performed using the Cell Counter plugin in ImageJ. All graphs were plotted 
with SigmaPlot 2001 or Microsoft Excel 2010. All statistical analyses were carried out with 
SigmaStat 3.5. 
  
77 
 
3. Embryonic phenotypes in the Gldc-deficient mouse 
model 
 
 
3.1. Introduction 
 
Much of the pathogenicity of non-ketotic hyperglycinemia (NKH) and GCS-associated 
neural tube defects (NTDs) is unknown. The complications of studying NKH, like many 
metabolic disorders, stem largely from its heterogeneous presentation and the lack of a 
suitable in vivo system to model its most common form. On the other hand, NTDs are far 
from lacking in animal models but their multifactorial aetiology remains notoriously 
difficult to unpick. The success of folic acid treatment is undeniable, but its mechanism of 
rescue is poorly understood and the phenomenon of folic acid resistance is largely 
unexplained. 
The first step in this project is to obtain a suitable mouse model for Gldc that would allow 
investigation of its requirement during embryonic development, involvement in folate 
metabolism and NTDs, modelling of the classical form of NKH, and testing of treatment 
options for its associated disease phenotypes. The various strategies for mouse 
mutagenesis and transgenesis are thus explored below. 
 
3.1.1. Classical mutagenesis  
Large-scale, classical mutagenesis projects in the mouse were originally performed to 
assess effects of germ-line mutations as a consequence of nuclear and chemical weapons, 
and were carried out in centres that were historically established as nuclear physics 
laboratories such as Oak Ridge and MRC Harwell (Silver, 1995). Whole body exposure to 
ionising radiation such as X-rays or injections with alkylating agents like N-ethyl-N-
nitrosourea (ENU) and chlorambucil (CHL) into differentiating germ cells were used to 
randomly target multiple regions of the genome. Ionising radiation produced large 
deletions, translocations and chromosomal aberrations, while ENU and CHL injections 
resulted in point mutations and large-scale, multi-locus deletions respectively (Russell et 
al., 1979, Russell et al., 1989).  
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The nature of classical mutagenesis techniques was such that target sites in the genome 
were entirely random and required positional cloning with sufficient molecular resolution 
to identify them. Where large lesions were produced, such as with ionizing radiation and 
CHL injections, multiple disease phenotypes may occur which complicates the task of 
discerning the specific genes responsible. On the other hand, the single nucleotide hits 
produced by ENU may at times be difficult to identify. As technology for generating 
genetically modified mice progressed, a more directed approach to mutagenesis was 
introduced with gene targeting. 
 
3.1.2. Gene targeting and transgenesis  
The most direct method for generating genetically modified mice begins with cloning of 
the desired gene with a ubiquitous or tissue-specific promoter, a positive selection marker 
and/ or reporter gene, and a 3’ polyadenylation (polyA) transcription termination site, 
into a plasmid, viral, or artificial chromosome backbone. The construct is then 
microinjected into the pronucleus of a fertilised oocyte, integrates randomly, and 
replicates along with the host genome (Jackson and Abbott, 2000).  
Gene targeting techniques were developed to create gene-specific mutations in ES cells 
and are based on the principle of homologous recombination between sequences in the 
construct and its precise endogenous counterpart for integration. ES cells with 
successfully integrated vectors can then be injected into blastocyst-staged embryos, and 
the resultant chimeric mice would be able to produce transgenic offspring if germ-line 
transmission from the ES cells is successful. Pioneering work on gene targeting was 
carried out in the labs of Oliver Smithies, Mario Capecchi, and Martin Evans, who jointly 
won the 2007 Nobel Prize in Medicine or Physiology (Evans and Kaufman, 1981, Smithies 
et al., 1985, Thomas and Capecchi, 1987). 
The classical “knock-out” model involves replacing or interrupting the endogenous coding 
sequence of a gene with a selection marker gene, resulting in a null allele. Vector 
constructs may be designed to cause a frameshift mutation or to remove the entire gene (if 
possible) to ablate gene function. The vector DNA is introduced into ES cells in culture. 
Successfully transfected clones are then used to produce chimeric mice by blastocyst or 
morula injection (Joyner, 2000).  A “knock-in” strategy was later devised, whereby a 
transgene is inserted into the target region and placed under endogenous transcriptional 
control. While the knock-out technique was limited to studying the effects of losing the 
gene, knock-ins allowed for more specific or subtle mutations to be examined (Joyner, 
2000).  
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3.1.3. Gene-trapping  
Gene-trap strategies were developed next, which reverted back to random integration of 
reporter genes, but in a way that allowed for successful transcription of the reporter gene 
only when the endogenous splicing mechanism is active. A gene-trap vector design 
contains a splice acceptor site at the 5’ end, a promoterless reporter gene such as lacZ or 
gfp with a polyA tail, and a selector marker gene such as neomycin (or a combined 
reporter/selector fusion gene such as β-geo). In-frame integration of the vector into an 
intronic sequence (or, alternatively, inclusion of an IRES sequence 5’ to the reporter) 
allows for splicing of fusion transcripts containing a truncated endogenous sequence 
followed by the vector reporter sequence and ending at the vector’s polyA tail (Joyner, 
2000). Usually, this also results in the disruption of the gene. Successful transription and 
translation of the reporter gene produces a signal (i.e. positive staining of β-galactosidase 
or green fluorescent protein, GFP) wherever and whenever the endogenous gene is 
actively expressed, allowing for visualisation of the spatiotemporal pattern of gene 
expression (Skarnes et al., 1992, Chalfie, 1995). 
The completion of the human genome project and, subsequently, the mouse genome 
project, made available a wealth of genetic information. That, combined with gene-
trapping techniques, provided a strategy for high-throughput generation of new 
mutations, as ES cell lines containing gene-traps can be mass-produced and stored in 
liquid nitrogen with relative ease. As the integration sites (i.e. the random targets of the 
gene-traps) of all these ES clones can be sequenced and identified, selected target genes 
can then be introduced into mice to produce transgenic animals ready for functional 
studies. Tens of thousands of ES cell lines are now made available through large-scale 
mouse mutagenesis projects such as the International Gene Trap Consortium (IGTC; 
http://www.genetrap.org/info/overview.html), whose members and affiliates include the 
European Conditional Mouse Mutagenesis Program (EUCOMM) and the North American 
Conditional Mouse Mutagenesis project (NorCOMM).  
 
This project utilises two Gldc gene-trap models available as ES cells from EUCOMM and 
NorCOMM. This chapter focuses on characterisation of the gene-traps and the embryonic 
phenotypes obtained.  
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3.2. Results 
 
3.2.1. Expression analysis of Gldc 
  
3.2.1.1. Gldc mRNA expression in neurulation-stage mice embryos 
The mRNA and protein expressions of GCS genes have been explored at late-
developmental and post-natal stages (Sakata et al., 2001, Ichinohe et al., 2004), but their 
expression patterns in early development are not known. As NTDs occur in the Amt 
knockout mouse, the question arises as to whether GCS genes are expressed at neurulation 
stages. An mRNA probe spanning exons 4 to 9 of the Gldc transcript was generated and 
whole mount in situ hybridisation was carried out on E8.5 to E10.5 wild-type embryos.  
Figure 6 shows the expression pattern of Gldc mRNA at E8.5 when neural tube closure has 
initiated and at E9.5 when cranial closure was complete but spinal closure still ongoing. At 
E8.5 (Figure 6A-E), Gldc mRNA was intensely expressed in the neural folds throughout 
the entire anterior-posterior length of the neural tube at all stages of neural tube closure 
(open neural folds, elevated but unfused folds, and fused folds) and in the branchial arches 
and foregut. At E9.5 (Figure 6F-J), strong expression of Gldc in the entire neural tube 
persisted. Intense staining was also found in the periphery of the branchial arches, optic 
vesicles, otic vesicles, hindgut, and limb buds. 
At E10.5 (Figure 7) when spinal neurulation is complete, Gldc mRNA was still present 
throughout the neural tube, branchial arches, optic vesicles, hindgut and limb buds but the 
staining was fainter and more ubiquitous than earlier stages. 
Thus, Gldc is present in the appropriate tissue (i.e. neural folds) at the appropriate stages 
for loss of function to have an effect on neural tube closure. Gldc expression also closely 
matched areas with high proliferation during those stages of embryonic development. 
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Figure 6. Expression pattern of Gldc mRNA in E8.5 and E9.5 wild-type embryos.  
(A) Whole mount in situ hybridisation for Gldc on an E8.5 embryo. (B-E) Sections through 
(A), where Gldc mRNA was expressed in open cranial folds (B), elevated but unfused folds 
(C), closed neural tube (NT) (D), and open posterior neuropore (E). (F) Whole mount in 
situ hybridisation for Gldc on an E9.5 embryo. (G) Dorsal view of (A). (H-J) Sections 
through (F, G), in which expression of Gldc persisted through the entire neural tube. Gldc 
expression was also seen in the branchial arch pouches (BA), optic vesicles (OP), otic 
vesicles (OV), foregut (FG) and hindgut (HG), and limb buds (LB).  
Other abbreviations: hindbrain (HB), forebrain (FB). Scale bars: 1 mm. 
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Figure 6. Expression pattern of Gldc mRNA in E8.5 and E9.5 wild-type embryos. 
83 
 
Figure 7. Expression pattern of Gldc mRNA in E10.5 wild-type embryos. 
(A) Whole mount in situ hybridisation for Gldc on an E10.5 embryo. (B-D) Sections 
through (A), where Gldc mRNA expression was overall less intense than at E8.5 and E9.5 
(as shown in Figure 6), but was nonetheless still specific to the neural tube, optic vesicles 
(OP), hindgut (HG), and limb bud (LB). (E, G) represent sense control embryos, with 
vibratome sections through them (F, H).  
Other abbreviations: hindbrain (HB), forebrain (FB). Scale bars: 1 mm. 
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Figure 7. Expression pattern of Gldc mRNA in E10.5 wild-type embryos. 
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3.2.2. Gldc gene-trap models 
 
3.2.2.1. Defining the locus and trapping efficiency of the GldcGT1 allele  
The Gldc mouse model is a novel model and is used in this project to determine whether 
loss of Gldc function is sufficient to cause NTDs. GldcGT1 gene-trap mice were generated 
from ES cells obtained from EUCOMM (Gldc clone EUCG0001_DO2) and crossed into a 
129/Sv wild-type background as described in Chapter 2. The GldcGT1 allele carries a 
conditional gene-trap construct that was reportedly inserted into intron 2-3 of the Gldc 
gene, and should contain a β-geo reporter which would stain for lacZ expression in ES cells 
and embryos (information provided by EUCOMM). 
To detect the gene-trap allele, PCR primers were designed to bind to the intronic sequence 
at the immediate 5’ end of the construct and to the LTR sequence (F2R1 primer pair in 
Figure 8A). A pair of neo primers also produced a PCR product in the presence of the 
gene-trap allele (F3R2 primer pair in Figure 8A). The wild-type allele is detected by a pair 
of PCR primers that bind to intronic sequences on either ends of the construct and only 
amplify in the absence of the construct (F1R3 primer pair in Figure 8A, B). This 
genotyping strategy, as illustrated in Figure 8C, was tested on genomic DNA from the 
GldcGT1 ES cell line as well as offspring of chimeric mice crossed with wild-type 129/Sv 
mice which, with successful germline transmission, would produce heterozygous GldcGT1/+ 
mice. 
When whole mount X-gal staining was carried out on mutant embryos from this initial 
cross to detect for Gldc-lacZ staining, none was observed (Figure 9). To investigate the 
lack of X-gal staining and initial problems with optimizing the genomic DNA PCR 
genotyping, the entire gene-trap was amplified and sequenced. Sequencing of the F2R1 
PCR product confirmed that the site of gene-trap insertion (i.e. the breakpoint) was 
between nucleotides 30,171,315 and 30,171,314 of intron 2-3 of the Gldc gene 
(ENSMUSG00000024827). Long-Range PCR was then carried out to amplify the construct 
from this breakpoint site and across the entire gene-trap to the intronic region at the 3’ 
end of the construct, producing a 4 kb-sized fragment.  
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Figure 8. Gldc gene-trap 1 (GldcGT1) design and genomic PCR genotyping strategy. 
(A) The GldcGT1 gene-trap allele showing the construct inserted between exons 2 and 3 of 
the Gldc gene. The F2R1 and F3R2 primer pairs were designed to amplify only in the 
presence of the construct. (B) The wild-type allele of the Gldc gene, showing the F1R3 
primer pair which is only able to amplify when the 4 kb construct in between them is 
absent. (C) The genomic PCR genotyping strategy for GldcGT1 mice, in which presence of 
only the F1R3 band denotes a wild-type (Gldc+/+), all 3 bands denote a heterozygote 
(GldcGT1/+), and only the F2R1 and F3R2 bands denote a homozygote (GldcGT1/GT1). 
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Figure 9. Whole mount X-gal staining of GldcGT1 E10.5 embryos. 
GldcGT1 embryos did not stain positive for Gldc-lacZ expression as predicted from the initial 
gene-trap design provided. 
 
Sequencing of various parts of this 4 kb fragment using a primer walking strategy 
(outlined in Chapter 2) led to the identification of the Frt, F3, loxP, and lox5171 sites on 
the 5’ end of the construct up to the neo reporter sequence by comparing to reference 
sequences found online at http://www.ncbi.nlm.nih.gov/nuccore/ (accession numbers: 
CS436287.1 for Frt, CS436288.1 for F3, 116807196 for loxP, and CS436285.1 for lox5171). 
However, the reporter sequence contained only a neomycin cassette and not the full β-geo 
sequence that was indicated in the original gene-trap design. This would explain the 
successful amplification of a neo PCR band but the lack of lacZ staining in the embryos. The 
full sequencing results (with annotation) are provided in Appendix 1. 
When initial matings to generate experimental litters were carried out with GldcGT1/+ pairs 
on the 129/Sv background, a large number of resorption and embryonic lethality was 
observed at E10.5. Very few GldcGT1/GT1 were successfully collected, and the few that 
survived to E10.5 exhibited severe growth retardation and occasional cranial NTDs. The 
number of viable mutants was insufficient to carry out experiments. To circumvent this 
problem, the chimeras were crossed to wild-type mice on a C57BL/6 genetic background 
to generate heterozygous mice. These mice were viable and fertile, and were inter-crossed 
to produce experimental litters. This cross was able to produce all 3 genotypes that 
survived to birth, with an average litter size of 7 and resorption rates of no more than 1 
per litter. The proportion of embryo genotypes collected followed a 1:2:1 Mendelian ratio 
(Table 10), indicating that no embryonic lethality had occurred in homozygous embryos. 
All experiments hereon in using the GldcGT1 allele was generated with this cross.  
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Stage 
(E-) 
No. of 
litters 
Average 
litter 
size 
Average no. of 
resorptions per 
litter 
No. of embryos 
Gldc+/+ GldcGT1/+ GldcGT1/GT1 
10.5 16 7.9 0.69 35 64 28 
11.5 23 7.6 1.04 30 94 51 
12.5 1 - - 1 5 3 
13.5 1 - - 1 0 3 
15.5 12 7.1 0.33 28 31 26 
16.5 1 - - 0 4 3 
18.5 9 6 0 12 27 15 
TOTAL - - - 107 225 129 
Proportion - - - 0.23 0.49 0.28 
Table 10. Litter information of GldcGT1/+ crosses on a C57BL/6 genetic background. 
 
To test the trapping efficiency of the GldcGT1 gene-trap, Gldc mRNA levels in adult mice 
were assessed. A quantitative RT-PCR (qRT-PCR) strategy was used on cDNA generated 
from liver and brain samples (where Gldc is known to be highly expressed). The qRT-PCR 
primers were designed to amplify a 338 bp product corresponding to exons 2 to 4 of the 
wild-type Gldc transcript (ENSMUST00000025778). In the gene-trap allele, alternative 
splicing from exon 2 to the splice acceptor site of the construct would result in a truncated 
mRNA missing exons 3 to 25 (illustrated in Figure 10A, B) which would fail to be detected 
by the wild-type primers (i.e. no wild-type Gldc mRNA is produced).  
As shown in Figure 10C, heterozygous mutants (GldcGT1/+) only produced 30-40% of wild-
type Gldc mRNA, while homozygous mutants (GldcGT1/GT1) showed 0–10% mRNA levels. 
The residual qRT-PCR product from homozygous mutants was run on an agarose gel, and 
demonstrated the same band size as the wild-type band. This would correspond to low-
level expression of Gldc (as opposed to a non-specific product) and indicates that the 
GldcGT1 gene-trap confers a strongly hypomorphic allele. 
Measurement of actual Gldc enzymatic activity was performed on liver samples using the 
[1-14C]glycine decarboxylation reaction which is based on release of labelled CO2 from 
glycine (carried out by Dr Tim Hutchin, Birmingham Children’s Hospital). Despite the 60% 
reduction in abundance of mRNA in GldcGT1/+ mice, enzymatic activity was still comparable 
to wild-type levels. However, enzymatic activity in GldcGT1/GT1 mice was almost completely 
undetectable (Figure 11).  
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Figure 10. Assessment of Gldc mRNA levels in GldcGT1 adult mice liver and brain. 
(A) Splicing of wild-type Gldc mRNA produces a transcript corresponding to the 25 exons 
of the Gldc gene. Primers for qRT-PCR were designed to amplify the region corresponding 
to exons 2 to 4. (B) Alternative splicing to the GldcGT1 gene-trap results in a truncated 
mRNA containing only exons 1 and 2, and the primers would fail to amplify a product. (C) 
qRT-PCR results showing levels of Gldc mRNA in GldcGT1 mutant liver and brain samples, 
normalised to their respective wild-types. In GldcGT1/+ mutants, 30–40% of mRNA was 
produced. In GldcGT1/GT1 mutants, only 0–10% of mRNA could be detected. Error bars 
represent mean ± SEM (ANOVA, p<0.001). 
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Figure 10. Assessment of Gldc mRNA levels in GldcGT1 adult mice liver and brain.   
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Figure 11. Enzymatic activity of Gldc in GldcGT1 adult mice livers. 
GldcGT1/+ mice livers show Gldc enzymatic activity comparable with wild-types at average 
106.6 and 97.2 pmol CO2/min/g respectively, while GldcGT1/GT1 livers showed a significant 
decrease in enzymatic activity, at average 4.5 pmol CO2/min/g. Error bars represent mean 
± SEM (*ANOVA, p<0.001).  
 
3.2.2.2. GldcGT2 gene-trap line 
Owing to the initial difficulties in genotyping and confirming efficiency of the GldcGT1 gene-
trap, an ES cell line containing a different Gldc gene-trap was ordered from NorCOMM 
(clone CMHD-GT_519C8). This cell line was similarly used to generate a second Gldc gene-
trap mouse model, designated GldcGT2, on C57BL/6 background.  
The GldcGT2 gene-trap construct was inserted into intron 19-20 of the Gldc gene. 
Alternative splicing to the construct’s splice acceptor site should result in truncated Gldc 
mRNA lacking exons 20 to 25. Genomic PCR genotyping was carried out using primers that 
bind to the EGFP reporter sequence for detection of the gene-trap allele, and intronic 
primers that bind to either ends of the construct for detection of the wild-type allele 
(Figure 12). The genotypes of litters generated by crosses of heterozygous GldcGT2/+ mice 
did not differ significantly from a 1:2:1 Mendelian genotype ratio (Z-test) (Table 11). 
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Figure 12. Gldc gene-trap2 (GldcGT2) design and genomic PCR genotyping strategy.  
(A) The GldcGT2 gene-trap is inserted between exons 19 and 20 of Gldc, where alternative 
splicing to the splice acceptor (SA) results in a truncated mRNA missing exon 20 onwards. 
F5R4 primers bind to the EGFP reporter sequence of the gene-trap allele. (B) The F4R5 
primer pair binds to a region in intron 19-20 and would only amplify in the absence of the 
gene-trap. 
 
Stage 
(E-) 
No. of 
litters 
Average 
litter 
size 
Average no. of 
resorptions per 
litter 
No. of embryos 
Gldc+/+ GldcGT2/+ GldcGT2/GT2 
10.5 12* 8 0.1 23 59 14 
11.5 6* 8.7 0 14 32 6 
13.5 5* 7.4 0 4 25 8 
14.5 2 9.5 0.5 3 9 7 
15.5 4 8.8 1 5 17 13 
16.5 1 8 0 2 3 3 
TOTAL - - - 51 145 51 
Proportion - - - 0.21 0.59 0.21 
Table 11. Litter information of GldcGT2/+ crosses on a C57BL/6 genetic background. 
*7 out of 23 litters at E10.5, E11.5, and E13.5 stages collected by Maria-Chiara Autuori  
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3.2.3. Developmental phenotypes of Gldc mutant embryos 
 
3.2.3.1. NTD incidence in GldcGT mutants 
Examination of experimental litters generated by heterozygous crosses of both GldcGT1 and 
GldcGT2 mice revealed that at E9.5 and E10.5, cranial neural folds remained open at the 
midbrain-hindbrain region of some homozygous mutants. This failure of closure resulted 
in exencephaly, which is characterised by the exposed brain tissue at E15.5 (Figure 13). 
 
Figure 13. NTDs in GldcGT1 mutant embryos. 
(A-C) Gldc+/+ embryos appeared normal at all stages of development. Cranial NTDs were 
observed in GldcGT1/GT1 embryos where neural folds were open in the midbrain-hindbrain 
region at E9.5 (D) and E10.5 (E) and resulted in exposed brain tissue at E15.5 (F). Arrows 
denote regions where the neural tube remained open. Scale bars: 1mm. 
 
More severe cranial phenotypes were observed in GldcGT2 mutants (Figure 14). Hindbrain 
exencephaly tended to extend further rostrally into the midbrain as well as to a more 
caudal somite level. In some mutants, the cranial neural tube was open throughout the 
midbrain and forebrain, resulting in a characteristic split face phenotype. This was often 
accompanied by what appears to be moderate to severe truncation of the forebrain, 
resulting in shortening of the rostro-caudal length of the cranial region. Craniorachischisis 
was also observed at very low frequencies.  
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Figure 14. NTDs and craniofacial defects in E10.5 GldcGT2 mutant embryos. 
(A) Gldc+/+ embryos from a GldcGT2/+ inter-cross appeared normal. The cranial NTDs in 
GldcGT2/GT2 (B, C, C’) and GldcGT2/+ (D, D’, E, E’) embryos showed varying severity. In (B) the 
midbrain-hindbrain region was unfused. In (C) the entire cranial region was open, 
resulting in split face with underdeveloped maxillary processes (dashed-line circles) and 
truncated forebrain as observed in a frontal view (C’). Hindbrain fusion occurred in (D) 
but at higher magnification (D’) the midbrain and anterior neuropore (dashed lines) were 
open on either sides of the closure 2 point (*). (E) Frontal view of a GldcGT2/+ embryo 
displaying craniorachischisis, with a dorsal view of the same embryo shown in (E’). 
Arrows denote regions where the neural tube remained open. Scale bars: 1mm.  
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The incidence of NTDs in GldcGT1 and GldcGT2 mutants are reported in Table 12 and Table 
13, respectively. The specific stage of cranial neural tube closure may vary between mouse 
strains and mutations may also delay closure to a later somite stage. To account for 
possible delayed closure, NTDs in GldcGT mutants were defined as an open neural tube in 
embryos with 18 or more somites, as all wild-type littermates had completed cranial 
closure by the 17-somite stage.  
 
Stage (E-) 
No. of NTDs/ Total no. of embryos (% NTD) 
Gldc+/+ GldcGT1/+ GldcGT1/GT1 
9.5 (≥18 somites) 0/45 0/76 11/38 (29%) 
10.5 0/35 0/64 2/28 (7%) 
11.5 0/30 2/94 (2.4%) 7/51 (13.7%) 
12.5 0/1 0/5 0/3 
13.5 0/1 0 0/3 
15.5 0/28 0/31 6/26 (23%) 
16.5 0 0/4 1/3 (33%) 
18.5 0/12 0/27 4/15 (27%) 
TOTAL 0/152 2/301 (0.7%) 31/167 (18.6%) 
Table 12. Incidence of NTDs in embryos with the GldcGT1 allele. 
 
Stage (E-) 
No. of NTDs/ Total no. of embryos (% NTD) 
Gldc+/+ GldcGT2/+ GldcGT2/GT2 
9.5 (≥18 somites) 0/18 0/32 9/11 (82%) 
10.5* 0/23 5a/59 (8.5%) 8b/14 (57%) 
11.5* 0/14 2/32 (6.25%) 6/6 (100%) 
13.5* 0/4 3/25 (12%) 3/8 (37.5) 
14.5 0/3 0/9 3/7 (43%) 
15.5 0/5 0/17 4/13 (31%) 
16.5 0/2 0/3 2/3 (67%) 
TOTAL 0/69 10/177 (5.6%) 35/62 (56.5%) 
Table 13. Incidence of NTDs in embryos with the GldcGT2 allele.  
a3 exencephaly (EX) only, 1 EX with forebrain truncation, 1 craniorachischisis 
b5 EX only, 3 EX with split face and/or forebrain truncation 
*7 litters (56 embryos) at E10.5, E11.5, and E13.5 stages collected by Maria-Chiara Autuori   
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On average, NTDs occurred in 18.6% of GldcGT1/GT1 and 0.7% of GldcGT1/+ embryos (Table 
12). There was a curious reduction in incidence of NTDs at E10.5 and E11.5 (7% and 
13.7%, respectively) compared with other developmental stages, in which the lowest 
proportion of NTDs was 23%. This discrepancy is investigated in Section 3.2.3.4. 
In the presence of the GldcGT2 allele, NTD incidence was an average of 57% in GldcGT2/GT2 
and 5.6% in GldcGT2/+ (Table 13). Craniorachischisis was also observed in two embryos, 
one E10.5 GldcGT2/+ embryo, and a 15-somite staged GldcGT2/GT2 embryo (not included in 
Table 13 as the somite count is below 18). Out of the total number of exencephalic 
embryos in both heterozygous and homozygous embryos (n = 44), 4 embryos (9.1%) 
displayed split face and/or forebrain truncation. Also not represented in this table are two 
more occurrences of craniorachischisis and higher numbers of exencephaly coupled with 
split face and/or forebrain truncation which occurred during and after the period of 
fenbendazole exposure (see Chapter 4 for details). 
In humans, cranial NTDs are known to occur at a higher incidence in females (Juriloff and 
Harris, 2012b). This finding is also true in several NTD mice models, e.g. Splotch2H (Burren 
et al., 2008). However, the NTDs in GldcGT1/GT1 embryos occurred in roughly the same 
proportion of males and females; no gender bias was observed (Figure 15). 
 
 
Figure 15. Sex of GldcGT1/GT1 embryos and occurrence of NTDs. 
The incidence of NTDs in GldcGT1/GT1 embryos appeared the same in both males (17.6%) 
and females (17.9%) (Z-test, P = 0.877).   
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3.2.3.2. mRNA and protein expression levels during neurulation 
To investigate the partial penetrance of NTDs in GldcGT embryos as well the difference in 
NTD incidence between the GldcGT1 and GldcGT2 alleles, mRNA expression levels were 
measured and assessed. Gldc mRNA levels in E9.5 and E10.5 embryos of both alleles were 
first quantified by qRT-PCR. For each experimental group (E9.5 and E10.5 of GldcGT1 and 
GldcGT2), one wild-type was chosen as the reference sample, set to a Relative Quantitation 
value of “1” (corresponding to an expression level at 100%) to which other samples were 
normalised. 
For the GldcGT1 allele (Figure 16A), heterozygous embryos showed about 40-50% of wild-
type Gldc mRNA levels. In homozygous embryos, this level was reduced to 10-30%. 
Homozygous embryos with NTDs showed 10–20% of wild-type levels.  
For the GldcGT2 allele (Figure 16B), a greater reduction in expression of wild-type mRNA 
was observed. With the exception of a few embryos, most heterozygotes showed 30% of 
wild-type mRNA levels, while most homozygotes showed no detectable Gldc mRNA at all. 
Most strikingly, Gldc mRNA was not detectable in heterozygous and homozygous embryos 
with NTDs for the GldcGT2 allele; they were apparently nulls. 
These findings suggest that the level of Gldc mRNA could partly explain the partial 
penetrance of NTDs in these embryos. A lower level of Gldc expression appeared to 
produce higher NTD incidence, as seen in the GldcGT2 allele where all embryos displaying 
NTDs were nulls. Hence, all embryos with NTDs showed very little to no detectable Gldc 
mRNA (this is especially true for the GldcGT2 allele), and there appears to be a correlation 
between mRNA levels and rate of NTDs. Heterozygotes had a larger spread of mRNA levels 
that typically fell between wild-type and homozygote values, and one heterozygous 
GldcGT2/+ mutant that presented with an NTD showed no detectable levels of mRNA.  
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Figure 16. mRNA levels in E9.5 and E10.5 embryos of the GldcGT1 and GldcGT2 alleles. 
(A) GldcGT1/+ embryos showed 40–50% of wild-type mRNA levels, while GldcGT1/GT1 
embryos showed 20–30% expression. In homozygous mutants with NTDs, the level of 
expression was about 10–20%. (B) Most GldcGT2/+ embryos showed 20–30% of wild-type 
mRNA levels, while most GldcGT2/GT2 embryos showed no mRNA. GldcGT2/+ and GldcGT2/GT2 
embryos with NTDs were complete nulls. (*) and (**) denote significant difference when 
compared with wild-type and heterozygotes, respectively. Error bars represent mean ± 
SEM (ANOVA, P<0.001).  
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3.2.3.3. Analysis of growth and development 
Perturbation of the FOCM in other mouse models (e.g. Splotch and curly tail) via diet-
induced folate deficiency has resulted in retardation of growth and development (Burren 
et al., 2008). As Gldc is an FOCM enzyme, GldcGT mutant embryos were predicted to also 
show similar defects. The rate of growth and development of GldcGT embryos were thus 
assessed by measuring crown rump length (CRL) and somite number (SN), respectively.  
GldcGT1/+ embryos did not show any difference in CRL and SN from wild-type embryos 
(Figure 17). However, GldcGT1/GT1 embryos had significantly reduced CRL and SN at E9.5 
and E10.5, indicating that they were growth and developmentally delayed. The same 
significant reduction in CRL and SN was seen in homozygous GldcGT2/GT2 embryos 
compared with wild-type and heterozygous embryos (Figure 18). In GldcGT2/GT2 embryos 
at E10.5, CRL values were reduced compared with wild-types and heterozygotes, but this 
difference was not significant (Figure 18A). The difference in SN values, however, was 
significant (Figure 18B). The CRL and SN of GldcGT2/+ embryos also showed non-significant 
reductions compared with wild-types. 
To investigate whether there was a correlation between the extent of growth and 
developmental retardation and occurrence of NTDs, a second CRL graph was plotted that 
divided the E9.5 homozygous mutant groups into those with NTDs (affected) and without 
NTDs (normal) (Figure 17A’ and Figure 18A’). All embryos with somite number below 18 
were excluded as embryos at an earlier stage than that could not be reliably scored for an 
NTD. This plot demonstrates that normal mutants did have decreased CRL, thus growth 
retardation occurs in homozygous mutants but is not necessarily accompanied by an NTD. 
Interestingly, NTD-affected mutants carrying the GldcGT1 allele were more severely 
growth-retarded compared to unaffected GldcGT1 mutants (Figure 17A’). It must be noted, 
however, that this analysis risks introducing selection bias by excluding embryos that may 
be developmentally retarded to below 18 somites when compared with a wild-type 
littermate, thus possibly underestimating their rate of NTD. 
When CRL values of GldcGT1 embryos were plotted against their respective SN values, no 
dissociation between rate of growth and rate of development was seen between different 
genotypes, as indicated by the overlapping regression lines in Figure 19. Thus, while 
homozygous embryos were smaller and less developed compared with wild-types, their 
sizes were appropriate to their developmental stages. Nonetheless, the mutants that 
exhibit NTDs tend to be growth and developmentally delayed, suggesting that 
developmental retardation may contribute to failure of closure.  
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Figure 17. Crown rump length and somite number of GldcGT1 embryos. 
GldcGT1/GT1 embryos have significantly reduced crown rump length, CRL (A) and somite 
numbers (B) at E9.5 and E10.5, when compared with Gldc+/+ and GldcGT1/+ (*). When E9.5 
normal and affected GldcGT1/GT1 embryos were analysed as separate groups (A’), the CRL of 
both groups showed significant reduction from Gldc+/+ (*), with the affected group showing 
further significant reductions compared with the unaffected mutant group (**). ANOVA, 
P<0.001. Sample sizes indicated in each bar, error bars represent mean ± SEM.  
101 
 
 
Figure 18. Crown rump length and somite number of GldcGT2 embryos. 
GldcGT2/GT2 embryos have significantly reduced crown rump length (A) and somite number 
(B) at E9.5 and E10.5, when compared with Gldc+/+. When E9.5 unaffected and affected 
embryos were analysed separately, both showed similar reductions in CRL but the 
reduction was only significant in the affected group. ANOVA, *P<0.001, **P<0.05. Sample 
sizes indicated in each bar, error bars represent mean ± SEM. 
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Figure 19. Regression curve of crown rump length versus somite number of GldcGT1 
embryos. 
When crown rump length of E9.5 and E10.5 embryos with more than 12 somites (after 
axial rotation has occurred) was plotted against somite number, with the exception of a 
few outliers, no overall dissociation between rate of growth and rate of development was 
observed. 
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3.2.3.4. Unusual cranial phenotypes in GldcGT1 mutants 
Amongst E10.5 and E11.5 GldcGT1 mutant embryos that did not show an open NTD, a small 
subset presented with a distorted cranial region and spots of haemorrhage (Table 14). 
 
Stage (E-) 
No. with unusual cranial phenotype/ Total no. of embryos 
Gldc+/+ GldcGT1/+ GldcGT1/GT1 
9.5 (≥18 somites) 1/45 (2.2%) 2/76 (2.6%) 1/38 (2.6%) 
10.5 1/35 (2.9%) 6/64 (9.4%) 6/28 (21.4%) 
11.5 0/30 8/94 (8.5%) 3/51 (5.9%) 
TOTAL 2/110 (1.8%) 16/234 (6.8%) 10/117 (8.5%) 
Table 14. Incidence of unusual cranial phenotypes in GldcGT1 embryos. 
 
To examine this phenotype in more detail, 10 of these embryos were sectioned in the 
transverse (Figure 20) or coronal (Figure 21) planes and compared with respective wild-
types.  
Among embryos with abnormal cranial phenotypes that were sectioned, 9 had 
neuroepithelial layers that successfully elevated and apposed but had a small region that 
remained unfused (shown in Figure 20E, and Figure 21E, K, R).  The hindbrain and 
forebrain cavities appeared “collapsed in” and the neuroepithelial layers were severely 
distorted (seen in Figure 20E, H, and Figure 21E, F, H, I, K, L, N, O, Q, R). In sections 
through the exencephalic embryo shown in Figure 20C, the neural folds in the hindbrain 
region were splayed open (Figure 20F, I, L). Interestingly, in 2 of these embryos with 
abnormal cranial region, the overlying surface ectoderm layer was found to be intact over 
the unfused neuroepithelial layer (shown in Figure 21F, H, I, N, O). 
Another common finding in these embryos was the presence of haemorrhagic spots in the 
cranial region (7 out of 10). Curiously, clumps of nucleated cells that often stained 
intensely red with eosin, resembling juvenile red blood cells (RBCs), were present in the 
extracellular matrix between the surface ectoderm and neuroepithelium and in the 
adjacent mesoderm (seen in Figure 20E, K, and Figure 21H, I, L, O, R). In 1 out of the 10 
embryos, the neuroepithelial layer appeared fused throughout but a thick layer of juvenile 
RBCs was found in between the surface ectoderm and neuroepithelium (Figure 22). 
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Figure 20. Transverse sections of GldcGT1 embryos at E11.5. 
A wild-type embryo (A), a mutant with an abnormal cranial region (B), and a mutant with 
an overt, visible NTD (C) were sectioned in the transverse plane as indicated by the dotted 
lines. (D, G, J) Sections through embryo (A) with the hindbrain (HB) and forebrain (FB) 
labelled. Regions boxed with dotted lines are shown in higher magnification in (D’, G’, J’) 
and indicate the fused neuroepithelium (NE) and surface ectoderm (SE) layers. (E, E’, H, 
H’, K, K’) Sections through embryo (B) show distorted hindbrain and forebrain, a region of 
unfused NE (E’), and clumps of cells that may be juvenile RBCs between the SE and NE 
layers (black arrows in E’ and K’). (F, I, L) Sections through embryo (C) with hindbrain 
exencephaly (white arrow), showing neural folds splayed open (*) and distorted forebrain.  
Scale bars: 1 mm for A-C; 0.5 mm for D-L. Sections were stained with H&E. 
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Figure 20. Transverse sections of GldcGT1 embryos at E11.5. 
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Figure 21. Coronal sections of GldcGT1 embryos at E10.5–E11.5. 
A wild-type embryo (A) and mutants with abnormal cranial phenotype (B, C) sectioned in the coronal plane as indicated by the dotted lines. White arrow 
indicates a visible opening in the midbrain of embryo (B’). (D, G, J, M, P) Sections through embryo (A), showing normal neural tube morphology with 
boxed regions shown in higher magnification on the right (D’, G’, J’, M’, P’). (E, E’, H, H’, K, K’, N, N’, Q, Q’) Sections through embryo (B), showing unfused 
neuroepithelium (NE) with the overlying surface ectoderm (SE) intact in some regions (H’, N’) and not in others (E’, K’). (F, F’, I, I’, L, L’, O, O’, R, R’) 
Sections through embryo (C), showing unfused NE underneath an intact SE (F’, I’, O’). Cells resembling juvenile RBCs (black arrows in H’, I’, L’, O’, R’) were 
found in regions corresponding to the haemorrhage, frequently between the NE and SE layers and surrounding mesoderm.  
Scale bars: 1 mm for A-C; 0.5 mm for D-R. Sections were stained with H&E. 
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Figure 22. E10.5 GldcGT1 embryo showing cranial haemorrhage. 
A homozygous mutant embryo showing distorted cranial region viewed from the left (A) 
and dorsally (B). (C) Coronal section through the region indicated by the dotted line in 
(A), showing presence of juvenile RBCs in the extracellular matrix between the surface 
ectoderm (SE) and neuroepithelium (NE) that corresponds to the spots of haemorrhage 
(black arrows). 
 
The distorted cranial phenotype appeared in both heterozygous and homozygous Gldc 
mutants carrying either the GldcGT1 or GldcGT2 alleles. To investigate whether the unfused 
neuroepithelium of these embryos ultimately fuses or if they fail in closure and become 
persistent exencephaly, the incidence of NTDs was compared with and without the 
addition of these embryos with the GldcGT1 allele. The developmental stages were grouped 
into three groups to allow comparison and statistical analysis: at E9.5 (before onset of the 
distorted cranial phenotype), E10.5–E11.5 (when the phenotype is present), and E15.5–
E18.5 (when any exencephaly present would be obvious and unambiguous).  
The incidence of NTDs in GldcGT1/GT1 embryos at E10.5–E11.5 was significantly lower than 
at E9.5, while the incidence at E15.5–E18.5 is comparable to E9.5 (Table 15). When 
embryos with the cranial phenotype were added to the numbers of NTDs, the incidence at 
E10.5–E11.5 increased to levels that are not significantly different from E9.5 or E15.5–
E18.5. 
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Stage (E-) 
No. of NTDs/ Total no. of embryos 
(%) 
No. of NTDs and cranial phenotype/ 
Total no. of embryos (%) 
Gldc+/+ GldcGT1/+ GldcGT1/GT1 Gldc+/+ GldcGT1/+ GldcGT1/GT1 
9.5  
(≥18 somites) 
0/45 
 
0/76 
 
11/38 
(29%) 
1/45 
(2.2%) 
2/76 
(2.6%) 
12/38 
(31.6%) 
10.5–11.5 
0/65  
 
2/158  
(1.3%) 
9/79  
(11.4%)* 
1/65  
(1.3%) 
16/158  
(10.1%) 
18/79  
(22.8%) 
15.5–18.5 
0/40  
 
0/62  
 
11/44  
(25%) 
0/40  
 
0/62  
 
13/44  
(29.5%) 
Table 15. Incidence of NTDs with and without inclusion of the unusual cranial 
phenotype in the GldcGT1 allele.  
Asterisk (*) denotes significant difference in NTD incidence compared with E9.5 embryos 
within the same genotype group (Z-test, p<0.05). 
 
3.2.3.5. Additional developmental phenotypes in GldcGT2 mutants 
In addition to NTDs, a proportion of GldcGT2 mutant embryos collected at stages E14.5–
E16.5 also exhibited eye defects and non-cranial haemorrhage (Table 16).  
Defect 
No. with defects/ Total no. of embryos (E14.5–E16.5) 
Gldc+/+ GldcGT2/+ GldcGT2/GT2 
Eye 0/10  1/29 (3.4%) 7/23 (30.4%) 
Haemorrhage 0/10  2/29 (6.9%) 2/23 (8.7%) 
Table 16. Incidence of eye defects and haemorrhage in GldcGT2 mutant embryos. 
 
The eye defects tended to be unilateral and resembled anophthalmia/ microphthalmia 
(Figure 23B, B’, C, C’), although this was not confirmed by histological examination. They 
were present in 3.4% of GldcGT2/+ and 30.4% of GldcGT2/GT2 embryos collected at E14.5 to 
E16.5. The microphthalmia-like eye defect was also observed in GldcGT1/+;GldcGT2/+ 
compound heterozygotes collected by Maria-Chiara Autuori. Non-cranial haemorrhage 
was present in very small numbers: 2 out of 29 of GldcGT2/+ and 2 out of 23 of GldcGT2/GT2 
embryos collected at E14.5 to E16.5 (Figure 23D, D’, E, E’). In 2 of the 4 embryos reported 
here, it appeared in one or both of the fore or hind limb buds. Eye defects and non-cranial 
haemorrhage at these stages of development have not been observed in embryos carrying 
the GldcGT1 allele. 
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Figure 23. Eye defects and haemorrhage in GldcGT2 mutant embryos. 
(A, A’) Normal left and right eye of a wild-type littermate. (B, B’) Unilateral eye defect in a GldcGT2/GT2 embryo showing a normal left eye and a degenerated 
right eye. (C, C’) GldcGT2/GT2 embryo with a degenerated left eye and no apparent right eye. (D) GldcGT2/+ embryo showing superficial haemorrhage on the 
trunk. (D’) Close-up of right forelimb bud of embryo (D), showing underdeveloped digits and haemorrhage. (E) Sagittal and (E’) dorsal view of a GldcGT2/GT2 
embryo with mild haemorrhage in the lower trunk along the spine (white and black arrows point to same region). 
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3.3. Discussion 
 
3.3.1. Gldc is required for neural tube closure 
The severe Amt null mouse (Narisawa et al., 2012) and mild GCS models (Oda et al., 2007, 
Kojima-ishii et al., 2008) from previous studies appear to represent two extremes of 
phenotypic severity in GCS deficiency. This thesis describes the GldcGT1 and GldcGT2 models 
with a more “intermediate” severity.  
As evident from in situ studies, the spatial and temporal pattern of Gldc mRNA expression 
in early embryonic development corresponds to the most commonly observed phenotype 
in GldcGT1 and GldcGT2 mutants, i.e. NTDs. While expression of Gldc is strong along the entire 
length of the neural tube at E8.5 and E9.5 and at all steps of neurulation (open neural 
folds, the recently closed neural tube, and intact neural tube), the type of NTD displayed is 
predominantly exencephaly with craniorachischisis only occurring in the presence of the 
more deleterious GldcGT2 allele. This corresponds to observations made in the Amt 
knockout, suggesting that cranial neural folds are more sensitive to the cellular 
consequences that result from a loss of GCS activity.  
Among other NTD mouse models, the cranial neural tube also appears especially sensitive 
to mutations in genes involved in, or influencing, neuroepithelial cell proliferation e.g. 
Nup50 (Smitherman et al., 2000), apoptosis e.g. Casp9 (Kuida et al., 1998 ), and actin 
cytoskeletal regulation e.g. n-cofilin (Gurniak et al., 2005). From the expression studies, 
Gldc mRNA is also strongly expressed in other highly proliferative (and apoptotic) tissue 
during neurulation-stages of development, such as the gut endoderm, branchial arches, 
optic and otic vesicles, and limb buds. The growth and developmental delay observed at 
E9.5 and E10.5 in both GldcGT1 and GldcGT2 homozygous mutants are also indicative of an 
overall proliferation defect. Eye defects were also observed in GldcGT2 mutants, correlating 
with the presence of Gldc mRNA in the optic vesicles, but eye development appears to be 
less sensitive to perturbations in Gldc function as defects were only precipitated by the 
stronger knockdown conferred by the GldcGT2 allele. It is possible that subtle defects in 
other tissue are also present but have not yet been characterised. 
The next chapter, Chapter 4, investigates FOCM disturbances and the possibility of a 
proliferation defect in Gldc mutants leading to NTDs in this model.  
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3.3.2. Partial penetrance of NTDs in Gldc mutants 
Unlike the 87% NTD rate reported in Amt null embryos (Narisawa et al., 2012), the Gldc 
mutants in this study showed considerably lower penetrance of NTDs despite both genes 
encoding for an enzyme in the GCS. Furthermore, despite carrying a mutation in the same 
gene, the penetrance of NTDs in GldcGT1 and GldcGT2 mutants are also different. 
The GldcGT1 allele in homozygosity still retains low levels of Gldc mRNA transcription, 
owing to splicing around the gene-trap vector. This results in residual levels of enzymatic 
activity only just above the detection limit of the assay (as measured in adult mutant mice, 
Figure 10C), which indicates that very low levels of enzymatic activity is still capable of 
allowing normal neurulation to proceed in about 80% of homozygous mutants (post-natal 
phenotype evaluation of GldcGT1 mutants is described in Chapter 5). The significantly 
lower levels of mRNA in NTD-affected compared with apparently normal homozygous 
GldcGT1/GT1 mutants support this hypothesis.  
In heterozygous adult mice liver, a 50% loss of Gldc mRNA still confers the same functional 
capacity for cleaving glycine as wild-type mice, as evident from their comparable levels of 
Gldc enzymatic activity. This corresponds to the mostly normal phenotype of 
heterozygous GldcGT1/+ embryos and mice, and the fact that non-ketotic hyperglycinemia 
(NKH) does not manifest in human heterozygous carriers of a mutated GLDC allele. When 
level of mRNA knockdown is higher, as produced by the GldcGT2 allele, the incidence of 
NTDs also increased in homozygous as well as heterozygous mutants, but not to the 
degree of the Amt null model.  
Viewed collectively, this suggests that mRNA expression levels could go some ways in 
accounting for the partial penetrance of a particular GCS model, with decreasing levels of 
Gldc mRNA conferring higher risk of NTDs (Table 17 below). Although not detected by 
qRT-PCR, it is possible that a very low level of Gldc mRNA is produced in GldcGT2/GT2 
embryos due to incomplete gene-trap activity, whereas the Amt allele may be truly null. 
Alternatively, there may be an effect of variation in genetic background or environmental 
conditions in the Amt mice (generated in a different laboratory) compared with Gldc-
deficient mice. 
However, mRNA expression alone does not predict which individual embryo will fail 
neural tube closure as there are homozygous GldcGT1/GT1 mutant embryos with comparable 
levels of mRNA as NTD-affected mutants, but which appeared to complete neural tube 
closure normally. In addition, some null GldcGT2/GT2 mutants also successfully completed 
closure. As enzymatic activity was not measured in neurulation-staged embryos, it would 
be interesting to determine whether NTD incidence also correlates with enzymatic activity 
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of the GCS. If enzymatic activity does not distinguish between normal and NTD-affected 
mutants, then other factors, possibly cellular or tissue morphogenetic changes affected by 
the Gldc mutation, might introduce a certain degree of “randomness” to influence the final 
phenotype. Partial penetrance of NTDs within mouse strains that are congenic occurs with 
many gene mutants. 
 
Allele and genotype Percentage mRNA level (%) NTD incidence (%) 
+/+ 100 0 
GldcGT1/+ 40 – 50 1 
GldcGT2/+ 20 – 30  6 
GldcGT1/GT1 10 – 20  20 
GldcGT2/GT2 0 > 56 
Table 17. Percentage mRNA level and NTD incidence in GldcGT1 and GldcGT2 embryos.  
mRNA levels were normalised to their respective wild-types. 
 
Chapter 6 will further discuss a similar relationship between the level of GCS enzymatic 
activity and the NKH disease spectrum based on case reports from the literature. 
 
3.3.3. Forebrain defects in GldcGT2 mutants  
In addition to failure of hindbrain neural tube closure, GldcGT2 mutants also present with 
additional and more severe cranial phenotypes. Exencephaly in GldcGT2 was sometimes 
accompanied by split face and/or forebrain truncation, with more frequent occurrences 
during and after treatment with the anti-helminthic drug, fenbendazole (see Chapter 4). 
The forebrain truncation seen in some exencephalic GldcGT2 mutants are reminiscent of 
mouse mutants for genes required in forebrain patterning, such as Six3 null embryos 
which lack a rostral forebrain (Lagutin et al., 2003). Forebrain patterning begins very early 
in development from the stage of neural induction, requiring signals from the anterior 
visceral endoderm (AVE), gastrula organizers, and axial mesendoderm coupled with 
inhibition of the Wnt/β-catenin, BMP and TGFβ signalling pathways. Graded levels of Wnt 
activity are required for posterior-to-anterior specification, while rostral forebrain 
specification requires inhibition of caudalising signals. Mutations in genes involved in AVE 
development and BMP or Wnt antagonism often result in forebrain truncations 
(Andoniadou and Martinez-Barbera, 2013, Lagutin et al., 2003, Lavado et al., 2008).  
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Craniofacial defects can also result from neural crest cell (NCC) defects. NCCs are a 
transient population of cells that are induced in the dorsal neural tube, undergo epithelial 
to mesenchymal transition, delaminate, and migrate away around a similar developmental 
temporal window as neurulation. They differentiate to give rise to a wide variety of cell 
types including bone and cartilage, melanocytes, smooth muscle cells, and neurons and 
glia of the peripheral and enteric nervous system (Sauka-Spengler and Bronner-Fraser, 
2008). Much of the cartilage, bone, and connective tissue that develop from the 
frontonasal, maxilla, and mandibular processes of the vertebrate head derive from cranial 
(mid- and hindbrain) NCC populations. Cranial NCCs originating from the mid-
diencephalon and anterior mesencephalon give rise to the frontal and premaxillary bones 
of the upper jaw, while posterior mesencephalic NCCs contribute to the maxillary bone of 
the upper jaw, dentary bone of the lower jaw, and the first branchial arch (Santagati and 
Rijli, 2003, Le Douarin et al., 2007). Unlike the spinal region where migration occurs after 
completion of closure, cranial NCC migration occurs prior to neural tube closure and has 
been proposed to play an important role in cranial neurulation from observations in 
several exencephalic mice models that also exhibit cranial NCC defects, such as Cited2 and 
Pax3 (Copp, 2005).  
Gldc is not known to be involved in any signalling pathways that affect embryonic 
patterning or suspected of neural crest cell involvement. However, this cannot yet be 
excluded. Alternatively, its involvement in folate metabolism may influence proliferation 
or apoptosis of cell populations in the forebrain and midbrain that effect head 
development. Further investigation with forebrain markers such as Hesx1, Six3, Bf1, and 
Fgf8 and NCC markers such as Sox9, Twist1, and Foxd3, are required to better define the 
forebrain defect and presence/absence of the telencephalon and NCC populations in 
GldcGT2 mutants.  
It can be argued that the forebrain truncation in GldcGT2 mutants are often accompanied by 
split face resulting from failure of forebrain and midbrain neural tube closure, and that is 
responsible for an apparent forebrain truncation. In the chick, ablation of cranial NCCs 
result in exencephaly and missing forebrain, midbrain, and facial structures (Creuzet et al., 
2006), but the abundance of exencephalic mouse mutants not accompanied by NCC defects 
is evidence that neural tube closure in mice is not needed for NCC migration and function. 
Fore- and midbrain exencephaly resulting in a split face phenotype also occurs in the Grhl2 
loss-of-function model but without truncation of the forebrain and a clearly 
distinguishable telencephalon (Brouns et al., 2011), suggesting that forebrain truncation is 
not a consequence of a split face phenotype. 
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3.3.4. Hypotheses for the unusual cranial phenotype 
The non-NTD, unusual cranial phenotypes characterised in E10.5 and E11.5 GldcGT1 
mutants (Figure 20, Figure 21, Figure 22) are a novel finding in NTD mouse models. 
They are not likely due to a reopening of an initially closed neural tube as NTD rates at 
E9.5 are comparable to the rates recorded at E15.5-E18.5. The histological appearance of 
these embryos indicates that neural tube closure progressed to median hinge point 
formation at the hindbrain neuropore. The neural folds were able to appose each other at 
the midline but ultimately do not adhere and fuse. This persistent opening could result in a 
loss of pressure from the fluid which normally fills a closed neural tube cavity pushing 
against the neuroepithelial walls. Thus, the hindbrain cavity appears “collapsed” and the 
neuroepithelium become severely distorted. Continuous distortion and degeneration from 
exposure to amniotic fluid might cause the lesion size to increase and result in a more 
typical exencephalic appearance in later stages. The appearance of an intact surface 
ectoderm overlying the small openings in the neural folds suggests that the surface 
ectoderm does not play a passive role in the normal closure process and may functionally 
contribute to closure, at least in the hindbrain region, and/or that a “wound healing” like 
process may occur over small open lesions in the neural tube. Nevertheless, the apparent 
transition of these “closed” lesions to exencephaly at later stages suggests that the surface 
ectoderm alone is insufficient to maintain closure.  
A recurring feature of this phenotype is the presence of clumps of cells resembling juvenile 
RBCs in between the neuroepithelium and overlying surface ectoderm layer (Figure 21 
and Figure 22). This could hint at a potential vascular defect and/or abnormal assembly 
of the extracellular matrix (ECM) between the two epithelial layers. In addition, localised 
haemorrhage was also present in some GldcGT2 mutant embryos, observed at E14.5-E16.5 
(Figure 23). 
 During vasculogenesis at E7.5, signals from the visceral endoderm induce the mesoderm 
to form blood islands, consisting of primitive endothelial cells and erythroblasts, in the 
yolk sac. As angiogenesis progresses through embryonic development, many signalling 
pathways such as the VEGF, TGF, Notch, and Wnt interact with ECM proteins such as 
angiopoietin 1, fibronectin, and integrins, and axon guidance signals such as Eph-ephrins, 
semaphorins, and Roundabout (ROBO) receptors to regulate endothelial cell proliferation 
and remodelling (Bohnsack and Hirschi, 2004, Herbert and Stainier, 2011).  
Defects in vascular development can result in localised haemorrhaging and oedema in the 
mouse. For example, some mouse models with vascular defects such as Vezf1 nulls, 
Sox18/Vegfd double knockouts, and p120-catenin nulls are hypervascularised or have 
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disorganised vasculature and display subcutaneous haemorrhaging. In Vezf1 nulls, lesions 
are present in the endothelial vessel walls that cause RBCs to leak into surrounding 
mesenchyme and connective tissue, producing localised spots of haemorrhage in the 
cranial and jugular region (Kuhnert et al., 2005). The superficial appearance of this 
haemorrhagic phenotype is not unlike the cranial haemorrhage observed in GldcGT1 mutant 
embryos and the haemorrhage in GldcGT2 mutants at E14.5-16.5. Further investigation is 
needed to determine if a vascular defect is present in Gldc mice or if the cranial 
haemorrhage is secondary to neural tube distortion. There is also insufficient data to 
suggest whether the blood cells near the tips of the neural folds are a cause or 
consequence of failure of closure. 
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4. Investigating a possible role of abnormal folate 
metabolism in Gldc-deficient neural tube defects 
 
 
4.1. Introduction 
 
The glycine cleavage system (GCS), in its role as predominant pathway for glycine 
catabolism, is intrinsically linked to glycine synthesis and other uses of glycine. One would 
assume that under healthy physiological conditions glycine cleavage would be closely 
balanced with synthesis and metabolic demand. In addition, the action of cleaving glycine 
plays a major role in providing one-carbon (1C) units for folate one-carbon metabolism 
(FOCM). However, glycine through GCS is by no means the only 1C donor available. Serine, 
for example, is another major 1C donor and could theoretically compensate for the lack of 
glycine-derived 1C units. The GCS contributes to the mitochondrial 1C pool and while 
mitochondrial FOCM has a key function in producing formate to be utilised in cytoplasmic 
FOCM reactions, formate can also be made elsewhere. 
Thus, the lack of GCS activity could potentially disrupt the balance of each of the synthetic 
and catabolic pathways alluded to above. This chapter investigates the biochemical 
consequences of the loss-of-function of Gldc and examines its contribution to NTDs, 
beginning with a description of the various sources of mitochondrial-derived 1C units and 
extra-mitochondrial formate. 
 
4.1.1. Mitochondrial-derived 1C units 
Mitochondrial-derived 1C units exit the mitochondria as formate and can be derived from 
a variety of sources, including glycine, serine, choline/ betaine/ dimethylglycine/ 
sarcosine, threonine and hydroxyproline/ glyoxylate (Figure 24). 
Glycine is the smallest amino acid consisting of two carbon units. Isotope tracer studies of 
glycine revealed that the C4, C5 and N7 atoms of purines are contributed by glycine. In 
fact, glycine can contribute to de novo synthesis of purines in two ways; by providing the 
C4, C5, and N7 backbone in the initial step, and by contributing to the 10-formyl-THF-
derived C2 and C8 atoms of the purine double-ring via GCS (Kikuchi et al., 2008, Fan et al., 
2014). In addition to use in protein synthesis and providing 1-carbon units for folate 
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metabolism and nucleotide synthesis, another major physiological role of glycine is as an 
inhibitory neurotransmitter in the brain stem, spinal cord and retina, and as an excitatory 
co-agonist of the NMDA receptor alongside glutamate (Johnson and Ascher, 1987). Glycine 
is primarily synthesized from serine, another major 1C donor, through SHMT (Stover, 
2004, Fan et al., 2014). It can also be synthesized from choline, threonine, or 
hydroxyproline (Wang et al., 2013).  
While choline, betaine, and sarcosine can be obtained through dietary means, the latter 
two are also synthesised de novo from choline catabolism which occurs primarily in the 
mitochondria of hepatic cells and produces glycine as an end product (Hoffmann et al., 
2013, Craig, 2004). Conversion of choline to glycine occurs through the actions of four 
demethylating enzymes. First, choline dehydrogenase (CHDH) converts choline to betaine 
(also known as trimethylglycine and glycine betaine). This is followed by betaine-
homocysteine-methyltransferase (BHMT) converting betaine to dimethylglycine, which is 
then converted to sarcosine (also known as N-methylglycine) by dimethylglycine 
dehydrogenase (DMGDH). Finally, sarcosine dehydrogenase (SARDH) produces glycine, 
which is cleaved by the GCS. The action of DMGDH and SARDH also releases 1C units 
which can combine with THF in the mitochondria (Tibbetts and Appling, 2010). Betaine, 
through the action of BHMT, also serves as an alternative 1C donor to the methylation 
cycle (in place of 5-methyl-THF) through remethylation of homocysteine to methionine 
(Christensen et al., 2015).  
Glycine can be synthesised from threonine through threonine dehydrogenase (TDH) and 
glycine C-acetyltransferase (GCAT; also known as aminoacetone synthase) (Wang et al., 
2011, Aoyama and Motokawa, 1981, Tressel et al., 1986). Mouse ES cells uniquely utilise 
threonine as their major 1C source through the action of TDH, and are able to proliferate 
faster than cancer cell lines. TDH is localized in the mitochondria, and threonine-derived 
glycine then feeds into the similarly mitochondria-localized GCS (Wang et al., 2011). GCAT 
along with GLDC, SHMT1, and serine synthesis genes (PSPH and PSAT1) were found to be 
upregulated in human lung cancer cells and were hypothesised to be fuelling 
tumourigenesis (Zhang et al., 2012). 
Wang et al. (2013) also highlighted another pathway for glycine synthesis from glyoxylate 
through the irreversible action of alanine:glyoxylate aminotransferase (AGT), which 
comprises the final step of hydroxyproline catabolism in the mitochondria of kidney cells. 
This pathway has been suggested as a potentially significant source of glycine, leading also 
to increased serine production in rat kidneys (Lowry et al., 1985a, Lowry et al., 1985b). 
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Serine is a significant 1C donor that is catabolised to glycine by SHMT or to pyruvate by 
serine dehydratase. It is assumed that in most vertebrates the former reaction (via SHMT) 
is the predominant pathway, especially in uricotelic animals such as chickens which do not 
have serine dehydratase (Kikuchi et al., 2008). Through SHMT, serine donates one of its 
carbon atoms to THF to form methyl-THF, producing glycine in the process. The SHMT 
enzyme has two isozymes: cytoplasmic (SHMT1) and mitochondrial (SHMT2) (Garrow et 
al., 1993, Anderson and Stover, 2009). Serine-to-glycine conversion via SHMT occurs 
readily, accounting for 40% of glycine flux in the whole body, while glycine-to-serine 
conversion accounts for about 46% of serine synthesis rate in healthy men and women 
(Lamers et al., 2007).  
The de novo L-serine biosynthesis pathway involves 3-phosphoglycerate dehydrogenase 
(PHGDH) which converts 3-phosphoglycerate (3PG), an intermediate in glycolysis, into 
phospho-hydroxypyruvate, followed by conversion to serine by phosphoserine 
aminotransferase 1 (PSAT1) and phosphoserine phosphatase (PSPH) (Possemato et al., 
2011). Tracer studies showed that in cancer cells serine is preferentially shunted by 
increased PHGDH activity into the FOCM, away from glycolysis and other serine metabolic 
pathways (such as serine hydratase) (Snell et al., 1987, Possemato et al., 2011, Locasale, 
2013). Like glycine, ᴅ-serine is also a strong agonist of the glycine-binding site of NMDA 
receptors (Henneberger et al., 2013). 
The action of the MTHFD1L enzyme converting 10-formyl-THF to THF produces formate 
in the mitochondria, which goes into the cytosol. 
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Figure 24. De novo sources of one-carbon units for folate one-carbon metabolism. 
Sources of 1C units through de novo synthesis of glycine and/or serine that occur primarily in the mitochondria are grouped within the beige-shaded area. 
Glycine can be derived from serine-glycine interconversion, hydroxyproline (through glyoxylate), threonine, and choline catabolism. Serine is 
biosynthesised from 3PG (intermediate of glycolysis), and releases 1C units when converted to glycine by SHMT1 or SHMT2. Catabolism of dimethylglycine 
and sarcosine by DMGDH and SARDH also releases 1C units.  
The pathway in the grey-shaded area illustrates breakdown of methanol, producing formate which enters the one-carbon cycle to be further metabolised.  
Reactions in the yellow-shaded area illustrate various other non-mitochondrial, non-folate-dependant, metabolic pathways that yield formate which may 
potentially enter the one-carbon cycle (dotted-line arrow). This includes tryptophan degradation via the kynurenine pathway, alpha-oxidation of phytanic 
acid, conversion of lanosterol to cholesterol, and of androstenedione to oestrogen. Formate is alternatively converted to water and carbon dioxide through 
the action of catalase. 
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Figure 24. De novo sources of one-carbon units for folate one-carbon metabolism. 
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4.1.2. Alternative sources of formate 
In addition to mitochondrial sources, formate can also be produced via several non-
mitochondrial, non-folate-dependant pathways (Figure 24) (Lamarre et al., 2013).  
In the cytosol, breakdown of methanol comprise two steps, the first of which converts 
methanol to formaldehyde. This step requires the action of alcohol dehydrogenase 1 
(ADH1) in humans and peroxisomal catalase in rodents, or may act though action of 
catalase and hydroxyl radicals in microsomes (Cederbaum and Qureshi, 1982). The second 
step involves aldehyde dehydrogenase (ALDH), which yields formic acid as an end 
product. Methanol metabolism is extensively studied in the context of methanol poisoning, 
in which the occurrence of acute metabolic acidosis is attributed to accumulation of formic 
acid (Tephly, 1991, Hansen et al., 2005). 
Tryptophan degradation through the kynurenine pathway in the cytosol involves 
conversion of tryptophan to N-formylkynurenine through the action of indoleamine 2,3-
dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO). N-formylkynurenine is then 
converted by kynurenine formamidase (also known as arylformamidase, AFMID) to 
kynurenine, a reaction which also yields formic acid (Schwarcz et al., 2012, Han et al., 
2012).  
Alpha-oxidation of phytanic acid, a branched-chain fatty acid, occurs in peroxisomes and 
involves a carbon-carbon cleavage, producing pristanoyl-CoA. Another yield of this 
cleavage is formate (Poulos et al., 1993, Croes et al., 1996, Verhoeven and Jakobs, 2001).  
In the cholesterol synthesis pathway, lanosterol is converted to cholesterol through three 
cytochrome mono-oxygenation steps by lanosterol 14α-demethylase (CYP51A1), a 
member of the cytochrome P450 family, in endoplasmic reticulum (ER). The first reaction 
yields an alcohol product, the second reaction an aldehyde, and the final step releases 
formic acid (Debeljak et al., 2003, Lepesheva and Waterman, 2007). Cholesterol then 
enters synthesis pathways of steroid molecules, in which conversion of androstenedione 
to oestrogen by the aromatase complex (another cytochrome P450 family member) in 
smooth ER of placental cells  also yields formate (Akhtar et al., 1982). 
Formate gets metabolised either by combining with THF and entering FOCM, or by being 
oxidised by catalase into water and carbon dioxide in the presence of hydrogen peroxide 
(Siu et al., 2013). What the contributions of non-mitochondrial derived formate are to total 
body formate, or as 1C donors to FOCM reactions (as opposed to being metabolised by 
catalase), is not well defined.  
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4.2. Results 
 
4.2.1. Gldc mutation increases glycine levels and disrupts FOCM  
 
4.2.1.1. Glycine levels in Gldc mutant embryos 
A biochemical hallmark of mutations in the GCS, as evident in NKH patients, is highly 
elevated glycine in body fluids. High glycine is often quoted as the cause of the pathology 
of NKH. As homozygous mutations in GCS genes have not been picked up in NTD patients 
(as anencephalic cases are fatal, NKH would not manifest and thus any possible GCS 
mutations would not be suspected), it remains unknown if high glycine by itself can cause 
NTDs. To what magnitude the increase in glycine levels is at early embryonic development 
is also unknown. 
The GldcGT1 mouse provides a model with which to investigate these questions. Embryos 
from heterozygous crosses were collected at E11.5, a day after neurulation is complete, 
and whole embryo preparations done for measurement of glycine as well as other amino 
acids using ion-exchange chromatography (carried out by Helen Prunty and Dr Simon 
Heales, Great Ormond Street Hospital for Children NHS Foundation Trust).  
Table 18 lists the levels of all detectable amino acids. At such early embryonic stages, 
GldcGT1/GT1 embryos showed a highly significant, 3-fold increase (P<0.001) in glycine levels 
compared with Gldc+/+ embryos. The increase in glycine levels of GldcGT1/+ embryos 
compared with wild-types was also highly significant. The only other amino acid to show a 
significant increase (with P<0.05) in mutants compared with wild-types is taurine. This is 
the earliest stage of development where significant elevation of glycine due to a GCS 
mutation is demonstrated, suggesting that whatever pathological effects glycine may have 
on brain development may already be in effect from just after neurulation. 
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Amino acid 
Concentration (nmol/mg protein) 
Gldc+/+ (n=6) GldcGT1/+ (n=6) GldcGT1/GT1(n=7) 
Alanine (ALA) 54.0 ± 5.54 68.2 ± 3.55 63.3 ± 7.29 
Asparagine (ASN) 8.78 ± 0.99 10.2 ± 0.43 8.96 ± 1.01 
Aspartic acid (ASP) 8.63 ± 0.85 11.2 ± 1.44 11.8 ± 2.12 
Glutamine (GLN) 22.2 ± 1.85 26.0 ± 2.54 21.2 ± 2.77 
L-glutamate (GLT) 63.1 ± 5.83 75.5 ± 4.32 71.3 ± 7.30 
Glycine (GLY) 22.6 ± 2.33 38.8 ± 2.73* 66.7 ± 7.00* 
Histidine (HIS) 4.03 ± 0.49 4.49 ± 0.22 4.06 ± 0.33 
Leucine (LEU) 8.00 ± 0.97 10.2 ± 0.59 9.39 ± 0.98 
Isoleucine (ILEU) 2.50 ± 0.33 3.43 ± 0.35 2.95 ± 0.39 
Lysine (LYS) 14.5 ± 1.31 17.5 ± 0.57 16.5 ± 1.66 
Methionine (MET) 2.69 ± 0.21 3.51 ± 0.29 3.05 ± 0.34 
Ornithine (ORN) 2.72 ± 0.39 3.13 ± 0.29 2.80 ± 0.35 
Phenylalanine (PHE) 3.61 ± 0.44 4.57 ± 0.22 3.91 ± 0.38 
Serine (SER) 16.1 ± 1.61 21.5 ± 1.72 17.0 ± 2.18 
Taurine (TAU) 66.1 ± 4.57 75.8 ± 3.71 90.6 ± 6.75** 
Threonine (THR) 8.45 ± 1.23 11.6 ± 1.01 10.6 ± 1.31 
Tryptophan (TRY) 1.13 ± 0.25 1.17 ± 0.11 1.11 ± 0.12 
Tyrosine (TYR) 3.16 ± 0.34 3.94 ± 0.21 3.75 ± 0.37 
Valine (VAL) 7.98 ± 0.81 9.54 ± 0.53 8.80 ± 0.88 
Table 18. Concentration of amino acids in whole GldcGT1 embryos. 
Values quoted are mean ± SEM, */** denotes significant difference compared with wild-
types (ANOVA, *P<0.001, **P<0.05). 
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4.2.1.2. In silico modelling of the effects of defective GLDC on folate cycling 
The second metabolic defect that may occur when glycine is not catabolised is disruption 
of FOCM due to glycine’s role as a 1C donor. The effects of not having glycine contribution 
on folate cycling and downstream pathways have been implicated but not characterised by 
experiments prior to this study. 
A mathematical model of intracellular hepatic folate metabolism (One-Carbon Metabolism 
Version 2.1), developed by Nijhout et al. (2006), was first used to make an in silico 
prediction of how the balance of folates might shift in response to defective glycine 
cleavage. This model is an extension of a previous model (Reed et al., 2006) to include 
mitochondrial components of FOCM, which was itself a combined model of previously 
published folate and methionine cycles (Nijhout et al., 2004, Reed et al., 2004, Prudova et 
al., 2005). The software utilises kinetic formulae and rate constants of cytosolic and 
mitochondrial folate enzymes to model levels of folate metabolites, utilising published 
experimentally observed values from a variety of human and rodent hepatic tissue and cell 
lines. The model was then tested by simulating specific mutations and disease conditions 
with known changes in FOCM parameters, for example the MTHFR 677C>T polymorphism, 
B12 deficiency, folate deficiency, combined B12 deficiency with folate deficiency or 
elevated folate levels, methionine loading, and effect of betaine on homocysteine. Changes 
predicted by the model were reported to be comparable to those observed in human 
populations and experimental rodents (Reed et al., 2006, Nijhout et al., 2006). 
When a perturbation is introduced to the model’s “normal” steady-state values, it 
computes the resulting changes in concentrations (µM) and velocities (µM/hr) of folate 
metabolites and enzymes as well as total cellular and blood concentrations of several 
amino acids. When the velocity of GLDC (abbreviated as mitochondrial GDC in the model) 
was changed from the model’s steady-state value of 1,664 µM/hr to 0 µM/hr (from 0 to -
100% change) to mimic the loss of GLDC enzymatic activity (shown as screenshots of the 
software in Figure 25), the model predicts a 150-fold increase in total cellular glycine 
from 1,203 to 179,215 µM, and a more modest 20-fold increase in blood glycine 
concentration from 221 to 4,092 µM. The increase in glycine levels matches observational 
evidence in NKH patients where GLDC activity is completely null, albeit to much 
exaggerated levels in the model.  
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Figure 25. One-Carbon Metabolism mathematical modelling software 
(A) Normal, steady-state values of substrate concentrations and enzyme velocities, with 
GDC at a default velocity of 1,664 µM/hr. (B) Changes in concentrations and velocities 
when GDC is set to 0%, i.e. enzyme velocity of 0 µM/hr (indicated in red box).  
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Figure 26 illustrates changes in folate metabolites of a 50% and 100% deficiency in GCS 
compared with normal values, plotted as percentage total folate (values combined 
cytosolic and mitochondrial fractions). In the 100%-GCS deficient profile, there was an 
increase in proportion of THF and corresponding decrease in 5-methyl-THF, 5,10-
methenyl-THF, 5,10-methylene-THF, and 10-formyl-THF. The predicted changes are that 
of decrease in 1C-carrying folates and increase in a non-1C-carrying folate. The 50%-GCS 
deficient profile showed intermediate levels between normal and 100% deficiency, though 
appeared to more closely resemble 100% deficiency values. 
Thus, the key comparisons to experimentally observe for would be the relative changes in 
proportion of 1C and non-IC carrying folates between wild-type and mutant embryos, and 
whether addressing this change is sufficient to correct the overall folate profiles and 
consequently rescue the phenotype. This is addressed in the following sections by using a 
mass spectrometry technique (Section 4.2.1.3) and dietary supplementation with a 1C 
source (Section 4.2.2.1), respectively. 
 
Figure 26. In silico prediction of hepatic folate profiles in normal and GCS-deficient 
conditions. 
In 100%-GCS deficient conditions (GDC activity set to 0%), the relative abundance of 
hepatic folates was predicted to show an increase in THF and decrease in 5-methyl-THF, 
5,10-methenyl-THF, 5,10-methylene-THF, and 10-formyl-THF. 50%-GCS deficient 
conditions was predicted to show intermediary levels between normal and 100%-GCS 
deficient. 
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4.2.1.3. Abnormal folate profiles in Gldc mutant embryos 
To test the predictions of the in silico experiment, E11.5 GldcGT1 embryos were collected 
and prepared for folate profiling using a liquid chromatography, tandem mass-
spectrometry (LC/MS/MS) method developed in the Copp and Greene lab (performed by 
Dr Kit-Yi Leung). This developmental stage was chosen as it is the earliest post-
neurulation stage at which the LC/MS/MS technique is able to reproducibly quantify seven 
glutamated forms of six folate metabolites in single embryos (Pai et al., 2015). The levels 
of individual polyglutamated forms were summated as one measurement for each folate.  
Figure 27 illustrates changes in the folate profiles of the three genotypes of GldcGT1 
embryos, expressed as percentage total folate. Unlike the in silico model in which the 
highest proportion of total folates consist of THF followed by 10-formyl-THF, 5-methyl-
THF, 5,10-methenyl-THF, 5,10-methylene-THF, and barely detectable levels of DHF, 
results from the LC/MS/MS measurements showed that the highest proportion of total 
folates consist of 5-methyl-THF, followed by THF and DHF, and levels of 5,10-methenyl-
THF, 5,10-methylene-THF and 10-formyl-THF that are only just above detection limit. The 
discrepancy could partly be due to a biological difference in proportion of folate 
metabolites between adult liver (on which the in silico model is based) and whole embryo 
samples.  
Nevertheless, when comparing GldcGT1/GT1 with Gldc+/+ samples, the changes observed 
agreed with that of the in silico modelling: significant increase was found in relative 
abundance of the non-1C-carriers DHF and THF, and significant decrease in 1C-carrier 5-
methyl-THF. The folate profiles in GldcGT1/+ were comparable with that of the wild-types, 
indicating that one allele of functioning Gldc is sufficient to produce a normal balance of 
folates. This finding is in agreement with results in Chapter 3 showing that GldcGT1/+ adult 
mice showed levels of enzymatic activity that did not differ significantly from Gldc+/+ mice. 
In wild-type conditions, mitochondrial-derived 1C units enter the cytoplasm as formate 
and combine with THF to make 10-formyl-THF. 5,10-methylene-THF then loses a 1C unit 
by conversion to 5-methyl-THF or to dTMP synthesis (thus making DHF, a non-1C-
carrying folate, in the process). The abnormal folate profiles displayed by GldcGT1/GT1 
embryos indicate that defective glycine cleavage is causing a decrease in 1C units to enter 
the folate cycle, resulting in a build-up of THF (and consequently DHF) as well as decrease 
in 1C-carrying folates, of which only changes in 5-methyl-THF levels were detectable by 
the assay. 
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Figure 27. GldcGT1 mutant embryos show altered folate profiles. 
Folate profiling by LC/MS/MS revealed significant increases in relative abundance of (A) 
dihydrofolate (DHF) and (B) tetrahydrofolate (THF) and significant decrease in (C) 5-
methyl-THF of E11.5 GldcGT1/GT1 mutants (n = 10) compared with wild-types (n = 7), while 
GldcGT1/+ embryos (n = 8) showed levels comparable to wild-types, which matches the 
changes predicted in the in silico modelling. In addition, there was a significant increase in 
levels of (D) 5,10-methenyl-THF in GldcGT1/+ embryos compared with wild-types. No 
significant changes were found in the relative abundance of (E) 5,10-methylene-THF or 
(F) 10-formyl-THF in the mutants compared with wild-types (*ANOVA, p<0.001). Error 
bars represent mean ± SEM. 
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Figure 27. GldcGT1 mutant embryos show altered folate profiles.  
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4.2.2. Abnormal folate profiles in Gldc mutation are caused by lack of 1C units 
To test the hypothesis of insufficient 1C units causing the changes in relative abundance of 
folate metabolites in GldcGT1 mutants, GldcGT1/+ mice were inter-crossed and pregnant 
females supplemented with 30 mg/mL of sodium formate in their drinking water to 
potentially restore 1C pools in homozygous mutant embryos. The concentration of 30 
mg/mL of sodium formate delivers 7,500 mg per kg body weight per day, and was chosen 
based on a previous study that achieved significant phenotypic improvement with that 
dose on Mthfd1L mutant mice, another mitochondrial FOCM model (Momb et al., 2013). 
 
4.2.2.1. Formate treatment rescues NTDs and normalises folate profiles 
Formate treatment was found to significantly reduce the frequency of NTDs in GldcGT1/GT1 
embryos analysed at E11.5, with an incidence of just 2% (1 out of 45 treated embryos), 
compared with 22% in a contemporaneous untreated cohort (Figure 28).  
 
 
Figure 28. Effect of formate treatment on NTD incidence in GldcGT1/GT1 embryos. 
Formate treatment reduced the incidence of NTDs in GldcGT1/GT1 embryos from 22% to 2%, 
which is a significant rescue effect (*Z-test, P = 0.007).  
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Formate treatment was hypothesised to have a rescue effect on NTDs by altering the 
proportion of folates. An alternative possibility is that excess glycine is the cause of the 
NTDs, and that formate treatment is able to correct this (through an unknown 
mechanism). To investigate this possibility, the levels of glycine in E11.5 formate-treated 
embryos were measured. Figure 29 below illustrates how glycine, as observed previously, 
remains unchanged at a significant 4-fold increase in GldcGT1/GT1 embryos compared with 
wild-types. When E11.5, formate-treated embryos were tested for changes in their folate 
profiles, GldcGT1/GT1 embryos showed relative abundances in folate metabolites that did not 
differ significantly from formate-treated wild-type embryos (Figure 30).  
The significant lowering of NTD frequency and normalisation of folate profiles with 
formate treatment, combined with unchanged elevation in glycine levels, strongly suggests 
that abnormal folate metabolism caused by disrupted supply of 1C units is responsible for 
the NTDs present in this model. 
 
 
Figure 29. Glycine levels in untreated and formate-treated E11.5 GldcGT1 embryos. 
Among untreated embryos, glycine levels were significantly elevated in GldcGT1/+ (n = 6) 
and GldcGT1/GT1 (n = 7) compared with Gldc+/+ (n = 6) embryos (graphical representation of 
glycine levels given in Table 18). In formate-treated embryos, glycine levels were also 
significantly increased in GldcGT1/GT1 (n = 4 per genotype) Error bars represent mean ± SEM 
(*ANOVA, p<0.001). 
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Figure 30. Normalisation of folates of GldcGT1 embryos after formate treatment.  
In formate-treated embryos, the abnormal folate profiles of untreated GldcGT1/GT1 embryos 
were normalised; there were no significant changes in levels of (A) DHF, (B) THF, (C) 5-
methyl-THF, (D) 5,10-methenyl-THF, (E) 5,10-methylene-THF, or (F) 10-formyl-THF 
between all genotypes (n = 8 per genotype, ANOVA). Error bars represent mean ± SEM. 
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Figure 30. Normalisation of folates of GldcGT1 embryos after formate treatment. 
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4.2.2.2. GldcGT1 foetuses show signs of toxicity on prolonged formate 
supplementation  
When mice were fed with formate-treated water until E15.5 or E18.5 (at point of embryo 
collection), other abnormalities were found. These were suspected as signs of formate 
toxicity as they have not been previously observed in untreated embryos collected at 
similar late-foetal stages. Prior to this, the teratological effects of prolonged formate 
supplementation on wild-type mice have not been studied.  
The most common abnormality is non-cranial haemorrhage (unlike the cranial 
haemorrhage observed in E10.5 and E11.5 mutants described in Chapter 3) such as in the 
lower spine where spina bifida lesions commonly occur (Figure 31C), or whole-body 
haemorrhage with accompanying oedema reminiscent of early heart defects (Figure 31F). 
The other abnormality that has been observed is a snout deformity with the appearance of 
missing/underdeveloped/degenerated mandibles seen in E15.5 (Figure 31B) and 
appearing worse in E18.5 (Figure 31E). 
The incidences of these defects are given in Table 19 below. They appear at a combined 
frequency of 7.7% in wild-types, 8.3% in heterozygotes, and 33.3% in homozygotes.  
 
Stage  
(E-) 
Phenotype 
No. with phenotype/ Total no. of foetuses 
Gldc+/+ GldcGT1/+ GldcGT1/GT1 
15.5 
(4 litters) 
Snout  0/5 0/16  2/5 
Haemorrhage 0/5 1/16 1/5 
18.5 
(7 litters) 
Snout 0/8 1/20 1/10 
Haemorrhage 1/8 1/20 1/10 
TOTAL BOTH 1/13 (7.7%) 3/36 (8.3%) 5/15 (33.3%) 
Table 19. Incidence of toxic effects of prolonged formate supplementation in E15.5 
and E18.5 GldcGT1 foetuses.  
The proportions of affected foetuses were not significantly different between Gldc+/+ and 
GldcGT1/+ (Z-test, P = 0.600), Gldc+/+ and GldcGT1/GT1 (Z-test, P = 0.236), or GldcGT1/+ and 
GldcGT1/GT1 (Z-test, P = 0.069). 
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Figure 31. Signs of non-genotype specific toxicity in GldcGT1 foetuses after prolonged 
formate supplementation.  
Toxic effects of prolonged formate supplementation was seen in GldcGT1 foetuses at E15.5 
(B, C) and appear worse at E18.5 (E, F), when compared to normal looking littermates (A, 
D). In (B) and (E), a snout deformity was observed, while in (C) and (F), haemorrhage and 
oedema were observed.  
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4.2.2.3. Folate deficiency does not exacerbate NTDs in Gldc mutants  
The effect of folate deficiency was tested by supplementing female GldcGT1/+ mice 3 weeks 
prior to mating and throughout pregnancy with a folate-deficient diet with added 1% 
succinylsulfathiazole, an intestinal antibacterial drug which prevents the synthesis of 
folates by gut flora (Walzem and Clifford, 1988). 
Diet-induced folate deficiency alone does not result in NTDs in rodents, but has been 
reported to exacerbate susceptibility to neural tube closure leading to increased incidence 
of NTDs in other mouse models such as curly tail (Burren et al., 2010), Shmt1 (Beaudin et 
al., 2011) and Splotch2H (Burren et al., 2008). Curiously, in the GldcGT1 model folate 
deficiency does not increase NTD incidence (Figure 32). The frequency of NTDs was 17% 
in treated compared to 18% in untreated embryos. This may be because the limiting factor 
in GldcGT1 mutants is shortage of 1C units, such that depletion in the folates themselves (i.e. 
the “scaffolding” molecules that carry the “functional” 1C units) did not worsen the 
phenotype, presumably because sufficient folate is available to carry the 1C units. 
 
 
Figure 32. Effect of folate deficiency on GldcGT1/GT1 embryos. 
GldcGT1/GT1 embryos among litters of diet-induced, folate-deficient female mice showed no 
significant changes in NTD incidence compared with untreated mutants (Z-test, P = 0.799).  
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4.2.2.4. Formate levels in Gldc mutant embryos 
To investigate whether there are changes in circulating levels of formate between the 
different genotypes and/or in heterozygous mice fed with different treatments, blood 
from GldcGT1 adult mice was collected by cardiac puncture and transferred into lithium-
heparin tubes. The blood was centrifuged at 3,500 rpm for 5 min to separate the plasma 
layer, and plasma formate was measured using gas chromatography (performed by Dr 
John and Margaret Brosnan, Memorial University of Newfoundland, Canada).  
Levels of circulating formate did not differ between the different genotypes (Figure 33), 
suggesting that sufficient formate is generated in Gldc-deficient mice to maintain 
circulating levels. Hence, the shortage of mitochondrial-derived formate may primarily be 
a cell-autonomous effect, or that endogenous formate is quickly metabolised by cytosolic 
folate cycling when released from the mitochondria. As formate may also come from other 
non-mitochondrial-derived sources, this suggests that formate utilised by cytoplasmic 
FOCM mainly derives from the mitochondria. 
The increase in formate levels of formate-treated heterozygotes confirmed that treatment 
administered through drinking water is efficient in delivering formate into maternal 
circulation. In heterozygotes with diet-induced folate deficiency, there was a significant 
increase in levels of circulating formate. This finding is consistent with previous studies in 
rats (Lamarre et al., 2012) and indicates that reducing the levels of folate molecules results 
in a surplus of unbound formate which is released into the circulation. 
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Figure 33. Plasma formate levels in untreated and formate-treated GldcGT1 mice. 
Plasma formate concentration of untreated GldcGT1 mice did not differ significantly 
between the three genotypes (3 Gldc+/+, 3 GldcGT1/+, and 2 GldcGT1/GT1) (ANOVA). In GldcGT1/+ 
mice fed with folate-deficient diet (n = 3), plasma formate levels were significantly 
elevated compared with untreated GldcGT1/+ mice (* t-test, P = 0.029). Plasma formate 
levels of formate-treated GldcGT1/+ mice (n = 3) showed a 3- to 20-fold increase compared 
with untreated mice. Error bars represent mean ± SEM. 
 
4.2.3. Effect of Gldc deficiency on cellular proliferation, growth, and development 
Downstream of folate metabolism, 1C units may enter nucleotide synthesis pathways, the 
methylation cycle by combining with homocysteine, and polyamine synthesis, all of which 
could be affected when folate cycling is disrupted. The following experiments focused 
mainly on cellular proliferation as an indication of disrupted nucleotide synthesis. 
Preliminary results from investigating the methylation cycle are also reported. The effect 
of altered balance of folate metabolites was further probed by introducing the Mthfr null 
mutation into GldcGT2 mice to block the flow of 1C units into methylation. 
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4.2.3.1. Formate treatment normalises growth 
The crown rump length (CRL) of E11.5 GldcGT1 embryos that were treated with formate 
were measured and compared to untreated litters. As reported at E9.5 and E10.5 
(Chapter 3), untreated E11.5 GldcGT1/GT1 but not GldcGT1/+ embryos showed significantly 
decreased CRL compared with wild-types (Figure 34). This difference was normalised in 
formate-treated homozygotes, which showed comparable CRL measurements to the wild-
types. There were no significant changes in CRL measurements between untreated and 
treated wild-types, suggesting that formate does not affect growth when 1C units are 
sufficient.  
The delay in growth of untreated mutants is suggestive of an overall proliferation defect 
which supplementation with formate was also able to correct. 
 
 
Figure 34. Effect of formate treatment on growth of GldcGT1 embryos. 
In untreated E11.5 GldcGT1 embryos, there was a significant decrease in crown rump 
length, CRL of GldcGT1/GT1 embryos (n = 36) compared with Gldc+/+ (n = 23) and GldcGT1/+ (n 
= 74). In formate-treated E11.5 embryos, no significant difference in CRL was observed 
between all genotypes (25 Gldc+/+, 45 GldcGT1/+, and 22 GldcGT1/GT1). Error bars represent 
mean ± SEM (*ANOVA, p<0.001). 
  
141 
 
4.2.3.2. Proliferation analysis of Gldc mutant embryos 
The rate of proliferation in the cranial neural tube of Gldc mutant embryos was directly 
assessed using immunohistochemical staining for phospho-histone H3 (PHH3) antibody, a 
marker of cells in late G2 and M-phase, which gives an indication of mitotic index. DAPI 
was also used to allow visualisation of all cell nuclei. Embryos at E9.5 (somite stage 18 to 
24) were used so that embryos could be scored for presence of an open hindbrain neural 
tube. Older embryos risk the possibility of secondary differences in proliferation (if any 
were to be found) after normal closure or a defect has occurred. In addition, Gldc mRNA 
expression at E10.5 was less intense than at E9.5 (Chapter 3), indicating that Gldc activity 
may decrease slightly at some point after E9.5 and specific effects on cell proliferation may 
be less detectable. 
The hindbrain neural tube was divided into 5 morphological regions for the proliferation 
analysis (Figure 35): transverse sections through the neural tube just caudal to the otic 
vesicles were annotated as region 1 (A1, B1), sections showing both otic vesicles were 
region 2 (A2, B2), where the branchial arches were visible and the left and right sides 
distinct from one another was region 3 (A3, B3), region 4 was where the forebrain with 
both optic cups were visible (A4, B4), and region 5 where both optic vesicles were 
separated from the forebrain and the midbrain is not visible (A5, B5).  
Samples of positive PHH3 and DAPI staining in “region 4” of a wild-type embryo with a 
normal, closed neural tube and a GldcGT1/GT1 mutant with an open region are shown in 
Figure 36. Due to interkinetic nuclear migration, in which nuclei in polarised epithelial 
cells that are undergoing mitosis would migrate to the apical surface of the cell layer (Lee 
and Norden, 2013), PHH3-positive nuclei were mostly located at the apical surface of the 
neural tube (Figure 36C, F). As this pattern of staining was seen in wild-type neural tubes 
(n = 5) and in mutants with closed (n = 3) and open (n = 4) neural tubes, interkinetic 
nuclear migration in Gldc mutants appeared to be unaffected. The stages of mitosis 
identified by PHH3 staining, as referenced from Li et al. (2005) and De Castro et al. (2012), 
is shown in Figure 36 (G-i – G-v). As it is often difficult to distinguish between two or 
more overlapping or adjacent PHH3-stained nuclei at G2 phase (Figure 36G-i), G2 phase 
nuclei were excluded from the counts.  
To account for possible variation in rate of proliferation at different axial levels of the 
hindbrain neural tube, four to six sections from each region of every embryo were 
analysed. The percentage of PHH3-positive cells as a function of the number of DAPI-
stained cells in each region (sum of all four to six sections per region), i.e. mitotic index, 
was calculated to represent the rate of proliferation in that region of the embryo.  
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Figure 37A illustrates the total mitotic index of all 5 hindbrain regions in wild-types and 
GldcGT1GT1 mutants (closed and open neural tubes), with the regional mitotic indices of each 
embryo broken down in Figure 37B. The total percentage of PHH3 staining was 
significantly lower in GldcGT1/GT1 mutants with an open neural tube compared with somite-
matched wild-types, indicating defective cellular proliferation. In normal GldcGT1/GT1 
mutants with closed hindbrain neural tubes, the mitotic index values are in a range 
between wild-type and affected mutant values. While there is variation in the mitotic 
indices of the different regions within the same embryo, no particular pattern of variation 
was observed across all embryos within and between genotypes. 
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Figure 35. Defining 5 regions of the E9.5 cranial neural tube for proliferation studies. 
Transverse sections through the hindbrain of an embryo with a closed neural tube (A0) and an NTD-affected (B0) (white arrowheads indicate open neural 
folds in B0-5), showing regions 1 to 5 (demarcated by red dotted lines) identified for proliferation analysis. A representative section from each region is 
shown in A1-A5 and B1-B5. Region 1 is identified as the region of the hindbrain (HB) just caudal to, but not including either of, the otic vesicles (OV), 
region 2 is where both otic vesicles (OV) are visible, region 3 where the first branchial arch (BA) is visible (outlined by white dotted lines in A3), region 4 
where the optic cups (OC) of the forebrain (FB) can be identified, and region 5 where both optic vesicles (OP) are separate entities from the forebrain. 
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Figure 36. Positive PHH3 staining in the hindbrain of GldcGT1 embryos. 
Transverse sections of a Gldc+/+ embryo with a closed cranial neural tube (A, B, C) and a 
GldcGT1/GT1 embryo with an open neural tube (D, E, F) were stained with DAPI nuclei stain 
and anti-PHH3 antibody. PHH3 staining identifies cell nuclei in G2 phase (G-i) and stages 
of mitosis: prophase (G-ii), metaphase (G-iii), anaphase (G-iv), and telophase (G-v). 
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Figure 37. Percentage of PHH3-labelled cells in GldcGT1 embryos. 
(A) NTD-affected GldcGT1/GT1 embryos showed an overall significantly reduced mitotic 
index compared with Gldc+/+ embryos (*t-test, P = 0.008). In GldcGT1/GT1 embryos in which 
the neural tube was closed, there was a bigger spread of values compared with NTD-
affected ones, and the mean value was not significantly lower than wild-type values (t-test, 
P = 0.200). Error bars represent mean ± SEM. When mitotic index scores are broken down 
by specific hindbrain regions (B), little variation is seen in the the different regions of the 
same embryo, with no discernible pattern of change from the most caudal (1) to rostral (5) 
regions.  
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Figure 37. Percentage of PHH3 labelled cells in GldcGT1 embryos.  
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4.2.3.3. Formate treatment normalises proliferation 
As formate treatment was able to rescue occurrence of NTDs (Figure 28) and normalise 
folate profile (Figure 30) and crown rump length (Figure 34) of GldcGT1/GT1 embryos, the 
next logical step was to examine the rate of proliferation in the hindbrain neural tube of 
formate-treated “rescued” GldcGT1/GT1 embryos, compared with treated wild-type 
littermates. 
From the line graph shown in Figure 37B, there appeared to be no pattern of variation in 
rate of proliferation between different regions of the hindbrain. Thus, when the same 
proliferation analysis was performed on E9.5 formate-treated embryos, four to six 
sections from region 4 and 5 were analysed. The rescued GldcGT1/GT1 embryos were found 
to have comparable mitotic indices to wild-type littermates (Figure 38), indicating that 
proliferation in the hindbrain neural tubes of GldcGT1/GT1 embryos was normalised by 
formate treatment. 
 
 
Figure 38. Percentage of PHH3 labelled cells in formate-treated GldcGT1 embryos. 
No significant difference in percentage of PHH3 staining was observed between E9.5 
treated wild-types and GldcGT1 homozygous mutants. Error bars represent mean ± SEM (t-
test, P = 0.998).  
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4.2.3.4. SAM/SAH analysis of Gldc mutant embryos 
A decrease in S-adenosyl methionine (SAM) combined with increase in S-adenosyl 
homocysteine (SAH) (thus decreasing SAM/SAH ratio) would suggest suppression of the 
methylation cycle, which is known to induce cranial NTDs (Dunlevy et al., 2006, Burren et 
al., 2008). Decreased SAM/SAH ratio has also been shown to be an effective marker of 
global DNA hypomethylation (Caudill et al., 2001). The levels of SAM and SAH in E11.5 
GldcGT1 whole embryos were measured by LC-MS/MS (performed by Dr K-Y Leung) to 
assess the efficiency of methylation in the GldcGT1 model.  
The SAM/SAH ratios of GldcGT1 embryos showed no significant differences between all 
genotypes and phenotypes (Figure 39). This suggests that compromised methylation is 
unlikely to be the mechanism underlying the NTDs in GldcGT1/GT1 embryos. 
 
 
Figure 39. SAM/SAH ratios of E11.5 GldcGT1 embryos. 
No significant differences in SAM/SAH ratio were found between the different genotypes 
of GldcGT1 mutant embryos, with or without NTDs. Error bars represent mean ± SEM 
(ANOVA).  
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4.2.3.5. Interaction between Gldc and Mthfr mutations 
The 677C>T polymorphism in MTHFR is of particular interest in human NTDs due to it 
being the first and one of few FOCM enzyme-encoding mutations which is associated with 
NTDs. While the mouse knockout model of Mthfr did not present with NTDs, post-natal 
mutant tissue showed suppressed methylation (Chen et al., 2001). This presents an 
opportunity to test for potential gene-gene interaction between the Mthfr mutation (which 
stops conversion of 5,10-methylene-THF to 5-methyl-THF, thus preventing 1C units from 
entering the methylation cycle) and Gldc mutation (reported in this thesis to produce a 
shortage of mitochondrial-derived IC units, hypothesised to predominantly affect 1C 
supply into both nucleotide synthesis and the methylation cycle).  
Given that both MTHFR and GLDC mutations may increase susceptibility to NTDs in 
humans, the potential for a genetic interaction was investigated. To test whether the 
presence of the Mthfr knockout allele in a Gldc-GT2/GT2 embryo affects NTD incidence, 
Mthfr+/- mice were crossed with GldcGT2/+ mice to produce double heterozygous 
(GldcGT2/+;Mthfr+/-) mice. These were then inter-crossed to produce double homozygous 
mutants (GldcGT2/GT2;Mthfr-/-) in experimental litters. The results of this experiment are 
presented in Table 20. 
In embryos that were wild-type for Gldc (i.e. GldcGT2 mutant allele was absent), no NTDs 
were present regardless of the Mthfr genotype. This finding corresponds with published 
data reporting the absence of NTDs in Mthfr null mice (Chen et al., 2001). When the Mthfr 
allele was absent, NTDs were present with a 43% incidence in embryos with the GldcGT2/GT2 
genotype and 7.1% in GldcGT2/+, which is comparable to a GldcGT2 heterozygous cross as 
reported in Chapter 3. In double homozygous (GldcGT2/GT2;Mthfr-/-) embryos, the rate of 
NTDs appeared lower (20%) than in GldcGT2/GT2;Mthfr+/+ embryos. This result clearly 
suggests that having a non-functioning Mthfr gene in addition to defective Gldc does not 
exacerbate the phenotype. A similar pattern was observed in heterozygous GldcGT2/+ 
embryos: NTD incidence was 7.1% when Mthfr genotyped as wild-type (GldcGT2/+;Mthfr+/+), 
but were not present when Mthfr was absent (GldcGT2/+;Mthfr-/-). 
To investigate how the Mthfr mutation alters the folate profile of GldcGT2 mutants, the 
proportion of folates in E11.5 whole embryos were measured by LC/MS/MS, as for GldcGT1 
embryos (Section 4.2.1.3) (performed by Dr Kit-Yi Leung). The folate profiles of wild-
type, individual homozygous mutant, and double homozygous mutant embryos from 
GldcGT2/+;Mthfr+/- double heterozygous litters were compared (Figure 40).  
In GldcGT2GT2;Mthfr+/+ mutants (effectively GldcGT2 mutant controls), there was an increase 
in proportion of DHF and THF, and decrease in 5-methyl-THF, when compared to the wild-
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types. Although only the changes in 5-methyl-THF were significant, this pattern mimics 
that seen in the GldcGT1 mutants (Figure 27). In Gldc+/+;Mthfr-/- mutants (effectively Mthfr 
knockout controls), there was a dramatic, significant decrease in 5-methyl-THF and 
increase in 5,10-methylene-THF compared to wild-types, as expected from lack of Mthfr 
enzyme to convert 5,10-methylene-THF to 5-methyl-THF. Other significant changes 
include increases in THF, 5,10-methenyl THF, and 10-formyl-THF compared with wild-
types, presumably as a result of the increased availability of 5,10-methylene-THF. 
In GldcGT2/GT2;Mthfr-/- mutants, the changes due to the Mthfr mutation appear to dominate 
their folate profiles when compared with wild-types: a dramatic, significant decrease in 5-
methyl-THF, and increases in proportion of all other folates, was observed. When 
compared with GldcGT2/GT2;Mthfr+/+ mutants, the addition of the Mthfr mutation further 
increased the proportion of DHF and THF. Interestingly, the proportion of the 1C-carrying 
folates 5,10-methenyl-THF, 5,10-methylene-THF, and 10-formyl-THF in GldcGT2/GT2;Mthfr-/- 
mutants were significantly increased (at the cost of a severe reduction in 5-methyl-THF) 
compared with GldcGT2/GT2;Mthfr+/+ mutants. As the Mthfr knockout mouse has defective 
methylation but does not present with NTDs, the NTDs observed in GldcGT2/GT2;Mthfr-/- 
double homozygotes are probably entirely caused by the GldcGT2 mutation. The increase in 
their proportion of 1C-carrying folates (compared to GldcGT2/GT2;Mthfr+/+ mutants) may be 
causing the slight decrease in NTD incidence of these mutants, though larger sample sizes 
would be needed to test whether this finding is statistically significant. 
 
151 
 
 No. of embryos with NTD/ Total no. of embryos (%) 
GldcGT2 allele +/+ +/+ +/+ GT2/+ GT2/+ GT2/+ GT2/GT2 GT2/GT2 GT2/GT2 
Mthfr allele +/+ +/- -/- +/+ +/- -/- +/+ +/- -/- 
E11.5 0/6 0/15 0/8 1/18 
(5.6%) 
2/71 
(2.8%) 
0/21 2/5 
(40%) 
4/17 
(23.5%) 
1/9 
(11.1%) 
E15.5 0/4 0/6 0/3 0/2 
 
0/13 0/7 1/2 
(50%) 
2/5 
(40%) 
1/3 
(33.3%) 
Total 0/10 0/21 0/11 1/20 
(5%) 
2/84 
(2.4%) 
0/28 3/7 
(42.9%) 
6/22 
(27.3%) 
2/12 
(16.7%) 
Table 20. Incidence of NTDs in GldcGT2/+;Mthfr+/- double heterozygous crosses. 
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Figure 40. Folate profiles of GldcGT2;Mthfr= double mutants.  
When compared with wild-types (Gldc+/+;Mthfr+/+, simplified as “+/+;+/+”) (indicated *), 
GldcGT2/GT2 mutants (GldcGT2/GT2;Mthfr+/+, simplified as “GT2/GT2;+/+”) showed significant 
decrease in proportion of 5-methyl-THF (C), while Mthfr-/- mutants (Gldc+/+;Mthfr-/-, 
simplified as +/+;-/-) showed significant decrease in 5-methyl-THF (C), and a significant 
increases (*) in THF (B), 5,10-methenyl-THF (D), 5,10-methylene-THF (E), and 10-formyl-
THF (F). The double homozygous mutants (GldcGT2/GT2;Mthfr-/-, simplified as “GT2/GT2;-/-) 
had significantly decreased proportions of  5-methyl-THF and increase in all other folates 
including DHF (A). When compared with GT2/GT2;+/+ mutants (**), the addition of the 
Mthfr mutant alleles in GT2/GT2;-/- mutant embryos resulted in significant decrease in 5-
methyl-THF but increase in the other folates (ANOVA, P<0.001). Error bars represent 
mean ± SEM. 
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Figure 40. Folate profiles of GldcGT2;Mthfr double mutants.  
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4.2.3.6. Effect of anti-helminthic treatment on GldcGT2 mutants 
Due to a pinworm outbreak in the animal facility, all mice were subjected to treatment 
with fenbendazole in their food pellets over a 3-month period. Fenbendazole is a common, 
broad-spectrum, anti-helminthic drug for laboratory rodents which has been reported as 
safe for life-long treatment of the animals but may have tumour promoter effects (e.g. by 
inducing expression of specific cytochrome isoforms such as 1A1, 1A2, and 2B1) in 
combination with other triggers and possible myelosuppression (Villar et al., 2007). 
However, no immunosuppressive, reproductive, or teratologic effects from therapeutic 
doses of fenbendazole have been reported in rodents to date (Villar et al., 2007). 
Litters from GldcGT2 heterozygous crosses that were collected during this period (where 
female mice consumed fenbendazole-containing diet prior to and during pregnancy until 
litters were collected) were analysed separately and their incidence of NTDs is reported in 
Table 21 below. There was a significant increase in the frequency of NTDs from 56.5% 
among 62 mutant embryos collected pre-treatment (as reported in Chapter 3) to 100% 
among 16 embryos when the dams were on fenbendazole treatment (Z-test, P = 0.002).  
When the mice were taken off fenbendazole treatment and returned to their normal diet, 
the rate of NTDs in GldcGT2/GT2 mutants fell to an average of 84% (n = 38 mutants) (Table 
22). While this is a reduction from the complete NTD penetrance when on fenbendazole, it 
remained significantly higher than the original rate from data collected prior to 
fenbendazole treatment (Z-test, P = 0.009). This indicates that fenbendazole may have 
persisting effects on GldcGT2 dams and/or their oocytes, even after they have been taken off 
the treatment. To definitively assign the change in NTD rates to fenbendazole treatment, it 
will be necessary to test whether the NTD frequency returns to pre-treatment levels in 
subsequent generations of mice and then to analyse sets of treated and untreated litters in 
parallel. 
As indicated in Table 23, exencephalic GldcGT2 mutants often exhibited split face and/or 
truncated forebrains similar to that reported prior to fenbendazole exposure in Chapter 3. 
Craniofacial phenotypes were also observed in embryos/foetuses collected at E14.5 to 
E17.5 after the fenbendazole treatment period (Figure 41), most commonly split face with 
the upper jaw splayed apart at the midline and a relatively normal lower jaw (Figure 41C’, 
I’). A smaller cleft was also observed in one E17.5 mutant foetus (Figure 41H’).  
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Stage (E-) No. of litters 
No. of NTDs/ Total no. of embryos (% NTD) 
Gldc+/+ GldcGT2/+ GldcGT2/GT2 
11.5 9 0/21 2/39 (5.1%) 10/10 (100%) 
15.5 2 0/2 0/8 3*/3 (100%) 
17.5 2 0/8 0/8 3/3 (100%) 
TOTAL 13 0/31 2/55 (3.6%) 16/16 (100%) 
Table 21. Incidence of NTDs in fenbendazole-treated GldcGT2 embryos. 
* 2 exencephaly, 1 craniorachischisis 
Stage (E-) No. of litters 
No. of NTDs/ Total no. of embryos (% NTD) 
Gldc+/+ GldcGT2/+ GldcGT2/GT2 
11.5 7 0/13 2/33 (6.1%) 10/15 (67%) 
14.5 4 0/7 1/24 (4.2%) 7/7 (100%) 
15.5 2 0/2 0/7 6/6 (100%) 
16.5 2 0/2 0/4 - 
17.5 3 0/10 0/12 9*/10 (90%) 
TOTAL 18 0/34 3/80 (3.8%) 32/38 (84%) 
Table 22. Incidence of NTDs in GldcGT2 embryos after fenbendazole treatment. 
* 8 exencephaly, 1 craniorachischisis 
Stage  
(E-) 
No. with craniofacial defects/ No. of exencephalic mutants (%) 
GldcGT2/+ GldcGT2/GT2 
 During fenbendazole treatment period 
11.5 2/2 (100%) 7/10 (70%) 
15.5 - 0/2 
17.5 - 0/3 
TOTAL 2/2 (100%) 7/15 (46.7%) 
 After fenbendazole treatment period 
11.5 1/2 (50%) 5/10 (50%) 
14/5 0/1 2/7 (28.6%) 
15.5 - 2/6 (33.3%) 
17.5 - 2/8 (25%) 
TOTAL 1/3 (33.3%) 11/31 (35.5%) 
Table 23. Incidence of craniofacial defects in exencephalic GldcGT2 mutants during 
and after fenbendazole treatment.  
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Figure 41. NTDs and craniofacial defects in E15.5 and E17.5 GldcGT2 mutants 
collected after the period of fenbendazole treatment. 
Wild-type Gldc+/+ at E14.5 (A) and E17.5 (D) with normal head morphology. (B, B’) E14.5 
GldcGT2/GT2 mutant with exencephaly but normal face (arrows indicate normal upper jaw), 
and (C, C’) exencephaly with split face (arrows indicate upper jaws splayed apart). E17.5 
GldcGT2/GT2 mutant with exencephaly (E), craniorachischisis (F), facial haemorrhage 
(arrows) (G), exencephaly with cleft upper jaw (arrow) (H, H’), and exencephaly with cleft 
face and proboscis (arrow) (I, I’). 
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4.3. Discussion 
 
4.3.1. Biochemical profiles of Gldc deficiency 
In silico predictions of hepatic folate metabolism carried out by Nijhout et al. (2006) 
reported that if all mitochondrial folate reaction velocities were set to zero (thus 
completely eliminating mitochondrial contribution), their model predicts a large reduction 
in activity of TYMS and AICART (i.e. in level of thymidylate and purine synthesis, 
respectively). In addition, MTHFD1 would favour its reverse reaction of converting 5,10-
methylene-THF to 10-formyl-THF, thus causing THF levels to rise and 5-methyl-THF levels 
to drop. Consequently, homocysteine levels would rise due to reduced input into the 
methylation cycle but levels of methionine and SAM would be less affected.  
Experiments in this chapter examined changes in folate metabolites resulting from 
elimination of GLDC both in silico and measured by LC/MS/MS. The data provide evidence 
for the importance of glycine cleavage contribution in maintaining sufficient formate pools 
for normal folate cycling.   
However, there are several limitations to using the current in silico model for modelling 
Gldc deficiency during development. The model was constructed using values derived 
from known experimental results and cannot account for unknown factors or predict 
novel elements in the pathway. In addition, it was built to model hepatic FOCM in adult 
tissue and there are some differences between hepatic and embryonic pathways (Dr Kit-Yi 
Leung, personal communication). If changes in FOCM parameters (as measured 
experimentally) were found that did not fit with theoretical in silico predictions, it would 
be more difficult to investigate hypothetical initial conditions that might bring about a 
particular, abnormal change.  
The protocol used for assessing folate and amino acid profiles of Gldc-deficient embryos in 
this chapter also has its limitations. E11.5 embryos were used because it is the earliest 
post-neurulation stage with sufficient material for reproducible measurements of single 
embryos. Ideally, neurulation-staged embryos at E8.5-E10.5 should be used to confirm 
that the abnormal folate profiles were present during neurulation. Gldc mRNA is restricted 
to specific tissues during neurulation (as shown by in situ studies in Chapter 3) and the 
Gldc enzyme is only localised in mitochondria. Thus, it is possible that the measured 
changes, from whole embryos, are of lesser magnitude as actually occurs in vivo in Gldc 
expressing cells due to dilution effects of surrounding tissue where Gldc is not expressed. 
Biochemical essays done on whole embryos would be less sensitive to changes occurring 
only in the mitochondrial fraction due to the presence of cytosolic content. In addition, a 
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recent study showed that mitochondria can maintain folate pools independent of, rather 
than in equilibrium with, cytosolic folates (Lawrence et al., 2014). A comparison of folate 
profiles between the mitochondrial and cytosolic fractions of Gldc-deficient embryos 
would be of interest to determine how the mutation influences 1C flux between 
mitochondria and cytosol.  
Nevertheless, significant elevation of glycine levels at E11.5 indicates that glycine is not 
being sufficiently catabolised and thus accumulating to potentially toxic levels, and the 
changes in mutant embryo folate profile indicates a disturbance in their folate metabolism 
corresponding to a lack of 1C units which could affect FOCM outputs. Experiments with 
formate supplementation provide evidence that the latter biochemical perturbation (lack 
of 1C units) underlies the NTD phenotype in Gldc-deficient mutants. 
 
4.3.2. Formate treatment and rescue 
The effectiveness of formate in rescuing NTDs and normalizing folate profiles in Gldc 
homozygous mutant embryos strongly suggest that NTDs in Gldc mutants result from 
insufficient supply of 1C units for FOCM. This, combined with the observation that glycine 
levels were elevated in formate-treated, NTD-rescued embryos, argue against the 
possibility that the NTDs were a result of toxicity from elevated glycine levels. 
Plasma formate levels in adult mice did not differ significantly between genotypes. It is 
possible that formate produced by the GCS is used in a cell-autonomous fashion and thus 
contribute little to circulating formate levels and/or that circulating formate is not a good 
indicator of cellular levels. Moreover, in terms of neural tube closure it is the cellular levels 
in the embryo that are crucial. Maternal formate supplementation could be protective by 
providing an excess of non-mitochondrial derived formate to be taken up by the cells in 
the embryos, as formate is rapidly transferred from maternal to foetal circulation (Hutson 
et al., 2013). In addition, formate levels were found to be much higher in foetal lamb 
plasma and amniotic fluid compared to maternal plasma, suggesting that there is higher 
demand for formate during developmental stages (Washburn et al., 2015).  
Formate metabolism is dependent on hepatic FOCM: conversion of THF to 10-formyl-THF 
oxidises formate. In folate-deficient conditions, circulating formate levels are known to be 
elevated (Lamarre et al., 2012, Lamarre et al., 2013). This finding was replicated in Gldc 
mice fed with a folate-deficient diet which also showed increase in plasma formate levels. 
As folate deficiency does not exacerbate NTD incidence, the “limiting factor” precipitating 
the phenotype is probably 1C units rather than the folate cofactors themselves, and that 
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depressing the levels of folates produces excess 1C units that enter circulation. This 
inference also implies that treating Gldc mutant mice with folic acid, a non-1C unit-
carrying synthetic folate, would not rescue their NTDs. Indeed, Amt knockout mice (also 
deficient in glycine cleavage) were not rescued by folic acid, but supplementation with 
methionine, a source of 1C units and precursor to SAM in the methylation cycle, was able 
to reduce their NTD rate from almost 90% to 60% (Narisawa et al., 2012). It would be of 
interest to test whether there is a protective effect of methionine in Gldc-deficient 
embryos. 
How could a 1C shortage subsequently result in NTDs? From a biochemical perspective, 
the disruption in FOCM could lead to disrupted methylation or impaired nucleotide 
synthesis. Formate supplementation is hypothesised to act by increasing 1C unit pools. 
Normalisation of folate profiles was observed, but it is not yet clear how the 1C units were 
distributed upon entering FOCM and the level of flux into various FOCM outputs cannot 
yet be distinguished. However, several indirect observations were made that argue in 
favour of nucleotide synthesis being the affected downstream pathway of FOCM which is 
corrected by formate supplementation. 
The finding that SAM/SAH ratio in Gldc-deficient mutants did not differ significantly from 
wild-types suggests that the methylation cycle is unperturbed by the loss of 1C units. 
SAM/SAH ratio alone does not completely rule out absence of a methylation defect, as any 
additional factors affecting levels of methionine or homocysteine could potentially distort 
the ratio. For example, changes in the transsulfuration pathway which is an alternative 
route for homocysteine catabolism (Blom, 2009), or degree of self-regulation via negative 
feedback loops and other enzymes such as BHMT and glycine N-methyltransferase to 
compensate for reduced 5-methyl-THF levels from the one-carbon cycle. Additional 
experiments such as directly measuring global DNA methylation, for example, would be 
needed. Other observations on the effect of formate treatment (see below) and that the 
presence of an Mthfr null mutation in Gldc-deficient mice does not worsen the phenotype 
(discussed in Section 4.3.4), would argue against methylation being causative.  
In addition to addressing the 1C shortage and conferring phenotype rescue, formate also 
corrects growth delay and normalises cellular proliferation in the hindbrain neural tube of 
Gldc-deficient mutants. Proliferation defects in Gldc embryos could result from impaired 
nucleotide production which formate treatment would presumably be capable of 
correcting. However, as proliferation defects could simply be a marker of perturbed FOCM 
and as formate treatment could potentially correct all downstream FOCM pathways by 
correcting FOCM, whether the proliferation defect causes the NTDs is not satisfactorily 
shown.  
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Further studies could include, for example supplementation of Gldc mutants with labelled 
formate to directly measure the amount of labelled 1C units in nucleotides. Nucleotide 
supplementation has been shown to be effective in rescuing NTDs in the folic acid-
resistant curly tail model by incorporation into embryonic DNA and stimulation of cellular 
proliferation (Leung et al., 2013). Thus, it would be interesting to perform 
supplementation of Gldc-deficient mice with nucleotides to attempt a rescue of 
proliferation but without correcting the 1C shortage (i.e. bypassing FOCM entirely). 
Observing a lowering of NTD incidence would provide experimental evidence to support 
proliferation as the causative factor.  
Nucleotide treatment has, in fact, been attempted in the Amt model: Amt knockout mice 
were supplemented with thymidylate (dTMP) but interestingly this did not rescue their 
NTD phenotype (Narisawa et al., 2012). Perhaps a higher dose of dTMP or dTMP in 
combination with another purine or pyrimidine precursor is required to stimulate 
sufficient increase in proliferation. It was reported that the highest levels of rescue 
conferred by nucleotide treatment in the curly tail mouse were achieved with combined 
thymidine and adenine, or thymidine and guanosine monophosphate (GMP) treatment 
(Leung et al., 2013).  
Some evidence from cancer studies also lends support to GLDC’s capabilities in affecting 
proliferation. GLDC retroviral knockdown in A549 cells resulted in a proliferation defect 
that could be rescued by sarcosine, an alternative 1C donor. However, knockdown in 
normal HLF cells did not cause a proliferation defect (Zhang et al., 2012).  
 
4.3.3. Formate toxicity 
Formate-treated Gldc embryos displayed signs of toxicity (snout defect, haemorrhage and 
oedema) when collected at stages E15.5 and E18.5. In other wild-type embryos (i.e. not 
litters from GldcGT1 inter-crosses) from the C57BL/6 background strain, supplementation 
with formate until E18.5 was also found to produce haemorrhage and oedema among 33% 
of foetuses, compared to no toxic signs in untreated wild-types (Sonia Sudiwala, personal 
communication). This implies that the haemorrhage and oedema, present in all genotypes 
of GldcGT1 embryos, were precipitated by long-term formate exposure. However, the snout 
phenotype only appeared in GldcGT1 mutants (both homozygotes and heterozygotes), and 
might be an uncharacterised abnormality of Gldc deficiency, perhaps a less severe form of 
the craniofacial defects observed among GldcGT2 foetuses. More E15.5-E18.5 formate-
treated litters would need to be analysed to investigate this possibility. 
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The precise mechanism underlying pathology of formate toxicity in developing embryos is 
currently unclear. The fact that the toxic effects were only observed at late stages rather 
than at neurulation stages would suggest a cumulative effect in the embryos of formate-
treated dams. This is supported by reports of formate being elevated in foetal lamb plasma 
and amniotic fluid which persisted in newborn up to 8-week-old lambs (Washburn et al., 
2015). The potentially toxic effects of formate are possibly another reason why circulating 
formate levels appear to be at low levels in wild-type mice (and why embryos would not 
benefit from a maternal supply of formate when not supplemented). 
Although formate can also be broken down to water and carbon dioxide by the catalase 
enzyme, the occurrence of formate and methanol toxicity would suggest that catalases do 
not play a major role in formate metabolism. In addition, the primary role of catalases is in 
breakdown of reactive oxygen species like hydrogen peroxide (Zamocky et al., 2008) and 
not formate, despite formate’s ability to bind stably to catalases (Loewen et al., 2004). 
Formate toxicity is commonly studied in the context of methanol poisoning, as methanol 
break down yields formaldehyde and subsequently formate. In vitro studies have shown 
that formate, given in doses of 0.5 mg/mL to 8 mg/mL, significantly affects embryo  
viability in a dose-dependent manner in rat but not mouse embryo culture systems (Harris 
et al., 2004, Hansen et al., 2005), and that it causes neuronal cell death in rat hippocampal 
slice cultures (Kapur et al., 2007). It is hypothesized that in methanol poisoning, formate 
induces toxic effects by causing acute metabolic acidosis due to insufficient levels of 
hepatic THF to cope with the increase in formate production  (Tephly, 1991).  
Despite the association of formate with toxic effects, calcium formate is used as a 
supplement, to supply calcium. It is possible that a “safe” dose of calcium formate would 
provide sufficient 1C units to ameliorate neural tube closure defects without causing toxic 
effects, particularly if treatment was not continued beyond neurulation stages. It will be 
interesting to carry out pilot experiments in mice to test whether cessation of formate 
supplementation after neural tube closure is complete can prevent NTDs without causing 
any subsequent abnormalities. 
 
4.3.4. Interaction of the Mthfr mutation with Gldc deficiency 
The action of Mthfr, which irreversibly catalyses conversion of 5,10-methylene-THF to 5-
methyl-THF, can determine whether the 1C unit in 5,10-methylene-THF is irreversibly 
shunted towards the methylation cycle or towards nucleotide synthesis. If the methionine 
cycle is disrupted (for example in B12 deficiency where methionine is not synthesized) a 
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functioning Mthfr could cause accumulation of 5-methyl-THF and hypothetically deplete 
the amount of other folates entering nucleotide biosynthesis. This is known as the “methyl 
trap” (Beaudin and Stover, 2007).  
Mthfr is the only FOCM enzyme whose action is unidirectional. Hence, when Mthfr 
function is disrupted, 5,10-methylene-THF accumulates but is not “trapped” and can 
participate in other FOCM reactions. Litters from a GldcGT2/+;Mthfr+/- double heterozygous 
cross revealed that NTD incidence did not increase when the Mthfr null mutation was 
introduced to GldcGT2 mutants. The folate profiles of GldcGT2/GT2;Mthfr-/- double homozygous 
mutant embryos is consistent with the hypothesis that the Mthfr mutation, by blocking 
flow of 1C units into methylation, is making available more 1C units for other FOCM 
outputs such as nucleotide synthesis. While the numbers of compound mutant embryos 
generated so far are insufficient to produce statistically significant results, the gene 
dosage/phenotype pattern observed shows a lower rate of NTDs with increasing numbers 
of Mthfr null alleles, suggesting a possible protective effect rather than exacerbating. 
Metabolic tracer studies using labelled 1C units would be required to confirm the ultimate 
fate of the 1C units that are shunted away from methylation. This experiment indicates 
that the Mthfr mutation does not increase risk of NTDs caused by 1C unit insufficiency, and 
also provides additional evidence that disrupted methylation is unlikely to be the cause of 
NTDs in Gldc-deficient embryos. 
This finding may have implications in human populations carrying both mutations. 
Variants in GCS genes that produced significantly decreased GCS activity were found in 
NTD patients, and the 677C>T polymorphism in MTHFR is an NTD risk allele in some 
populations. It is possible that the 677C>T polymorphism is not directly causative in 
populations where an association with NTDs was found, but that it acts in combination 
with another NTD risk factor, which is not a GCS enzyme mutation. This implies that if 
both a 677C>T polymorphism and a GCS gene mutation are present together, this might 
paradoxically confer a protective effect. These findings highlight the difficulty of 
interpreting data from association studies that consider only one gene at a time. 
 
4.3.5. Effect of fenbendazole on phenotypes resulting from Gldc deficiency 
Fenbendazole produces its anti-helminthic effect by selectively binding β-tubulin to inhibit 
polymerisation of microtubules, thus disrupting mitotic spindle formation and mitosis in 
helminths, but is reported to show little effect on mammalian microtubules (Lacey, 1990). 
Concerns have been raised about its potential effects on the mammalian host. It has been 
shown to induce mitotic arrest at metaphase in human lymphocyte cultures (Holden et al., 
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1980), decrease proliferation of splenic B lymphocytes in mice (Landin et al., 2009), and 
exacerbate acetaminophen (an analgesic drug)-induced hepatotoxicity by prolonging 
suppression of hepatic glutathione (Gardner et al., 2012). 
The complete penetrance of NTDs upon exposure to fenbendazole in GldcGT2/GT2 
homozygous mutants but not wild-type mice indicates an interaction between 
fenbendazole and the Gldc mutation. In addition, the rate of exencephalic mutants with the 
split face and/or forebrain truncation phenotype rose from 9% pre-fenbendazole 
(reported in Chapter 3) to 53% (9 out of 17 total exencephalic GldcGT2/+ and GldcGT2/GT2 
mutants, Table 23) in litters collected during the exposure period. Fenbendazole may 
have a non-appreciable effect on wild-type mice with robust FOCM, but produce a 
synergistic worsening of a phenotype that is caused by 1C depletion. This observation is in 
striking contrast with the folate-deficient diet treatment (Figure 32), which was a 
contemporaneous gene-environment interaction study that did not exacerbate NTDs in 
the GldcGT1 model. 
It should be noted that these observations were not results of a parallel controlled 
experiment, and thus the effects of other environmental factors cannot be completely 
ruled out. However, GldcGT2/GT2 mutant embryos without NTDs were successfully retrieved 
after the mice were returned to a normal diet, which strongly indicates that fenbendazole 
was responsible for the phenotype exacerbation. The incidence of exencephaly with split 
face and/or forebrain truncation also reduced to 35% (12 out of 34 total exencephalic 
GldcGT2/+ and GldcGT2/GT2 mutants, Table 23). The severe split face phenotype observed in 
several mutants collected at E14.5-E17.5 is most likely a later phenotype corresponding to 
progression of the split face and/or forebrain truncation observed at E10.5-E11.5, rather 
than a unique defect induced by fenbendazole.  
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5. GldcGT1 mouse as a model for non-ketotic 
hyperglycinemia 
 
 
5.1. Introduction 
 
The relatively low penetrance of NTDs in the GldcGT1 model allowed for sufficient 
homozygous mutants to survive to birth, weaning, and adulthood. In this chapter, post-
natal characterisation of the GldcGT1 model was carried out to assess its suitability as a 
model for classical NKH. Hypotheses for the pathology of NKH as well as NKH-associated 
brain malformations are thus reviewed below. 
 
5.1.1. Pathology of NKH 
Glycine (and ᴅ-serine) along with glutamate are co-agonists for NMDAR activation. Glycine 
also binds to glycinergic receptors (GlyR) to produce a postsynaptic inhibitory response. 
NMDAR activity has been linked to seizures in various experimental models, and 
antagonists of NMDAR glycine binding sites have been used as antiepileptic drugs (Lason 
et al., 2013). The mediator role of GABA and GlyR in cation-chloride cotransporter 
mechanisms have been similarly implicated in seizure activity (Blaesse et al., 2009). 
NMDAR signalling is involved in both cell death and cell survival, by promoting neuronal 
survival and antioxidant defences as well as inducing neuronal cell death via 
mitochondrial apoptosis in neuropathological states (Hardingham and Bading, 2003, 
Hardingham and Bading, 2010).  
In NKH patients, it is thus reasonable to assume that the excitatory effect of glycine on 
NMDARs is the cause to the intractable seizures, and the inhibitory effect on GlyRs in the 
brain stem and spinal cord is causing the apnea, hypotonia, and hiccupping symptom 
(Korman et al., 2006). Sakata et al. (2001) studied the expression pattern of GCS genes in 
adult rat brains and noted the many overlaps in expression patterns with that of NMDAR 
complexes, suggesting that GCS may be regulating concentrations of glycine near NMDARs. 
Administration of high doses of sodium benzoate to NKH patients in order to sequester 
glycine is a common treatment course which generally helps ameliorate seizures. When 
sodium benzoate therapy was stopped in a late-onset NKH patient, her seizures recurred 
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(Van Hove et al., 1998). High levels of glycine have also been demonstrated to induce 
hyperexcitability of NMDARs in hippocampal slice cultures, resulting in neurotoxicity and 
consequently cell death (Newell et al., 1997). The toxic effect of high glycine could then be 
prevented by blocking NMDAR activation with 7-chlorokynurenic acid, a competitive 
glycine site antagonist (Barth et al., 2005). 
There is also evidence of contributions from pathways that do not involve NMDAR or GlyR 
signalling in the pathology of NKH. Ichinohe et al. (2004) observed that the brain 
malformations in NKH patients are mainly hypoplastic in nature (such as atrophy of white 
matter and agenesis of the corpus callosum) and hypothesised that they may be a result of 
impaired proliferation and differentiation of neural progenitor cells (NPCs). They showed 
that Gldc and Amt mRNA and protein are highly expressed throughout the developing rat 
brain and in neurogenic areas of the adult rat brain, and suggested that the GCS’s 
participation in folate metabolism, which links to cellular proliferation, may be the 
underlying pathway being affected.  
Some in vitro evidence suggests that glycine may be contributing to NKH pathology via 
oxidative stress pathways. The addition of glycine to wild-type, rat cerebral cortex 
homogenates resulted in increased levels of markers of lipid peroxidation and decreased 
levels of glutathione (primary antioxidant in the brain) in a dose-dependent manner, 
indicating that glycine provokes lipid oxidative stress damage (Leipnitz et al., 2009). The 
same group later found that glycine suppresses activity of several mitochondrial enzymes 
including citrate synthase [but not other enzymes in the tricarboxylic acid (TCA) cycle], 
complexes I-III, II, and II-III of the electron transport chain, and creatine kinase in the rat 
cerebral cortex, and also suppresses Na+,K+-ATPase activity of synaptic plasma 
membranes (Busanello et al., 2010).  They hypothesised that the inhibition of creatine 
kinase and Na+,K+-ATPase are a response to glycine-induced oxidative damage. These 
findings would seem contradictory to the contribution of glycine as one of the amino acids 
utilised in synthesis of the glutathione tripeptide molecule, the other major amino acids 
being glutamate and cysteine (Aoyama et al., 2012).  
 
5.1.2. Expression analysis of GCS genes in rat brains 
To better understand the neuropathology of NKH, an expression analysis of Gldc, Amt, and 
Gcsh mRNA and protein in adult rat brain was performed by Sakata et al. (2001), followed 
by a more thorough study in developing and adult rat brains by Ichinohe et al. (2004). GCS 
genes, especially Gldc, are most intensely expressed in highly proliferative and neural 
progenitor regions. In E15 and E18 rat brains, all three genes were highly expressed in the 
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neuroepithelium surrounding the lateral and fourth ventricles and the aqueduct, as well as 
in the external granular layer of the cerebellum. At P7 and P14 post-natal stages, intense 
expression of Gldc was found in the olfactory bulb, subventricular zone, throughout the 
rostral migratory stream, the dentate gyrus, and the external granular and Purkinje cell 
layer of the cerebellum (Ichinohe et al., 2004).  
In addition, Gldc is co-expressed with nestin-expressing NPCs during foetal development, 
and then later with GLAST (an astrocyte-specific glutamate-aspartate transporter) in 
radial glial cells of the subventricular zone and Bergmann glia of the cerebellum of adult 
rat brain. It is hypothesized that the GCS genes are providing 1C units for proliferation of 
NPCs as well as regulate glycine concentration for proper function of NMDAR, and thus 
disruption in these genes results in the hypoplastic brain malformations and recurring 
seizures in NKH patients (Ichinohe et al., 2004). 
At 7- or 8-week adult stages, GCS genes remained highly expressed in the olfactory bulb, 
dentate gyrus, and cerebellar Purkinje and granular cell layer. Expression was also found 
in glial cells of the corpus callosum and glial-like cells of all layers of the cerebral cortex, 
with Gcsh showing additional expression in neuronal layers. Examination of the spinal 
cord revealed abundant expression of Amt and Gcsh in grey matter (Sakata et al., 2001). 
 
5.1.3. Treatment options 
Effective treatment of NKH does not exist; measures are taken to decrease glycine levels 
by administration of sodium benzoate (which conjugates glycine and secretes it out) to 
varying degrees of success, as glycine levels tend to return to pathological levels when 
treatment is stopped. Treatment with strychnine, an inhibitor of GlyR, has been tested and 
found to be of little clinical value (von Wendt, 1979, von Wendt et al., 1980). On the other 
hand, treatment with NMDAR antagonists such as dextromorphan and ketamine is able to 
ameliorate seizures and improve EEG findings in most patients. They have also been noted 
to improve hypotonia and prevent apnea, which are attributed as GlyR inhibitory signs 
(Kure et al., 1997, Korman et al., 2006, Suzuki et al., 2010). 
Anticonvulsants such as phenobarbitone and diazepam are also used alongside NMDAR 
antagonists for seizure control. The use of valproic acid, on the other hand, is 
contraindicated, as valproic acid inhibits the GCS and results in hyperglycinemia and 
hyperglycinuria in non-NKH, epileptic patients (Mortensen et al., 1980). With NKH 
patients, administration of valproic acid results in worsening of symptoms, most notably 
severe chorea and increased seizure activity (Hall and Ringel, 2004, Morrison et al., 2006, 
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Tsuyusaki et al., 2012). Korman et al. (2006) reported that immediate treatment, before 
the onset of symptoms, of prenatally diagnosed NKH with benzoate and ketamine was able 
to delay onset but cannot prevent severe long-term progression of the disease.  
Treatments using precursors of 5,10-methylene-THF and providers of 1C units such as 
Leucovorin (i.e. 5-formyl-THF, or folinic acid), folic acid, serine, methionine, choline, and 
sodium formate have been tried but none proven clinically beneficial (Van Hove et al., 
1998, Trijbels et al., 1974, Wijburg et al., 1988, De Groot et al., 1970, Tada et al., 1969). 
However, these treatments were mostly performed on single patients and thus the lack of 
clinically beneficial findings may simply be due to insufficient testing. Only one study 
found that providing 10-fold amount of methionine in addition to a serine- and glycine-
free diet to one NKH patient was able to decrease plasma glycine levels, but glycine levels 
returned to pathological levels once treatment was stopped (De Groot et al., 1970).  
 
5.1.4. Corpus callosum genesis and agenesis 
The corpus callosum is the largest white matter tract in the brain, crossing the longitudinal 
fissure and connecting the left and right hemispheres. It allows for inter-hemispheric 
sensory and motor communication and is implicated in cognitive functions (Edwards et al., 
2014).  
The genesis of the corpus callosum must first be preceded by Fgf- and Shh-guided 
patterning of the midline and commissural plate (Smith et al., 2006a, Hayhurst et al., 
2008), followed by secretion of axon guidance cues and correct specification of neurons to 
become callosal projection neurons (Fame et al., 2011). At E15.5 in a mouse brain, neurons 
arising from the cingulate cortex cross the midline and enter the contralateral cortex, 
“pioneering” a path for commissural neurons soon to follow (Rash and Richards, 2001). At 
E17, the first callosal neurons arise from layer II/III, VI, and V of the cerebral cortex and 
follow the path of the pioneer neurons. Guidance cues are provided by midline glial 
structures secreting attractive/repulsive signalling molecules (e.g. Semaphorin 3C), 
GABAergic and glutamatergic neuronal populations in the corpus callosum, Eph/ephrin 
signalling between callosal axons and midline structures, and repulsive cues between 
axons from the medial and lateral cerebral cortices (Niquille et al., 2009, Nishikimi et al., 
2013, Edwards et al., 2014). Callosal axons that have crossed respective contralateral 
hemispheres form synapses with postsynaptic neurons, some of which are transient 
connections. Reshaping of the axons then follows, in which specific axonal connections are 
permanently established while excess neurons are eliminated (Innocenti and Price, 2005). 
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Agenesis of the corpus callosum (ACC) is a rare congenital disorder that can occur in 
isolation or in association with other neuropathological disorders. It arises when some of 
its developmental mechanisms are disrupted, and can manifest as complete absence of any 
callosal fibres, partial agenesis with a shorter anterior-posterior length, or 
hypoplasia/thinning (Edwards et al., 2014). ACC caused by disrupted axonal guidance may 
result in rerouting of neurons to form longitudinal bundles in the ipsilateral cortex, i.e. 
Probst bundles. More recently, asymmetrical connections between the frontal lobe and 
contralateral occipital and/or parietal lobes have also been found in partial ACC patients 
(Tovar-Moll et al., 2007). While ACC by itself is not a life-threatening condition, it has been 
associated to a number of brain abnormalities, neurological dysfunctions, and behavioural 
disorders, including micro and macrocephaly, epilepsy, schizophrenia, and ADHD. The 
majority of ACC cases are so sporadic that genetic studies are difficult and about 68% of 
cases have unknown causes (Schell-Apacik et al., 2008, Siffredi et al., 2013).  
The occurrence of ACC has been noted in various metabolic and/or mitochondrial 
disorders including NKH, pyruvate dehydrogenase deficiency (Lissens et al., 2000), 
fumarase deficiency (Coughlin et al., 1998), and leukoencephalopathy in which a 
disruption in complex I, II or IV of the electron transport chain is present (Sofou et al., 
2013). While a direct link between the two is unclear, occurrences of ACC in these cases 
are hypoplastic in nature and are likely secondary to general white matter loss. 
 
5.1.5. The ventricular system and hydrocephalus 
In higher vertebrates, as the closed neural tube starts to differentiate to distinct regions of 
the brain, the ventricular system begins as fluid-filled cavities known as the telencephalon, 
mesencephalon, and rhombencephalon. These cavities then develop into two lateral 
ventricles, the third ventricle, and the fourth ventricle. The cerebrospinal fluid filling the 
cavities are produced in the choroid plexus, predominantly in the lateral ventricles, flow 
through the foramen of Monroe into the third ventricle, enter the fourth ventricle via the 
aqueduct of Sylvius, and drain out into the subarachnoid space. The ventricular walls are 
covered in a layer of specialized epithelial cells known as ependymal cells. These cells 
have motile (9+2 configuration) cilia which contribute to the directionality of CSF flow 
(Fliegauf et al., 2007, Perez-Figares et al., 2001).  
When the flow of CSF is disrupted, causing a build-up of fluid within the ventricular 
system, this results in a condition known as hydrocephalus that presents at, or shortly 
after, birth. Hydrocephalus is a common complication seen in other central nervous 
system pathologies such as NTDs, intra-ventricular and subarachnoid haemorrhages, 
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tumours, and infections, although the precise pathological mechanisms that precipitate it 
are not always known. It is also difficult to distinguish between brain damage that is 
causative of hydrocephalus or that occurs as a consequence of the stretching of the 
ventricular walls and compression of surrounding structures (McAllister, 2012). 
In general, hydrocephalus is classified as being either communicating or non-
communicating. Communicating hydrocephalus describes the presence of an obstruction 
within the ventricular system that blocks the flow of CSF, such as narrowing or closing of 
the aqueduct (i.e. aqueduct stenosis), or the presence of tumours within or adjacent to the 
ventricular wall. Non-communicating hydrocephalus refers to any impairment of flow 
distal to the ventricles, such as impaired absorption in the arachnoid vili, or Chiari 
malformations in which there is a downward displacement of the cerebellum into the 
foramen magna (Perez-Figares et al., 2001, Di Rocco et al., 2011). Hydrocephalus is also 
commonly found in cilia disorders such as primary ciliary dyskinesia (PCD) and Bardet-
Biedl Syndrome (Fliegauf et al., 2007). In rare cases, it can be caused by excessive 
production of CSF, such as in choroid plexus papilloma (Fujimoto et al., 2004). 
Hydrocephalus was first reported in one out of eight NKH patients studied by Van Hove et 
al. (1998), followed by a more thorough report on four patients (Van Hove et al., 2000). All 
four presented with absence or thinning of corpus callosum, very delayed or absent 
myelination, and presence of a posterior fossa cyst in their MRI scans.  The cyst was not 
observed until onset of acute hydrocephalus, and appeared to enlarge as ventriculomegaly 
worsen. All cases had an acute onset between 2 to 6 months and required urgent shunting. 
With no evidence of impaired resorption of CSF by arachnoid vili, the report concluded 
that the presence of the cyst was the cause of an obstructive hydrocephalus in these 
patients. More cases of hydrocephalus with similar MRI findings was reported in 2009 (Yis 
et al., 2009) and in 2012 (Manel et al., 2012).  
Parallels were drawn to the Dandy-Walker malformation, in which the cerebellar vermis is 
hypoplastic and cysts form in the fourth ventricle, subsequently resulting in 
hydrocephalus and enlargement of the posterior fossa (Treble-Barna et al., 2014, Basson 
and Wingate, 2013). The origin of the cyst, however, is not known. The occurrence of 
hydrocephalus in NKH patients is considered rare, with only 5 reported cases out of 62 
patients reviewed by Hoover-Fong et al. (2004). It is generally associated with poor 
prognosis. Dobyns (1989) mentioned findings of ventricular enlargement in 5 out of 15 
NKH patients that had been reported up until then. Flusser et al. (2005) also reported mild 
enlargement of ventricles accompanied by increased frontal subarachnoid fluid in atypical 
NKH patients which they diagnosed as external benign hydrocephalus. There was no 
follow-up data for patient outcome in either report.  
170 
 
5.2. Results 
 
5.2.1. Mendelian ratios of post-natal GldcGT1 and GldcGT2 mutant pups 
Heterozygous matings of GldcGT1/+ mice were performed and pregnant mice were left to 
litter down as described in Chapter 3. The litter information and Mendelian ratios of post-
natal mice as genotyped at 10 days of age (P10) are summarized in Table 24 below.  
At P10, fewer numbers of GldcGT1/GT1 pups was observed than would be expected from 
Mendelian ratios (15 instead of 21), although this difference does not reach statistical 
significance (Z-test, P = 0.347). These litters were sacrificed at 5 weeks of age for 
collection of brain samples. Out of the 15 GldcGT1/GT1 mutant pups reported above, 6 mice 
(40%) developed acute hydrocephalus at varying ages between 10 days and 5 weeks.  
 
 Gldc+/+ GldcGT1/+ GldcGT1/GT1 Total 
No. of pups at P10 20 49 15 84 
Expected no. of pups (1:2:1) 21 42 21 84 
Table 24. Ratio of genotypes of P10 GldcGT1 mice from 15 litters.  
Figures did not account for 2 pups (Gldc+/+ and GldcGT1/GT1) found dead at P1, and 1 pup of 
unknown genotype. 
 
Likewise, seven litters of GldcGT2/+ heterozygous crosses were similarly left to litter down 
and surviving pups were ear-clipped and genotyped at about P10. Litter information and 
Mendelian ratios are summarized in Table 25 below. At P10, unlike with GldcGT1/GT1 pups, 
no surviving GldcGT2/GT2 pups was observed compared to the expected 11. This difference is 
significant (Z-test, P=0.001). 
 
 Gldc+/+ GldcGT2/+ GldcGT2/GT2 Total 
No. of pups at P10 15 29 0 44 
Expected no. of pups (1:2:1) 11 22 11 44 
Table 25. Ratio of genotypes of P10 GldcGT2 mice from 7 litters. 
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5.2.2. Survival studies and hydrocephalus incidence 
As some GldcGT1/GT1 homozygous mutants were able to live past 6 weeks and found to be 
viable, homozygous matings were set up in order to expedite generation of mutants to 
study their survival rates and incidence of hydrocephalus. Several wild-type and 
heterozygous GldcGT1 mice at similar date of births (within the same week) as the mutants 
were also followed up as age-matched environmental controls.  
The survival curve of GldcGT1 mice is shown in Figure 42. While all wild-type and 
heterozygous mutants survived to the end of the study (1 year from start of study), only 
58% of homozygous mutants survived to adulthood (6 weeks) and 45% past 16 weeks 
onto a year. About 22% of the mutants developed hydrocephalus at any age between 3 and 
13 weeks, with majority occurring between 5 and 7 weeks. The cause of the pre-natal 
deaths not attributed to hydrocephalus is not known; some of those pups were simply 
found dead in their cages without any obvious physical malformations or illnesses. 
Hydrocephalic mice were recognizable by a characteristic dome-shaped head (Figure 
43A) and had to be culled within 48 hours as the onset and deterioration of health was 
very rapid. Their craniums were noticeably enlarged (Figure 43B) and their skulls more 
brittle. Opening of the skulls revealed evident swelling of the brain and haemorrhage 
(Figure 43C). Histological examination of the brain revealed severely enlarged ventricles 
with obvious thinning of the cortex and distorted hippocampus (Figure 43D, E). 
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Figure 42. Survival curve of GldcGT1 mice. 
Only 58% of GldcGT1/GT1 mice survived to 6 weeks of age, while no Gldc+/+ or GldcGT1/+ 
displayed any early lethality. About 22% of GldcGT1/GT1 mice developed acute 
hydrocephalus with varied ages of onset as indicated with (*). 
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Figure 43. Hydrocephalus in GldcGT1/GT1 mice. 
GldcGT1/GT1 mice with hydrocephalus, showing (A) dome-shaped head (arrow), (B) 
enlarged cranium, and (C) swelling and haemorrhage of the brain. Coronal sections 
through (D) wild-type and (E) hydrocephalic mutant brains revealed grossly enlarged 
lateral ventricles (LV), thinning of the neocortex (double-sided arrows), and a distorted 
hippocampus (HC) in the mutant brain. Sections were stained with cresyl violet.  
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As gender differences in NKH patients have been implicated (Hoover-Fong et al., 2004), 
the mutants used in the survival studies were sexed and the hydrocephalus and survival 
rates between the two genders are summarised in Table 26 below. A higher percentage of 
males (65%, 13 out of 20 males) were able to survive to adulthood compared to females 
(33%, 7 out of 21 females), although this difference is not significant (Z-test, P = 0.082). 
Strikingly, all 10 hydrocephalic mice were female (Z-test, P < 0.001). The hydrocephalus 
phenotype is not exclusive to female Gldc mutants as male mutants not used for the 
survival study have been found with hydrocephalus. 
 
 
Hydrocephalic 
deaths 
Non-hydrocephalic deaths 
before 6 weeks 
Survive to 6 
weeks 
Total 
Male 0 7 (35%) 13 (65%) 20 
Female 10 (47%) 4 (19%) 7 (33%) 21 
Unknown 0 4* 0 4 
Table 26. Number of hydrocephalus, non-hydrocephalic deaths before 6 weeks, and 
survivors up to 6 weeks in GldcGT1/GT1 mice. 
 
5.2.3. Elevated glycine in plasma and urine of Gldc mutant mice 
The biochemical hallmark of NKH is elevation of glycine in body fluids, thus concentration 
of glycine (and other amino acids) in the plasma and urine of Gldc mutant mice was 
determined using ion-exchange chromatography and displayed in Table 27 and Table 28, 
respectively (measured by Helen Prunty and Dr Simon Heales, Great Ormond Street 
Hospital for Children NHS Foundation Trust). Concentrations in the urine samples were 
normalised to creatinine levels as determined by LC/MS/MS (measured by Dr Kit-Yi 
Leung). 
Similar to the changes found in E11.5 Gldc mutant embryos (Chapter 4), there was a 
significant increase in glycine levels in both the plasma and urine of GldcGT1/GT1 compared 
to Gldc+/+ mice. Other amino acids of interest due to their role as 1C donors to FOCM are 
serine and threonine.  Interestingly, threonine levels were decreased in both GldcGT1/+ and 
GldcGT1/GT1 plasma and urine, while serine levels were decreased in only the plasma of 
GldcGT1/+ and urine of GldcGT1/GT1 mice. In addition to those changes, GldcGT1/GT1 mice also 
showed elevation of aspartic acid and 3-histidine levels in their plasma, and decreased 
levels of leucine and isoleucine in urine.  
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Amino acid 
Concentration in plasma (µmol/L) 
Gldc+/+ (n=3) GldcGT1/+ (n=3) GldcGT1/GT1 (n=3) 
Alanine (ALA) 514.7 ± 40.4 472.7 ± 36.7 542.7 ± 35.9 
Asparagine (ASN) 74 ± 6.4 62 ± 3.1 71.3 ± 2.9 
Aspartic acid (ASP) 12 ± 0 15.3 ± 2.4 21.3 ± 1.3* 
Citrulline (CIT) 78 ± 13.6 71.3 ± 2.4 73.3 ± 4.8 
Glutamine (GLN) 526.7 ± 67.1 526.7 ± 50.8 529.3 ± 48.2 
L-glutamate (GLT) 36.7 ± 1.8 60.7 ± 15.9 35.3 ± 2.4 
Glycine (GLY) 238.7 ± 12.7 283.3 ± 17.5 884.7 ± 109.6* 
Histidine (HIS) 68 ± 7.0 63.3 ± 1.8 52 ± 5.3 
3-Histidine (3-HIS) 1.3 ± 0.7 3.3 ± 0.7 4.7 ± 0.7* 
Leucine (LEU) 208.7 ± 16.7 169.3 ± 26.1 154 ± 7.0 
Isoleucine (ILEU) 107.3 ± 6.6 92.7 ± 9.3 78.7 ± 9.3 
Lysine (LYS) 388.7 ± 23.7 334 ± 32.5 293.3 ± 29.1 
Methionine (MET) 78.7 ± 5.2 63.3 ± 6.6 70 ± 5.3 
Ornithine (ORN) 100.7 ± 7.1 123.3 ± 33.6 78 ± 12.0 
Phenylalanine (PHE) 72.7 ± 5.3 63.3 ± 5.2 64.7 ± 1.8 
Serine (SER) 154 ± 3.5 127.3 ± 4.8** 147.3 ± 5.2 
Taurine (TAU) 546.7 ± 123.1 472 ± 17.5 384.7 ± 57.8 
Threonine (THR) 218 ± 6.4 155.3 ± 7.1** 172.7 ± 4.8** 
Tryptophan (TRY) 110 ± 11.7 82 ± 15.1 77.3 ± 20.7 
Tyrosine (TYR) 107.3 ± 14.5 92 ± 16.0 100.7 ± 5.8 
Valine (VAL) 245.3 ± 14.8 209.3 ± 31.8 191.3 ± 7.9 
Table 27. Concentration of amino acids in Gldc mice plasma. 
Significant increases are indicated with (*) while decreases are indicated with (**), as 
compared to Gldc+/+ (ANOVA, p<0.05). 
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Amino acid 
Concentration in urine (µmol/ µmol creatinine) 
Gldc+/+ (n=3) GldcGT1/+ (n=3) GldcGT1/GT1 (n=3) 
Alanine (ALA) 2.25 ± 0.94 1.43 ± 0.38 0.74 ± 0.14 
Arginine (ARG) 1.10 ± 0.62 0.67 ± 0.12 0.48 ± 0.14 
Asparagine (ASN) 0.87 ± 0.06 1.13 ± 0.31 0.77 ± 0.27 
Aspartic acid (ASP) 3.11 ± 1.58 1.24 ± 0.33 1.19 ± 0.30 
Citrulline (CIT) 0.51 ± 0.05 0.23 ± 0.14 0.21 ± 0.06 
Cysteine (CYS) 0.31 ± 0.12 0.45 ± 0.11 0.40 ± 0.06 
Glutamine (GLN) 2.47 ± 0.27 2.98 ± 0.85 1.27 ± 0.09 
L-glutamate (GLT) 1.34 ± 0.98 0.56 ± 0.14 0.47 ± 0.15 
Glycine (GLY) 3.58 ± 0.67 3.79 ± 0.30 5.34 ± 0.32* 
Homocysteine (HCYS) 2.75 ± 1.05 1.82 ± 0.32 1.14 ± 0.12 
Histidine (HIS) 0.51 ± 0.05 0.37 ± 0.14 0.16 ± 0.02 
1-Histidine (1-HIS) 0.61 ± 0.06 0.71 ± 0.07 0.55 ± 0.06 
3-Histidine (3-HIS) 0.47 ± 0.004 0.55 ± 0.04 0.34 ± 0.04 
Leucine (LEU) 1.21 ± 0.47 0.829 ± 0.14 0.42 ± 0.09** 
Isoleucine (ILEU) 0.25 ± 0.06 0.17 ± 0.04 0.04 ± 0.02** 
Lysine (LYS) 5.43 ± 3.05 2.72 ± 0.43 2.01 ± 0.50 
Methionine (MET) 3.26 ± 0.88 1.86 ± 0.50 1.11 ± 0.24 
Ornithine (ORN) 0.36 ± 0.16 0.24 ± 0.03 0.22 ± 0.01 
Phenethylamine (PEA) 7.84 ± 0.46 6.44 ± 2.07 4.75 ± 0.61 
Phenylalanine (PHE) 0.85 ± 0.39 0.67 ± 0.11 0.44 ± 0.03 
Serine (SER) 1.14 ± 0.32 0.59 ± 0.16 0.33 ± 0.05** 
Taurine (TAU) 13.0 ± 4.90 5.78 ± 1.96 9.47 ± 1.13 
Threonine (THR) 2.28 ± 0.18 0.82 ± 0.22** 0.82 ± 0.09** 
Tyrosine (TYR) 0.74 ± 0.19 0.67 ± 0.21 0.31 ± 0.04 
Valine (VAL) 0.77 ± 0.21 0.45 ± 0.14 0.22 ± 0.04 
Table 28. Concentrations of amino acids in Gldc mice urine. 
Significant increases are indicated with (*) while decreases are indicated with (**), as 
compared to Gldc+/+ (ANOVA, p<0.05).  
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5.2.4. Late-foetal ventriculomegaly in Gldc mutant mice 
To determine if the hydrocephalus phenotype was congenital and has a pre-natal onset, 
E18.5 GldcGT1 foetuses were collected. An illustration of the ventricular system of an E18.5 
mouse brain is provided in Figure 44, where the position of the brain ventricles relative to 
one another is shown. Coronal sections were made through non-exencephalic brains (n = 5 
of Gldc+/+ and n = 12 of GldcGT1/GT1) in Figure 45, Figure 46, and Figure 47.  
Out of the 12 GldcGT1/GT1 mutants histologically examined, 6 showed obvious dilation of 
their lateral and third ventricles (Figure 45), hereon in referred to as “affected” mutants. 
Examination of the aqueduct (Figure 46) revealed stenosis in these affected mutants, in 
which the narrowest regions of their aqueducts were closed. The subcommissural organ 
(SCO) located on the roof of the aqueduct was completely obliterated. In the wild-types 
and normal, unaffected mutants, the aqueduct retains a small opening throughout with the 
SCO clearly visible. The pineal gland, a small structure located superior to the SCO, was 
also missing in affected mutants. Further posterior to this stenosis (i.e. pass the point of 
obstruction), the aqueduct and fourth ventricle of affected mutants were not dilated and 
remained comparable in size to wild-type and normal mutants (Figure 47). Other 
structures such as the choroid plexus and corpus callosum appeared comparable between 
all groups. 
The presence of an obstruction in the ventricular system of Gldc mutants from E18.5 
indicates that the hydrocephalus is congenital and non-communicating. Owing to the 
comparably normal fourth ventricle and aqueduct at regions past the obstruction, the 
cause of the dilated lateral and third ventricles can be attributed to aqueduct stenosis. 
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Figure 44. The ventricular system in an E18.5 mouse brain. 
Diagram of a sagittal view of an E18.5 mouse brain. (A-D) Representative, H&E-stained, 
coronal sections progressing in an anterior-posterior manner with their estimated 
positions indicated (in dotted lines) in the diagram above. The diagram was drawn with 
references from coronal sections of wild-type Gldc mice, the Allen Developing Mouse Brain 
Atlas (available from: http://developingmouse.brain-map.org) and Fliegauf et al. (2007). 
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Figure 45. E18.5 GldcGT1/GT1 brains show dilation of lateral and third ventricles. 
Coronal sections of (row 1A-E) Gldc+/+, (row 2A-E) normal GldcGT1/+, and (row 3A-E) affected GldcGT1/GT1 brains at E18.5, progressing in anterior-posterior 
sequence. Affected GldcGT1/GT1 mutant brains (3A-E) revealed consistent dilation of the lateral (LV) and third ventricles (III V) through all the sections, 
compared to unaffected mutants and wild-type controls. Other abbreviations: corpus callosum (CC), choroid plexus (ChP). Sections were stained with H&E. 
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Figure 46. Aqueduct stenosis and obliteration of the subcommissural organ in E18.5 
GldcGT1/GT1 brains.  
Coronal sections of Gldc+/+ (column 1A-4A), normal GldcGT1/+ (column 1B-4B), and affected 
GldcGT1/GT1 (column 1C-4C) brains at E18.5 through the aqueduct region. In affected 
GldcGT1/GT1 mutant brains with dilated ventricles (1C-4C), the aqueduct (AQ) is closed and 
the subcommissural organ (SCO) is absent (shown with arrows), compared to wild-types 
and normal, unaffected mutants. The pineal gland (PI), shown in sections (2A, 3A) in the 
wild-type and (1B, 2B) in the normal mutant, is absent in the affected mutant (1C-3C). 
The left-most row (1-4) indicates the area (dotted box) that is being shown in the close-
ups on the right, progressing in an anterior-posterior fashion from 1 to 4. 
Scale bars: 2 mm for 1-4; 0.2 mm for all A-C close-ups. Sections were stained with H&E. 
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Figure 46. Aqueduct stenosis and obliteration of the subcommissural organ in E18.5 
GldcGT1/GT1 brains.  
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Figure 47. Sections of E18.5 GldcGT1 brains showing normal fourth ventricles. 
Coronal sections of Gldc+/+ (row 1A-1C), normal GldcGT1/+ (row 2A-2C), and affected 
GldcGT1/GT1 (row 3A-3C) brains at E18.5 through the aqueduct (AQ) and fourth ventricle 
[(IV) V] in anterior-posterior sequence, showing no observable difference in size of the 
ventricles between all groups. 
Scale bars: 0.5 mm. Sections were stained with H&E. 
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5.2.5. Analysis of the corpus callosum 
At E18.5, no obvious thinning or absence of the corpus callosum was detected in GldcGT1/GT1 
mutants via examination of coronal sections (as described in the previous section). 5-week 
old brains were collected and examined to further confirm this finding, as any hypoplasia 
or partial agenesis would presumably be more obvious at post-natal stages. The brains 
were bisected to reveal a sagittal view of the corpus callosum and stained whole and en 
bloc with gold chloride to visualize the commissures. Measurements of the anterior-
posterior length of the corpus callosum were then made. 
No difference in the anterior-posterior length of the corpus callosum was found between 
genotypes (Figure 48). In two GldcGT1/GT1 brains with hydrocephalus, the corpus callosum 
cannot be identified due to the severely enlarged ventricles. As the anterior and 
hippocampal commissures were still present (albeit slightly deformed) in these brains, the 
corpus callosum was more likely obliterated by the hydrocephalus rather than missing 
due to genuine agenesis during development.  
 
5.2.6. Analysis of the cerebellum 
Several gold chloride-stained, 5-week old brains of GldcGT1 mice that were used in the 
corpus callosum analysis also had their cerebellums photographed for preliminary 
examination of the cerebellum (Figure 49). The cerebellar vermis of hydrocephalic 
mutants appeared mildly compressed along the anterior-posterior axis. No Dandy-Walker 
(DW)-like malformation resembling that seen in NKH patients, or severe loss of volume 
and/or foliation as seen in the DW mouse model (Blank et al., 2011), was observed.  
Vermis folia were identified with reference to Blank et al. (2011) and Sgaier et al. (2007) 
as anatomical guides for labelling the folia of the mouse cerebellum, specifically comparing 
wild-type mice to mice with cerebellar foliation defects. Further validation of the 
anatomical labelling of wild-type cerebellum was carried out by referring to the Allen 
Mouse Brain Atlas (available from: http://mouse.brain-map.org). In GldcGT1 samples, the 
wild-types, heterozygotes, and non-hydrocephalic homozygotes (n = 2, each) all showed 
comparable amount of foliation (marked in Roman numerals II to X). In hydrocephalic 
mutant brains (n = 2), one folium anterior to the primary fissure is missing due to the loss 
of a fissure between folia II/III. Thus, a subtle foliation defect may be present alongside the 
hydrocephalus, but a more careful examination of histologically prepared sections is 
required before a conclusion can be drawn.   
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Figure 48. Corpus callosum analysis. 
(A) Normal Gldc+/+ and (B) hydrocephalic GldcGT1/GT1 5-week bisected brains, with boxed 
areas shown at higher magnification in (A’) and (B’), respectively. (A’) indicates how the 
anterior-posterior lengths of the corpus callosum (CC) of non-hydrocephalic brains were 
measured (double-sided arrow). (C) No difference in anterior-posterior lengths of the 
corpus callosum was found between all genotypes (n = 5, each). The corpus callosum 
cannot be identified in the hydrocephalic GldcGT1/GT1 mutants (n = 2). The brains were 
stained en bloc with gold chloride solution. 
Other abbreviations: hippocampal commissure (HC), anterior commissure (AC).  
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Figure 49. Preliminary cerebellar folia analysis. 
Cerebellar size and foliation (traced out in dotted red lines) was comparable between (A) 
Gldc+/+, (B) GldcGT1/+ and (C) non-hydrocephalic GldcGT1/GT1 5-week brains. (D) 
Hydrocephalic GldcGT1/GT1 brains appeared compressed along the anterior-posterior axis 
(compare double-sided white arrows) and were missing one folia anterior to the primary 
fissure (red arrows). Roman numerals represent folia II to X of the cerebellar vermis. 
Sample size, n = 2 for each comparison group. 
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5.3. Discussion 
 
5.3.1. Gldc mutant mice exhibit characteristic features of NKH 
The GldcGT1 mutant mice exhibit several features that are hallmarks of human NKH: they 
have significantly elevated levels of glycine in their plasma and urine, virtually no hepatic 
Gldc enzymatic activity (as shown in Chapter 3), occurrence of early, post-natal deaths 
amongst pre-weaning mutant pups, and about 20% incidence of hydrocephalus. These 
findings make the Gldc mutant mouse a suitable model for studying the pathology of 
classical NKH and would be valuable for testing treatment options. This is unlike the Amt 
knockout mouse, in which NTDs are almost fully penetrant (Narisawa et al., 2012), and the 
low/high-GCS transgenic lines with higher levels of residual Gldc enzymatic activity and 
phenotypes that more closely resemble atypical NKH (Oda et al., 2007, Kojima-ishii et al., 
2008). 
There are several possibilities that may account for the occurrence of early post-natal 
lethality in Gldc mutants that were not caused by hydrocephalus. Although the post-natal 
Mendelian ratios from heterozygous crosses do not reflect significant loss of mutants, the 
number of mutants born were nonetheless fewer than would be expected. This could 
partly be attributed to being born with anencephaly and eaten shortly after birth by the 
mother. The relatively normal appearance of the dead pups (within a few days of age) 
occasionally found in the cages would suggest that other mechanisms are at play to cause 
early lethality. Occurrence of respiratory distress and epileptic seizures, the major causes 
of death amongst neonates with NKH, was possibly present but missed in these pups. 
Neither phenotype has so far been observed in surviving pups or in adult mutant mice, 
although this does not rule out possible aberrant EEG readings and the occurrence of very 
mild seizures that go unnoticed. 
A common brain imaging finding in NKH patients that does not appear to be present in 
Gldc mutant mice is agenesis or dysgenesis of the corpus callosum. It is likely that the 
corpus callosum defects seen in NKH patients are secondary to a mechanism that is 
causing a more generalized loss of white matter and myelination, neither of which were 
particularly obvious in the brains of Gldc mutant mice as observed at 5 weeks of age. 
Due to the similarities in corpus callosum development between mice and humans, mice 
models have been used extensively to study ACC. Several genes associated to human ACC 
syndromes are also found with a corresponding callosal phenotype in the mouse [listed in 
Edwards et al. (2014)], for example MKS3 in Meckel-Gruber syndrome patients with the 
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rat Wpk mutation (Smith et al., 2006b), and HESX1/Hesx1 mutation in septo-optic 
dysplasia (Dattani et al., 1998). 
In hydrocephalic Gldc mutants, the relatively normal staining of the hippocampal and 
anterior commissures suggest that the obliteration of the corpus callosum in those brains 
were likely secondary to the grossly enlarged ventricles, and not due to a real agenesis of 
the corpus callosum resulting from a defect in the interhemispheric crossing of 
commissural neurons. In addition, all E18.5 mutants with enlarged ventricles did not show 
any overt corpus callosum agenesis. 
The ventricular dilation seen in some Gldc mutants at late-foetal stages is suggestive of a 
chronic pathology underlying their hydrocephalus, and that it begun at developmental 
stages. The various causes of hydrocephalus in other mice models, as well as hypotheses of 
the likely cause in this particular model, are discussed in following sections. 
 
5.3.2. Pathogenesis of hydrocephalus 
In more recent years, some findings have challenged the classical separation of obstructive 
and non-obstructive causes of hydrocephalus. Finding obstructions that block the flow of 
CSF is by no means the end to explaining the pathology of hydrocephalus, as it simply begs 
the question of how the obstruction arose in the first place. It has also been suggested that 
the obstructions are not the cause of CSF accumulation in the ventricles, but rather a 
consequence of the dilating ventricles pushing on, and causing further narrowing of, the 
narrowest regions in the CSF pathway (i.e. the aqueduct), which then causes the dilation to 
worsen. For example, aqueduct stenosis has been argued as being a consequence (rather 
than cause) of hydrocephalus (Williams, 1973), though several studies have observed this 
defect preceding the onset of ventricular enlargement (Takeuchi and Takeuchi, 1986, 
Somera and Jones, 2004). 
Several hypotheses have been formulated to address this issue, for example disruption in 
the ependymal monolayer lining the ventricles. Loss of integrity of ependymal cells, 
especially in the aqueduct regions, is frequently reported in hydrocephalus mouse models. 
It has been reported to occur through a variety of pathways such as cell polarity, cell-cell 
junctional complex assembly, proliferation, differentiation, and maturation of ependymal 
cells, and proliferation and migration of other NPCs, as summarized in Table 29 and by 
Huh et al. (2009). Ependymal disruptions have also been shown in human foetuses with 
communicating hydrocephalus in which the aqueduct is not obstructed (Dominguez-Pinos 
et al., 2005). Perturbations in the ependymal cell lineage leading to ependymal denudation 
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have been shown to occur before the onset of hydrocephalus in mice models, suggesting 
that the loss of ependymal integrity is not secondary to the stretching of walls of the 
dilating ventricles but rather is contributing to the cause.  
Alterations in the subcommissural organ (SCO) are another frequently reported 
histological finding in hydrocephalus, often accompanying ependymal disruptions and 
aqueduct stenosis. The SCO is a secretory gland consisting of hypendymal cells underlying 
a layer of ependymal cells, located at the roof of the narrowest region of the aqueduct and 
and posterior to the pineal gland. The SCO is thought to play a role in CSF circulation and 
absorption, but its involvement in the pathology of hydrocephalus is unclear (Perez-
Figares et al., 2001). Underdeveloped and displaced SCO caused by X-irradiation of 
pregnant rats was hypothesized to cause the aqueduct stenosis and subsequent 
hydrocephalus in their litters, due to reduced amount of SCO secretion to keep the 
aqueduct open (Takeuchi and Takeuchi, 1986). Hypotrophic SCO with normal ependymal 
lining of the aqueduct has been reported in hydrocephalic human foetuses (Castaneyra-
Perdomo et al., 1994). A comprehensive review of hydrocephalic mice mutants with an 
SCO phenotype is provided by Huh et al. (2009). 
There is also evidence of suboptimal proliferation of neural progenitor cells (NPCs) in 
hydrocephalus mouse models (Table 29). This finding is often present in combination 
with other defects such as aqueduct stenosis in the Wrp-NestinCre mouse (Kim et al., 2012), 
disrupted ependymal lining in the hyh mouse (Jimenez et al., 2009), and defective cilia in 
the myc-Klf4 mouse (Qin et al., 2011). It has also been reported independent of other 
hydrocephalus-associated phenotypes, e.g. in Pak4-NestinCre (Tian et al., 2011) and Bbs1-
PdgfrαCre (Carter et al., 2012) mice. While a causative relationship has not been 
established, it is clear that suboptimal proliferation is involved in the pathogenicity of 
some of these cases of hydrocephalus, especially in mice with communicating 
hydrocephalus where no obstruction can be found.  
Owen-Lynch et al. (2003) demonstrated that the CSF of hydrocephalic Texas (H-Tx) rat 
brains had an inhibitory effect on proliferation of NPCs in vitro, which suggests that the 
contents of the CSF itself plays a role in brain development. Interestingly, the same team 
observed low levels of 10-formyl-THF in the CSF of H-Tx rat brains, and that 
supplementation with THF and 5-formyl-THF was able to decrease the incidence of 
hydrocephalus in these rats but supplementation with folic acid increased the incidence 
(Cains et al., 2009). This finding may be of relevance to the Gldc mutant mouse which is 
also demonstrated to have an altered folate profile. 
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Gene Protein description Obstruction Phenotype Reference 
Aspp2 Apoptosis-stimulating protein of p53 N.R. NPC proliferation defect (Sottocornola et al., 2010) 
Bbs1 Bardet-Biedl Syndrome protein N.R. NPC proliferation defect, abnormal ependymal cilia (Davis et al., 2007) 
Bbs1-PdgfrαCre Bardet-Biedl Syndrome protein N.F. NPC proliferation defect, abnormal ependymal cilia (Carter et al., 2012) 
Cdc42-NestinCre GTP-binding protein Aqueduct Tight junction assembly defect, ependymal 
denudation 
(Peng et al., 2013) 
Dlg5 Epithelial cell structure maintenance  Aqueduct Tight junction assembly defect, no aqueduct lumen (Nechiporuk et al., 2007) 
Dnaic1 Dynein, axonemal, intermediate chain Aqueduct No ependymal cilia (Ostrowski et al., 2010) 
FoxJ1 Forkhead transcription factor N.R. Radial glia differentiation defect, abnormal 
ependymal cilia 
(Jacquet et al., 2009) 
Lgl1 Maintenance of cell polarity N.R. NPC proliferation and differentiation defect, 
ependymal over-proliferation 
(Klezovitch et al., 2004) 
Lhx9 Pineal homeobox N.R. Pineal gland hypoplasia (Yamazaki et al., 2014) 
Msi1 RNA-binding Aqueduct NPC proliferation defect, abnormal SCO, 
ependymal denudation 
(Sakakibara et al., 2002) 
Myo9a Myosin class IX Aqueduct Tight junction assembly defect, ependymal 
maturation defect 
(Abouhamed et al., 2009) 
N-WASP-
NestinCre 
Actin nucleation regulator Aqueduct Tight junction assembly defect, ependymal 
maturation defect 
(Jain et al., 2014) 
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Gene Protein description Obstruction Phenotype Reference 
Pak4-NestinCre p21-activated kinase N.R. NPC proliferation defect, adherens junction 
assembly defect 
(Tian et al., 2011) 
Rnd3 Rho family GTPase Aqueduct Notch signalling defect, ependymal over-
proliferation 
(Lin et al., 2013) 
Wrp-NestinCre WAVE-associated Rac GTPase-
activating protein 
Aqueduct NPC migration defect, astrogliosis (Kim et al., 2012) 
Table 29. Hydrocephalic mouse mutants with NPC proliferation and/or ependymal defects.  
Mutants listed in a review of SCO agenesis by Huh et al. (2009) were not included in this table.  
Abbreviations: neural progenitor cell (NPC), none reported (N.R.), none found (N.F.).  
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Oreskovic and Klarica (2011) proposed a new model for CSF hydrodynamics in which 
pathologies that change the osmolality of the CSF, interstitial fluid, and/or blood may 
disrupt the osmotic and hydrostatic pressure between the three fluids, thus resulting in 
net movement of water across the brain parenchyma into the ventricles. This implies that 
any pathology that causes a sustained elevation in solutes, thus increasing the osmolality 
of the CSF, may be the cause of increased movement of water into the ventricles.  
 
5.3.3. Hydrocephalus in Gldc-deficient mice 
As demonstrated in the results, aqueduct stenosis is present in GldcGT1 mutant mice with 
dilated ventricles. In addition to the narrowing of the aqueduct, the SCO and pineal gland 
appear to be absent. This model is thus a non-communicating hydrocephalus model, but 
the question remains as to what caused the aqueduct to narrow, and whether this is 
causative of the ventricular enlargement.  
There appears to be no obvious denudation of the ependymal layer infiltrating the 
aqueduct lumen, and the fact that the ventricles are obviously dilated by E18.5 would 
suggest that lack of ependymal cilia, which only reaches maturity at a post-natal age, is not 
the cause. The defect in formation of the SCO is a striking clue for explaining the narrowing 
of the aqueduct. As Gldc mRNA and protein is expressed in radial glial cells (Ichinohe et al., 
2004) from which ependymal cells are derived (Spassky et al., 2005), this would suggest 
that suboptimal proliferation of radial glia could lead to a defect in formation of glia-
derived structures such as the SCO. This is further supported by the finding that GldcGT1/GT1 
embryos showed a defect in proliferation at neurulation stages (Chapter 4).  
The presence of SCO-spondin, the first detectable glycoprotein to be secreted by the SCO, 
can be detected from E14.5 (Goncalves-Mendes et al., 2003), although the morphological 
development of the SCO organ itself would have begun earlier, shortly after neural tube 
closure, at the diencephalon-mesencephalic boundary of an E11.5 mouse embryo. The 
formation of the pineal primordium begins at E14.5 in the mouse and by E16.5, the pineal 
gland and the region of the mesencephalic vesicle that is to be the future aqueduct as well 
as the SCO structure is clearly recognisable (Kaufman, 1992), while pineal genes such as 
Crx and NeuroD1 can be detected from E17.5 in rat embryos (Munoz et al., 2007).  
The absence of the SCO could be causing the narrowing of the aqueduct (in regions where 
the SCO should be present), either due to lack of secretory signals helping to regulate 
aqueduct narrowing, or simply lack of the SCO structure itself physically keeping the 
aqueduct open. In addition, work carried out by another member of the lab, Maria-Chiara 
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Autuori, revealed that ventricle size in GldcGT1/+;GldcGT2/+ compound heterozygotes at E16.5 
were still comparable to wild-types. The lack of secretory signals from the SCO, which is 
needed for pineal gland development, could also explain the absence of the pineal gland in 
hydrocephalic mutants.  
If this SCO agenesis hypothesis is correct, defects in formation of the SCO and pineal gland 
should be present prior to the formation of the aqueduct, and may be predictive of a 
hydrocephalus phenotype later. E14.5-16.5 are suitable stages to observe for defects in the 
development of the aqueduct, and if they are present prior to onset of ventricular 
enlargement. However, if initial defects in SCO development are what precipitate the 
aqueduct stenosis, abnormalities (such as defective proliferation or differentiation of 
neural precursors of the radial glia lineage) may already be present from as early as E11.5. 
Such findings have precedence in the hyh mutant mouse and the H-Tx rat models. In the 
hyh mutant on a C57BL/10J background, ependymal denudations and delayed SCO-
spondin expression precedes the onset of hydrocephalus, but does not result in prenatal 
aqueduct stenosis (Jimenez et al., 2001), while in the H-Tx model, reduced SCO-spondin 
expression precedes aqueduct stenosis which precedes hydrocephalus (Somera and Jones, 
2004).  
The osmotic pressure hypothesis is another attractive mechanism for explaining the 
hydrocephalus in Gldc mutant mice, in which highly elevated levels of glycine in body 
fluids are present. However, if osmotic pressure alone is responsible for causing the 
hydrocephalus, the aqueduct and fourth ventricle would presumably be dilated as well. In 
addition to that, glycine would presumably continue to build up in the CSF of these mutant 
mice as they age, which would suggest that all mutants, sooner or later, would show 
ventricular dilation and develop hydrocephalus, and this does not appear to be the case. 
However, this possibility has not been ruled out and it is also possible that it could 
contribute to worsening of the ventricular dilation. 
In NKH patients with hydrocephalus that is severe and requires shunting, the presence of 
a posterior fossa cyst and a DW-like malformation is often present as well. Hydrocephalus 
(as well as aqueduct stenosis) is a frequently reported complication of patients with DW 
malformation (Spennato et al., 2011). Mutations in ZIC1 and ZIC4 are implicated in DW 
malformation, which has a characteristic hypoplasia of the cerebellar vermis (Grinberg et 
al., 2004). Cerebellar hypoplasia is often attributed to a defect in the rapid growth of the 
cerebellum that is driven by proliferation of granule cell progenitors in the external 
granular layer (EGL), mostly coordinated by the Purkinje neuron layer (Basson and 
Wingate, 2013). The Zic1;Zic4 double knockout mouse presents with brain malformations 
that resemble the DW phenotype and have reduced Shh-derived proliferation of the EGL 
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(Blank et al., 2011). However, hydrocephalus has not been reported in this mouse model, 
unlike with DW patients. 
The mildly compressed cerebellum in hydrocephalic Gldc mutant brains could arguably be 
a consequence of the grossly dilated lateral ventricles pushing out at, and distorting, 
surrounding structures. However, it is unlikely to lead to the observed loss of one anterior 
folium in the vermis. As Gldc mRNA is reportedly present in the Purkinje layer and EGL of 
adult mice (Ichinohe et al., 2004), a reduction or loss of Gldc expression in the mutant may 
lead to subtle proliferation defects in progenitor populations (not unlike the Zic1;Zic4 
model) during cerebellar development.  
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6. General Discussion 
 
 
The physiological significance of the glycine cleavage system (GCS) in breaking down 
glycine has been recognised since the 1960s, as a consequence of efforts to determine the 
enzyme defect responsible for non-ketotic hyperglycinemia (NKH) (Gerritsen et al., 1965, 
Ando et al., 1968, Tada et al., 1969). The discovery of its importance in folate one-carbon 
metabolism (FOCM) came about relatively recently owing to improved appreciation of 
mitochondrial FOCM reactions (Pike et al., 2010, Tibbetts and Appling, 2010), along with 
their association with neural tube defects (NTDs) (Narisawa et al., 2012). 
The GldcGT1 and GldcGT2 mouse models presented in this thesis will allow in-depth 
exploration of the role of the GCS in embryonic brain development in vivo and the 
pathogenesis of two distinct disease phenotypes: the rare metabolic disorder, NKH, and 
the common congenital malformation, NTD. The incidence of hydrocephalus in the GldcGT1 
model also provides an opportunity to study this common but aetiologically complex 
neonatal condition. The findings in this thesis are summarised in this chapter and 
hypotheses regarding other unexplored disease mechanisms are also discussed. 
 
6.1. Phenotypic spectrum of Gldc deficiency  
 
6.1.1. Effect of background strain on disease severity in Gldc-deficient mice 
During the generation of Gldc-deficient mice, a background strain effect was noticed. The 
GldcGT1 allele caused high resorption rates in homozygous mutants on the 129/Sv 
background, but transferring them to a C57BL/6 background strain by inter-crossing and 
repeated back-crossing was able to drastically improve survival of the mutants. This 
indicates the presence of genetic modifiers in either backgrounds that can alter disease 
severity, and which may also contribute to the partial penetrance of the NTD phenotype. 
Genetic modifiers have previously been recognised to significantly alter phenotype 
incidence in other NTD mouse models including Splotch2H (Fleming and Copp, 2000) and 
curly tail (De Castro et al., 2012). Alternatively, it is possible that the 129/Sv background is 
more sensitive to defects in folate metabolism at earlier stages of development, as severe 
insufficiency of folate uptake is known to result in early embryonic lethality. 
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The incidence of hydrocephalus and late-foetal ventricular dilation in GldcGT1 mutants was 
found to be higher than the prevalence of hydrocephalus reported in NKH patients. 
Similarly, hydrocephalus in primary ciliary dyskinesia (PCD) is much more common in 
PCD mouse models than human patients. In these models, strain differences were also 
found to have an impact on incidence of hydrocephalus. PCD models on a C57BL/6 
background developed severe, chronic hydrocephalus with gliosis and ependymal 
disruptions and die within a few weeks, while those on a 129 or mixed background do not 
develop any gross hydrocephalus (Lee, 2013). Thus, it is possible that a genetic modifier in 
the C57BL/6 background also exacerbates the hydrocephalus in Gldc mice.  
The effect of background strains on NTDs and hydrocephalus caused by the Gldc mutation 
can be tested by backcrossing GldcGT1 or GldcGT2 into other background strains. 
 
6.1.2. Partial penetrance of NTDs in Gldc mutant mice and comparison with the 
spectrum of NKH severity 
In Chapter 3, attempts were made to explain the partial penetrance of NTDs in Gldc 
mutant embryos. There is precedent from NKH case reports on levels of mRNA and/or GCS 
activity showing an effect on severity of the disease manifestation, made obvious by 
comparing between neonatal/classical forms and the late-onset/atypical forms of NKH.  
Kure et al. (1997) reported levels of GCS activity that were less than 1% in all 26 neonatal 
NKH patients and 2–5% in all 4 late-onset cases. They subsequently reported 2 patients 
presenting with a typical neonatal onset but who later showed dramatic improvements 
(i.e. transient NKH) and had compound heterozygous GLDC mutations conferring 5.5–
7.5% residual GCS activities (Kure et al., 2004). Flusser et al. (2005) made a similar 
observation in analysis of GLDC mRNA levels from lymphoblastic cell lines of NKH 
patients: atypical, mild cases showed 4-6% residual levels and had much better clinical 
outcomes than is reported of the classical form of the disease. The highest level of residual 
GCS activity found in an NKH diagnosis (32%) to date was reported by Korman et al. 
(2004), who described 3 patients with novel, homozygous GLDC mutations and persistent 
biochemical features of NKH, but had transient neonatal or no symptoms followed by a 
normal outcome. 
Several attempts have been made to explain the spectrum of severity in NKH, particularly 
in the mild forms caused by AMT mutations. Okamura-Ikeda et al. (2010) elucidated the 
crystal structure of AMT and found that the mutations in NKH patients that altered the 
THF binding site of AMT conferred severe reduction (80%) in enzyme activity. They 
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suggested grouping AMT mutations to three different sites on the AMT enzyme (folate 
binding site, catalytic site, and N-terminal domain) that affect its overall activity to varying 
degrees, thus resulting in varying disease severity. In addition, mutant AMT protein from 
mild, undiagnosed NKH patients (who were originally screened in search of inherited 
autism genes) was found to be poorly soluble compared with wild-type protein, 
suggesting that a temperature-sensitive stability defect rather than a complete catalytic 
failure may explain their mild presentation (Yu et al., 2013). 
This explanation is plausible for the variable severity of NKH caused by different 
mutations in human patients but cannot account for the partial penetrance of NTDs 
observed in the models which all carry the same mutation. However, it does provide an 
example of how slight changes in GCS enzymatic activity, particularly in the lower ranges, 
can have drastically different outcomes in disease severity. 
 
6.2. Abnormal FOCM in Gldc deficiency  
 
6.2.1. Potential mechanisms for abnormal FOCM to result in NTDs 
Sub-optimal FOCM can be viewed as either a problem of impaired folate status due to 
insufficient dietary supply or impaired absorption, or impaired utilisation of folate in the 
cells due to a genetic abnormality in the metabolic cycle itself (Beaudin and Stover, 2009). 
The exact mechanism or pathways by which a defect in FOCM leads to failure of neural 
tube closure, however, is not clear. 
Very severe folate deficiency is incompatible with life and subtle impairments in FOCM can 
result in significant changes in folate and homocysteine levels, but most NTD-affected 
pregnancies do not show maternal folate-deficient status. It is generally assumed that 
increased folate intake (e.g. by folic acid supplementation) helps to overcome a dietary 
insufficiency or a problem in folate metabolism. Studies in the Cited2 mouse have shown 
that folic acid supplementation can rescue the NTDs of a genetic model with no evidence 
of an initial FOCM impairment (Barbera et al., 2002), suggesting that folic acid can also 
produce a protective effect where the primary defect is not FOCM-related.  
The ways in which impaired FOCM can potentially affect neural tube closure include 
decreased de novo purine and/or pyrimidine synthesis leading to decreased proliferation 
or increased uracil misincorporation, and disruptions in the methylation cycle leading to 
global hypomethylation and homocysteine toxicity (Figure 50). The challenge lies in 
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determining causation, as more than one of these defects may be present at once and may 
simply indicate a disturbance in folate metabolism. 
 
 
Figure 50. Schematic representation of possible mechanisms through which 
impaired FOCM may lead to NTDs (description in text). 
 
6.2.1.1. Effect of FOCM on proliferation 
Folate deficiency is commonly associated with conditions such as megaloblastic anaemia 
and immunosuppression caused by low blood cell count. Arrest at mitotic S-phase 
followed by apoptosis of the blood cells was often observed, which were reversible by folic 
acid or nucleoside treatment (Koury et al., 2000, Courtemanche et al., 2004). This suggests 
that folate deficiency can indeed result in a folic acid-responsive defect in cell 
proliferation. 
During neurulation, there is a high demand for rapid cellular proliferation for the neural 
tube to expand, elongate and elevate. NTD mouse models of genes involved in cell cycle, 
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proliferation, differentiation, and apoptosis (see Chapter 1) suggest that imbalance in 
proliferation and apoptosis has a role in NTD pathology, especially in the cranial neural 
tube (Copp, 2005).  
Treatment with nucleotides (thymidine in combination with adenine or GMP) of the folic 
acid-resistant curly tail mouse was able to significantly rescue spina bifida by correcting 
the hindgut proliferation defect in this model (Leung et al., 2013). In several FOCM mouse 
models showing embryonic lethality such as Mthfd1 (Christensen et al., 2005, MacFarlane 
et al., 2009), Mthfd1S (Christensen et al., 2013), and Mthfd2 (Patel et al., 2003), 
observations from in vitro studies of fibroblasts generated from all their null stem cells 
were consistent with a defect in purine synthesis. Insufficient purine synthesis was thus 
hypothesised to be the cause of their embryonic lethality. The embryonic lethality in 
Mthfs-nulls was also suspected to result from defective purine synthesis, as MTHFS was 
shown to associate with the purinosome complex (Field et al., 2011).  
 
6.2.1.2. Increased genome instability 
Another way in which reduced thymidylate synthesis may affect neural tube closure is 
increased misincorporation of uracil into DNA during cell replication, which increases the 
chances of DNA strand breaks and lead to increased genome instability. Folate deficiency 
resulting in decreased thymidylate pools and increased uracil misincorporation is a 
common finding in cancer (Blount et al., 1997, Goulian et al., 1980).  
Direct experimental evidence linking FOCM defects, increased uracil misincorporation and 
NTDs is so far lacking. However, evidence of genomic instability such as telomeric loss, 
centrosome amplification, and chromosomal abnormalities has been reported in NTD mice 
models. Mice deficient for telomerase RNA component (TERC) showed significant 
telomere loss and chromosomal instability (Herrera et al., 1999). They exhibited NTDs 
that increased in incidence with every generation, with increased neuroepithelial 
apoptosis, and hematopoietic defects. However, this finding did not extend to TERC 
variants and human NTDs (Benz et al., 2004). Mouse embryonic fibroblasts generated 
from Gadd45a-/- and Trp53-/--null embryos (both of which have low incidence of 
exencephaly) displayed chromosomal aberrations, aneuploidy, and abnormal 
amplification of centrosomes (Hollander et al., 1999). Strikingly, when the Gadd45a 
mutant was crossed to the Brca1 mutant, all Brca1Δ11/Δ11;Gadd45a-/- double homozygous 
mutants exhibited exencephaly with significantly increased apoptosis in vivo and 
decreased proliferation in vitro, and centrosome amplification (Wang et al., 2004). 
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6.2.1.3. Abnormal FOCM and hypomethylation 
The methylation cycle is intimately linked to the one-carbon cycle, and folate deficiency is 
commonly reported with hypomethylation, alongside uracil misincorporation, in cancers 
(Ghoshal et al., 2006, Wang et al., 2014b, McGlynn et al., 2013, James et al., 2003). 
Suppression of methylation processes can have consequences for epigenetic regulation at 
a local or genome-wide scale. Several lines of evidence point towards defective 
methylation or other alterations in the epigenome resulting in NTDs (Greene et al., 2011, 
Blom, 2009). 
Neural tube closure has been shown to be sensitive to perturbations in the methylation 
cycle, as treatment of mouse embryos in culture with an inhibitor of SAM production was 
able to induce exencephaly without causing generalised developmental retardation 
(Dunlevy et al., 2006). Inactivation of DNA methyltransferases Dnmt3a and Dnmt3b 
completely prevented de novo methylation in ES cells. Dnmt3a-/- null mice were normal at 
birth but died by 4 weeks, while Dnmt3b-/- null embryos exhibited NTDs and were 
embryonically lethal. Dnmt3a-/-;Dnmt3b-/- double homozygotes showed significant loss of 
methylation, were severely developmentally delayed and died before E11.5 (Okano et al., 
1999). Mouse models with perturbation in other epigenetic mechanisms that also 
exhibited NTDs include hypomorphs or loss of acetyltransferase activity of the histone 
acetylation gene, Gcn5 (Bu et al., 2007, Lin et al., 2008), mutants of chromatin remodelling 
proteins such as BRG1 and Brd2 (Bultman et al., 2000, Gyuris et al., 2009), and mutants for 
histone demethylase encoding-gene, Fbxl10 (Fukuda et al., 2011). 
In human NTD cases, Wang et al. (2010) showed that methylation of long interspersed 
nucleotide element-1 (LINE-1), which may be indicative of global DNA methylation, was 
significantly decreased in DNA from NTD-aborted foetuses. They also showed that folate 
deficiency was able to induce LINE-1 hypomethylation in mouse ES cells (Chang et al., 
2013). However, late gestation supplementation with folic acid (beyond 12 weeks) was 
found to be associated with reduced methylation of LINE-1 elements (Haggarty et al., 
2013). 
 
6.2.1.4. Homocysteine toxicity 
A common consequence of perturbing FOCM and methylation is a decrease in 
homocysteine remethylation, resulting in a build-up of homocysteine to toxic levels. For 
example, both the MTHFR 677C>T polymorphism in humans and Mthfr mutation in mice 
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resulted in hyperhomocysteinemia (Jacques et al., 1996, Frosst et al., 1995, Chen et al., 
2001). 
The pathology of homocysteine toxicity in cardiovascular diseases is commonly attributed 
to its activation of the coagulation system or by inducing oxidative stress, causing damage 
to endothelial tissue (Glushchenko and Jacobsen, 2007, Li et al., 2006). Homocysteine 
toxicity has also been hypothesised to act by inducing apoptosis (Kruman et al., 2000) and 
by over-activating NMDARs resulting in excitotoxicity (as it is an agonist of the glutamate 
binding site) (Lipton et al., 1997, Ho et al., 2002). Hyperhomocysteinemia has been shown 
to result in cytoplasmic swelling and mitochondrial degeneration in the cerebral 
vasculature of folate-deficient rats (Kim et al., 2002). However, there is not yet any direct 
evidence of homocysteine toxicity resulting in NTDs. Treatment of mouse and rat embryos 
in culture with homocysteine resulted in generalised toxicity but did not induce NTDs, 
suggesting that increased levels of homocysteine in NTD pregnancies may serve as a 
marker of perturbed FOCM but is not causative of the NTD (Greene et al., 2003, Vanaerts et 
al., 1994). 
 
6.2.2. Proposed mechanism underlying NTDs in Gldc-deficient mutant embryos 
Taking into consideration the various possible mechanisms by which abnormal FOCM 
could result in NTDs and the experimental findings in this thesis, the most likely 
mechanism for Gldc deficiency to result in NTDs is summarised in Figure 51. Impaired 
glycine cleavage due to Gldc deficiency results in decreased production of mitochondrial-
derived 1C units. This causes a decrease in 1C units entering cytosolic FOCM reactions and 
thus suppresses purine and thymidylate synthesis. Consequently, there is a decrease in 
cellular proliferation in tissues which express Gldc, i.e. the neuroepithelium, which results 
in failure of neural tube closure.  
Outstanding questions include whether decreased nucleotide synthesis alone is sufficient 
to cause the phenotype, if uracil misincorporation is increased as a result of Gldc 
deficiency, whether apoptosis is abnormal in the neural tube of Gldc-deficient mice, and 
how a decrease in proliferation of neuroepithelial cells lead to failure of neural tube 
closure. 
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Figure 51. Proposed mechanism for Gldc deficiency to result in NTDs. 
 
6.2.3. Does a deficit of one-carbon units contribute to NKH-related phenotypes?  
The pathogenesis of NKH is mostly attributed to excess glycine as a result of impaired GCS 
activity. This thesis presents evidence for foetal malformation (i.e. NTDs) that can be 
caused by GCS-derived abnormalities in FOCM. It has been hypothesised that some of the 
brain malformations in NKH may be due to abnormal FOCM rather than an effect of excess 
glycine, as GCS components were found to be highly expressed in developing 
neuroepithelium and post-natal neural progenitor niches such as the dentate gyrus 
(Ichinohe et al., 2004). In fact, another FOCM enzyme, Shmt1, has also been implicated in 
neurogenesis in the mouse. Shmt1 was found to be present in the dentate gyrus and 
heterozygosity for a null mutation in Shmt1 results in impaired dTMP synthesis and affects 
hippocampal neurogenesis (Abarinov et al., 2013). 
Abnormalities in FOCM due to GCS deficiency have not been directly investigated in the 
context of NKH, possibly due to the lack of a suitable GCS mouse model previously. 
Treatment of NKH patients with 1C donors showed little success (Van Hove et al., 1998), 
which suggests that either 1C insufficiency is not a major contribution to the pathology of 
NKH unlike in the NTDs in Gldc-deficient mice, or that intervention that far into the disease 
progression was too late. It is also possible that this treatment route was not tested 
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sufficiently, as very few patients were treated, there was no matched control group, and 
the selection of dosage was not based on measured biochemical outcomes. If abnormal 
FOCM can account for some of the foetal brain malformations, an ideal strategy would be 
to correct FOCM at appropriate developmental stages before the malformations occur. 
This would be of particular relevance to the hydrocephalus phenotype in GldcGT1 mutants, 
which occurs in NKH and which is shown in this thesis to stem from malformations 
present at late-foetal stages (see Figure 52 for diagrammatic summary of the possible 
mechanisms that can give rise to hydrocephalus in Gldc-deficient mice). 
A straightforward way of testing this hypothesis is to supplement GldcGT1 mutants with 
formate beyond neurulation stages and investigate whether there are changes in post-
natal occurrence of hydrocephalus. However, formate was shown to produce toxicity upon 
prolonged supplementation (Chapter 4). The 7,500 mg/kg/day dose used in Chapter 4 
was based on previously published results in Mthfd1L null embryos (Momb et al., 2013). 
The Mthfd1L nulls displayed a severe phenotype of 100% NTD penetrance and embryonic 
lethality that was partially rescued by the 7,500 mg/kg/day dose of formate. A 5,000 
mg/kg/day dose showed a lesser degree of rescue, suggesting a dose-dependent effect.  
As the phenotype and NTD incidence of GldcGT1/GT1 homozygous embryos are not as severe 
as Mthfd1L nulls and could be completely rescued by formate, it might be possible to 
determine a lower dose of formate which can confer the same level of rescue but does not 
result in toxicity. Alternatively, formate treatment could be stopped at a stage where the 
subcommissural organ (SCO) is visible and the aqueduct appreciably narrows 
(approximately E16.5). Foetuses could then be examined at E18.5 for signs of ventricular 
enlargement. As formate has been shown to be present in the milk of lactating sheep and 
in newborn lamb plasma (Washburn et al., 2015), it would be possible to stop formate 
supplementation at E15.5-E16.5 (i.e. to allow for embryonic development of SCO, pineal 
gland, and aqueduct) and resume treatment after birth. This might prevent excessive 
accumulation of formate while formate remains in post-natal GldcGT1 mutant plasma long 
enough to have an effect on incidence of hydrocephalus. 
Hydrocephalus in NKH frequently present with a posterior fossa cyst and a cerebellar 
defect resembling Dandy-Walker (DW) malformation (Van Hove et al., 2000). Williams 
(1973) suggested that aqueduct stenosis resulting from (rather than being causative of) 
enlargement of the lateral ventricles can lead to a flattening of the tentorium, which may 
displace the cerebellum downwards, a hypothesis that could link aqueduct stenosis to a 
cerebellar displacement phenotype. The fourth ventricle appears normal in Gldc mutant 
mice and the DW malformation involves an upward displacement of the tentorium and 
severe hypoplasia of the vermis. Therefore, it is possible that different morphogenetic 
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processes are involved in the development of hydrocephalus in NKH patients and in the 
Gldc model, in which no severe abnormalities of the cerebellum is observed. It would be 
interesting to determine whether aqueduct stenosis is present in hydrocephalic NKH 
patients.  
In DW malformation where hydrocephalus is also frequently reported, it has been 
suggested that the superior vermis may herniate into the quadrigeminal cistern, resulting 
in compression and thus stenosis of the aqueduct (Spennato et al., 2011, Cinalli et al., 
2011). This gives a potential mechanism for a cerebellar defect to result in aqueduct 
stenosis. However in the Gldc mouse model, no severe, gross deformities in the cerebellum 
were observed. While a defect in cerebellar foliation may be present, it does not seem 
likely that this could produce the amount of compression that would result in aqueduct 
stenosis, as overall cerebellar size did not appear grossly abnormal. 
 
 
Figure 52. Summary of possible mechanisms that could lead to hydrocephalus in 
Gldc-deficient mice. 
The two main metabolic disturbances caused by Gldc deficiency are reduced supply of 
mitochondrial 1C units resulting in abnormal FOCM, and elevation of glycine (blue). A 
number of possible mechanisms may follow (magenta), leading to the late-foetal 
malformations and post-natal occurrence of hydrocephalus (grey).   
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6.3. Glycine toxicity in Gldc deficiency 
 
While NTDs in Gldc-deficient mice are most likely due to 1C insufficiency, it should be 
noted that tissue glycine levels at E11.5 are significantly elevated, and remain elevated in 
adult plasma and urine. The potential toxic effects of glycine in this model have not been 
extensively assessed. There is a possibility that glycine is involved in late-foetal and post-
natal phenotypes due to the persistent exposure of Gldc-deficient tissue to elevated 
glycine. Korman et al. (2006) found that cord blood plasma glycine levels in a patient with 
atypical NKH were within the reference range but CSF glycine was very high at birth, 
which suggested that the placental circulation was able to prevent build-up of glycine in 
the foetal circulation, but the developing foetal brain would have been exposed to high 
levels of glycine through development. Thus, Gldc-deficient mice could mimic the 
conditions present in NKH during prenatal stages.  
The effects of high glycine have been reported on several occasions and speculated to 
cause much of the pathology of NKH. The two main hypotheses for mechanism of glycine 
toxicity is over-activation of NMDARs and mitochondrial toxicity, both of which have been 
introduced in Chapter 5. This section draws from further studies not performed in the 
context of NKH, and briefly discusses how Gldc-deficient mice may be used to probe these 
possibilities. 
 
6.3.1. Over-activation of NMDARs in NKH-related phenotypes  
During central nervous system development, NMDAR activation (coupled with GlyR 
inhibition) in neuronal and glial precursor populations contributes to neuronal migration, 
cell survival and cell fate and may influence morphogenetic events (Nguyen et al., 2001). 
However, the effect of high glycine on NMDARs leading to neuronal survival or death are 
complicated by the downstream effects of NMDAR signalling, which can be both survival 
and death promoting (also known as the “NMDAR paradox”). Synaptic NMDAR signalling 
can activate neuroprotective pathways by suppressing apoptosis and/or reducing 
peroxide levels (i.e. boosting antioxidant capabilities) and promoting neuronal survival, 
while extrasynaptic NMDAR signalling could, inversely, favour pro-apoptotic pathways. 
Synaptic NMDARs contain both the GluN2A and GluN2B subunits, while extrasynaptic 
NMDARs are GluN2A-enriched (Hardingham and Bading, 2010). 
NMDAR/GlyR signalling provides a second possible mechanism (other than FOCM) 
through which proliferation and/or apoptosis in the brain may be affected by the loss of 
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glycine cleavage. Staining for mitotic and apoptotic markers can be performed to assess 
the level of proliferation and apoptosis in, for example, the developing hippocampus or 
dentate gyrus region of Gldc-deficient late-foetal and/or post-natal brains. Assessment of 
the neural progenitor subtypes affected could be performed by staining with neuronal 
(e.g. NeuN) or glial (e.g. glial fibrillary acidic protein, GFAP) markers and correlating them 
with sites of Gldc expression. 
Just as the FOCM-driven hypothesis in the previous section can be tested by rescue 
experiments with sodium formate, so can the effects of glycine toxicity be tested by 
supplementation with sodium benzoate. As benzoate is commonly given to NKH patients 
for sequestering glycine, it would be interesting to attempt to correct the elevated glycine 
in Gldc-deficient mice and determine whether amelioration of any phenotypes occur (e.g. 
early post-natal survival and hydrocephalus rates). It is more likely that both abnormal 
FOCM and high glycine contribute to the phenotypes, thus a rescue experiment using both 
formate and benzoate could also be attempted. It would also be interesting to test whether 
sequestering glycine would have any effect on the NTD phenotype. It should be noted that 
the cellular abnormalities caused by GCS deficiency will not necessarily be entirely 
corrected, so enzyme replacement or gene therapy may be required. 
 
6.3.2. Possibility of mitochondrial dysfunction in Gldc deficiency  
The clinical presentation of NKH bears striking resemblance to that of mitochondrial 
disorders with an underlying metabolic defect. For example, autosomal recessive 
fumarase deficiency (Coughlin et al., 1998) and X-linked pyruvate dehydrogenase 
deficiency (Brown et al., 1994) are disorders affecting the tricarboxylic acid (TCA) cycle 
(and thus energy metabolism) with a clinical presentation that resembles NKH: severe 
neurological impairment, corpus callosum defects and white matter atrophy, ventricular 
dilation, DW malformation, hypotonia, lethargy, seizures, and feeding difficulties, but with 
the additional presence of lactic acidosis which does not occur in NKH.  
Mitochondrial dysfunctions are commonly reported in patients with organic acidurias, 
either as a primary effect due to a mutation in nuclear genes encoding components of the 
TCA cycle or oxidative phosphorylation (OXPHOS), or secondarily through inhibition of 
mitochondrial function by endogenous metabolites that accumulate in organic acidurias 
(Wajner and Goodman, 2011). This includes methylmalonic and proprionic acidemia, i.e. 
ketotic hyperglycinemia, in which there was a decrease in amount of OXPHOS complexes 
and ATP production, 50% reduction in mitochondrial DNA, and abnormal mitochondrial 
ultrastructures (Schwab et al., 2006).  
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Experiments performed in rat cerebral cortex homogenates suggest that high glycine can 
induce oxidative stress damage and result in mitochondrial energy dysfunction (Busanello 
et al., 2010, Leipnitz et al., 2009). Taken together, this suggests that accumulation of 
glycine to toxic levels could potentially lead to secondary mitochondrial dysfunction, 
which may contribute to the pathology of NKH. In addition, mitochondrial FOCM was 
recently found to be required for NADPH production which is important for reductive 
reactions and redox defence. Knockdown of both cytoplasmic MTHFD1 and mitochondrial 
MTHFD2 in HEK293T cells resulted in reduced redox defence, increased reactive oxygen 
species, and impaired resistance to oxidative stress. Thus, a loss of Gldc activity could 
disrupt mitochondrial FOCM and potentially alter redox balance (Fan et al., 2014). 
In future experiments, the possibility of a mitochondrial dysfunction in Gldc-deficient mice 
could be probed in a number of ways. Decreases or increases in mitochondrial number, 
abundance and activities of OXPHOS and/or TCA cycle enzymes as well as changes in 
mitochondrial distribution and morphology might indicate presence of mitochondrial 
dysfunction. Measurement of oxygen consumption rates and respiratory control ratio 
would provide good functional indication regardless of the specific mitochondrial 
component affected (Brand and Nicholls, 2011). In addition, altered levels of glutathione, 
lipid peroxidation, and reactive oxygen species (i.e. various measures of oxidative stress) 
as well as caspase activation and apoptosis may serve as signs of mitochondrial 
dysfunction (Sas et al., 2007).  
 
6.3.3. Alternative pathways for glycine catabolism  
When considering the potential toxic effects of glycine, it is worth briefly considering other 
pathways of glycine catabolism that do not involve the GCS and their contributions to 
regulating overall glycine levels in the body. As described in Chapter 4, glycine can be 
utilised in the synthesis of serine through SHMT. Glycine is also consumed in a reaction 
catalysed by the glycine N-methyltransferase enzyme which converts SAM to SAH and 
generates sarcosine (Ogawa et al., 1998). The primary role of this reaction appears to be 
for the regulation of SAM/SAH ratio, as the production of sarcosine does not appear to 
serve any other significant metabolic function (Luka et al., 2009). However, sarcosine can 
act as a potential 1C donor. 
In addition, other pathways for glycine catabolism have also been reported, such as 
through formation of glyoxylate and formate, conversion to pyruvate through serine, and 
the succinate-glycine cycle  (Nakada et al., 1955). Conversion to pyruvate as a pathway for 
glycine (and serine) catabolism did not occur at significant levels in rat liver (Nakada et al., 
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1955) or cancer cells (Fan et al., 2014). The succinate-glycine cycle was discovered to be 
involved in the synthesis of pyrrole rings and subsequently porphyrin in heme (Shemin et 
al., 1955), but does not appear to utilise significant amounts of glycine. Glycine is also used 
in synthesis of creatine (Brosnan et al., 2009) and the antioxidant glutathione (Wang et al., 
2014a, Aoyama et al., 2012), conjugation of bile (Maekawa et al., 2014), and conjugation of 
benzoic acid (Kristensen et al., 2009). However, the significance of these alternative 
pathways is not clear, and the GCS remains the most important pathway for glycine 
catabolism in vertebrates (Yoshida and Kikuchi, 1972, Yoshida and Kikuchi, 1973, Wang et 
al., 2013). 
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Appendix: GldcGT1 gene-trap sequence 
The GldcGT1 gene-trap construct was sequenced from 2 kb fragments that were amplified 
using Long-Range PCR (see Chapter 2, Section 2.1.4). The site of gene-trap insertion and 
all Frt, F3, loxP, and lox5171 sites were confirmed (see Chapter 3, Section 3.2.2.1) and 
annotated below: 
 
AGCACTTATGCTAACTAGATAATGTTAAACATTTGTGGAGCGCCTCCTGT
GGGCACTTTTGAAAAGTGCTTTTTGTGTATTATTTATTTAGTCCTCATTA
CAGTCTGTGAACGGAGTCCCTCTCTCTCCCCCCTCTGCCGTTTGTTTTAG
AGATAAGGGTCTCAATTGTGTTGCCCAGGCTGGTCATGTTCATGGACTCC
AATGCTTCTCTAATCTTCCCTTCCCAGATACCTGGGACTCTAGGCCCACAT
GACCATTGCACAGCTATTAACCCCTTTAAAAGAAAGAAACCGTGGTATAC
AGAGGCTCTTTAACTTGCCAGGGTCTTAGCCCGTGACCTTTGGATGGGAGC
AGAATGCAAACTCAGGCCATCTGACTCCATTGCCAACCCCCACTCCCCACC
CCCCAATGATGACATTGCTGTTTTCATGGTGTCCCAGGCAAAGCAGAGAA
CTCCTGTCCTGGCTCTTCTAAGGTGCACAAGCCAGTCATCCTTTTGTCTTG
TGCAAACTGCCCCTTTGGGAATGAGACACCACAGTGAGGCTAAGTGTGGA
GTTCTCAGGCCCACCAC//TGAAAGACCCCCGCTGACGGGTAGTCAATCAC
TCAGAGGAGACCCTCCCAAGGAACAGCGAGACCACAAGTCGGATGCAACT
GCAAGAGGGTTTATTGGATACACGGGTACCCGG 
(missing sequences) 
TACAGGTGGGGTCTTTCATTCCCCCCTTTTTCTGGAGACTAAATAAAATCT
TTTATTTTATCGATTCAAGCCACTATGCGCACAGCTGGTCGAGCCCGGGCC
CTCGAGAATTCGAAGTTCCTATTCCGAAGTTCCTATTCTCTAGAAAGT
ATAGGAACTTCAGCAGATCCTTATTTGTCATATTGTAAGTGCTTTCTCTA
ATCACTTTCTTTCATGGCAAGCAGGGTATGGATCTGCTGAAGTTCCTATT
CCGAAGTTCCTATTCTTCAAATAGTATAGGAACTTCGTTGCTAGAAGC
GGTTTTCGGGAGAATACGACTCACTATAGGGCGAATTGATAACTTCGTA
TAGCATACATTATACGAAGTTATCCAAGCTTCACCATCGACCCGAATTG
CCAAGCATCACCATCGACCCATAACTTCGTATAGTACACATTATACGAA
GTTATCGAATTCCTACGTACTAGATTCCATGTAAATTTGTAGCCAGCTTC
CTTCTGATTTTCAATGTTTCTTCCAAAGGTGCAGTCTCCAAAGAGATTAC
GAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACA
TTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAA
ACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTT
Gldc intron 2-3 
 
F2 primer 
 
 
 
 
 
 
 
 
// insertion site 
Vector sequence 
 
 
 
 
Frt 
 
F3 
 
loxP 
 
lox5171 
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CAAGGAAAAAGATACATATAAGCTATTTAAAAATGGAACTCTGATAATTA
AGCATCTGAAGACCGATGATCAGGATATCTACAAGGTATCAATATATGAT
ACAAAAGGAAAAAATGTGTTGG 
(missing sequences) 
ACATCTATCTCATCATTGGCATATGTGGAGGAGGCAGCCTCTTGATGGTC
TTTGTGGCACTGCTCGTTTTCTATATCACCAAAAGGAAAAAACAGAGGAG
TCGGAGAAATGATGAGGAGCTGGAGACAAGAGCCCACAGAGTAGCTACGG
ATCCCATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGG
AGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGAT
GCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAG
ACCGACCTGTCCGGTGCCCTGAATGAACTGCAGGACGAGGCAGCGCGGCTA
TCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGACGTTGT
CACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGG
ACCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTG
ATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACC
ACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGT
CTTGTCGATCAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGC
CGAACTGTTCGCCAGGCTCAAGGCGCGCATGCCCGACGGCGAGGATCTCGT
CGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCC
GCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATC
AGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAA
TGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAG
CGCATCGCCTTCTATCGCCTTCTTGACGAGTTCTTCTGAGGGGATCAATT
CTCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATC
TGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCC
CACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGT
AGGTGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGA
GGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGGGCTCTATGG
CTTCTGAGGCGGAAAGAACCAGCTGGGGCTCGATCCTCTAGAGTCGACCTC
GAGTACCACCACACTGGGATCCGATAACTTCGTATAATGTATGCTATAC
GAAGTTATCCAAGCATCACCATCGACCCTCTAGTCCAGATCTCACCATCG
ACCCATAACTTCGTATAATGTGTACTATACGAAGTTATTCTAGACTCT
TCCGCTTCCTCGCTCCACCGCGGCTTCGATACCGTCACGAGAAGTTCCTAT
ACTTTCTAGAGAATAGGAACTTCGGAATAGGAACTTCGTTAACGAAGT
TCCTATACTATTTGAAGAATAGGAACTTCGGAATAGGAACTTCAGCAA
CGGATCCGGCCGGCGCCTAGAGAAGGAGTGAGGGCTGGATAAAGGGAGGA
TCGAGGCGGGGTCGAACGAGGAGGTTCAAGGGGGAGAGACGGGGCGGATG
 
 
 
 
 
 
 
Neo sequence 
 
 
 
F3 primer 
 
 
 
 
 
 
 
 
 
 
R2 primer 
 
 
LR-F1 
 
 
 
loxP 
 
lox5171 
Frt 
F3 
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GAGGAAGAGGAGGCGGAGGCTTAGGGTGTACAAAGGGCTTGACCCAGGGA
GGGGGGTCAAAAGCCAAGGCTTCCCAGGTCACGATGTAGGGGACCTGGTC
TGGGTGTCCATGCGGGCCAGGTGAAAAGACCTTGATCTTAACCTGGGTGA
TGAGGTCTCGGTTAAAGGTGCCGTCTCGCGGCCATCCGACGTTAAAGGTT
GGCCATTCTGCAGAGCAGAAGGTAACCCAACGTCTCTTCTTGACATCTAC
CGACTGGTTGTGAGCGATCCGCTCGACATCTTTCCAGTGACCTAAGGTCAA
ACTTAAGGGAGTGGTAACAGTCTGGCCCTAATTTTCAGACAAATACAGAA
ACACAGTCAGACAGAGACAACACAGAACGATGCTGCAGCGCTGCAGCAGA
CAAGACGCGCGGCTTCGGTTCCAAACCGAAAGCAAAAATTCAGACGGAGG
CGGGAACTGTTTTAGGTTCTCGTCTCCTACCAGAACCACATATCCTGACGG
GGTCGGATTCCACATCGACTCCCTTCCTCAGGTCGGGCCACAAAAACGGCC
CCCAAAGTCCCTGGGACGTCTCCCAGGGTTGCGGCCGGGTGTTCAGAACTC
GTCAGTTCCACCACGGGTCCGCCAGATACAGAGCTAGTTAGCTAACTAGT
ACCGACGCAGGCGCATAAAATCAGTCATAGACACTAGACAATCGGACAGA
CACAGATAAGTTGCTGGCCAGCTTGCCTCCCGGTGGTGGGTCGGTGGTCCC
TGGGCAGGGGTCTCCCGATCCCGGACGAGCCCCCAAATGAAAGACCCCCGC
TGACGGGTAGTCAATCACTCAGAGGAGACCCTCCCAAGGAACAGCGAGAC
CACAAGTCGGATGCAACTGCAAGA 
(missing sequences) 
CAGGTTGAAGGAAGTTGTTATGGAGGCCCAGTGCTTGCTTGGGTGAGAAA
CAACCCCTTCCTGACAAACCTGGAGGATGCTGATGCAGGCAGGGACCAGCA
AGTAAAGGACGGAGCCTAAGGGTTCCATCAGTCTGGAAAGAGTCTTCCTC
TCCAACCCTTCAGAAAGTGAAAAATAATATTATTTATTTATTTATTTAT
TTATTCACATTCCTAATGCTGCCCCCCCCCCATCGCCCCAGAAAAATACTT
TTATCGGTCTCTCAGTAAGTTATTACTCAAGAGAAACAAGCAATACCTCT 
 
 
 
 
LR-R1 primer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gldc intron 2-3 
 
R3 primer 
 
 
